

BRIDGE TO THE FUTURE



AMSTERDAM
25-28 SEPTEMBER 2024

PROGRAMME BOOKLET

Editorial / Publisher

European Academy of Dermatology and Venereology (EADV)

eadv.org


Further information about the event

eadv.org/congress

Download the official app

The EADV Congress 2024 app will bring the EADV Congress to your smartphone or tablet! The official app offers a tailor-made mobile overview of the EADV Congress. [Read more](#)

Join the conversation **#EADVCongress**



Follow EADV official social media channels to stay up to date with activities and announcements and interact with other professionals in the field.



Facebook



Instagram



LinkedIn



X (formerly Twitter)



Table of contents

Table of contents.....	3
EADV President's welcome letter	4
Welcome from the EADV Scientific Programming Committee.....	5
The Academy.....	6
Continuing medical education – Continuing professional development (CME-CPD)	7
Abstract reviewers.....	8
Subspecialty and international societies	9
Scientific programme	10
Session formats.....	10
Wednesday, 25 September 2024	12
Thursday, 26 September 2024	46
Friday, 27 September 2024.....	84
Saturday, 28 September 2024.....	115
Practical workshops.....	142
Patient organisations area	146
General information.....	147
Internet access / Wi-Fi.....	147
Onsite facilities	148
Official language.....	149
Scientific sessions.....	149
Certificates and accreditation	149
Abstracts and ePosters	150
Exhibition hall	150
Other services	151
Childcare facility	151
First aid room and emergency numbers	151
Opening plenary session and networking symposium	152
Privacy.....	153
Official mobile app	154
The venue.....	155
Registration.....	157
EADV Congress ticket types	157
Press information for journalists and media representatives.....	158
Healthcare professional information and definition	159
EXHIBITION	161



EADV President's welcome letter

Dear Colleagues,

On behalf of the entire EADV Board, I am delighted to welcome you to our EADV Congress in Amsterdam. This hybrid event offers both onsite delegates and remote participants the chance to update their clinical knowledge and engage in the latest advances in dermatology and venereology.

The congress will be opened by an internationally renowned keynote speaker Dr. Bertrand Piccard, who will spotlight the human impact on the climate and suggest actionable steps we can take in our personal lives to protect our planet. The scientific congress programme promises deep structured insights into all major fields of dermatology and updates on hot topics, including rapid changes in the understanding and treatment of common diseases such as atopic dermatitis, psoriasis, and skin cancer – from surgery to systemic therapy. Special focus sessions will provide a 'deep dive' into bullous diseases, hidradenitis suppurativa and cutaneous lymphomas.

Expect nine more plenary lectures from global experts on topics of broad relevance. The 2024 EADV Congress is session rich with 160+ thematically perfectly structured symposia, more than 20 subspecialty sessions and the extremely popular "Late breaking news". To foster direct exchanges, we will showcase more than 3600 ePosters, engage delegates in hands-on workshops and provide practical insights delivered by over 600 leaders in dermatology and venereology.

Most esteemed figures in the field of dermatology and venereology from Europe, USA, Asia and other continents will share their latest insights in clinics and clinical research. The 2024 EADV Congress will present a high-level of scientific content and a 'Residents Track' and new 'EADV Games' dedicated to young dermatologists.

The Congress is being hosted at the RAI Amsterdam congress centre. Nestled in the heart of the city, it is one of Europe's most prominent and modern venues, committed to environmental sustainability and innovative technologies. With its leading-edge technology, the RAI offers most practical approaches for popular plenary sessions, symposia, ePosters and novel interactive formats.

Amsterdam is known for its unique artistic heritage, elaborate canal systems and houses with gabled facades - a legacy of the city's 17th-century Golden Ages. Beyond the 2024 EADV Congress, Amsterdam offers an unforgettable atmosphere that each of us will cherish.

As president, I am committed to continuing the path of transformation initiated by my predecessors, towards the professionalisation of our academy. The recent success of our congress programming by the Scientific Programming Committee, evidenced by the record-breaking attendance in Berlin, underscores our achievements as an academy. I look forward to personally welcoming you where we will jointly experience the vibrant spirit of dermatology and venereology.



Prof. Dr. Martin Röcken
2022-2024 President of the EADV

Welcome from the EADV Scientific Programming Committee

Dear Colleagues,

A warm welcome to the 33rd EADV Congress in Amsterdam! We are thrilled to present an outstanding program that showcases the very best in dermatology. This year's congress is packed with cutting-edge advancements and practical insights on how to integrate these innovations into your clinical practice.

With 600 exceptional speakers, each carefully selected for their expertise, you'll experience an array of engaging talks covering the entire spectrum of dermatology.

Our mission is to make this the most unforgettable dermatology congress ever—a gathering that truly has something for everyone. Whether you're from academia, private practice, or just starting your career, this congress is designed with you in mind.

As in the past, we've organized sessions into "Updates," "Training and Education," and "Controversies," with the ever-popular "Focus on" sessions diving deep into hot topics like bullous diseases, hidradenitis suppurativa, and cutaneous lymphomas.

This year, we're placing a special emphasis on the future of dermatology with a full-day "Resident's Track," crafted by and for young dermatology professionals. And don't miss the thrilling EADV GAMES—a dermatology quiz where residents from 18 European countries will battle it out for the top spot. It's going to be a competition like no other!

Our plenary talks will feature nine world-renowned speakers addressing the hottest topics in dermatology today, from neoadjuvant therapy in melanoma to the role of artificial intelligence, climate change, JAK inhibitors, pustular psoriasis, and STIs. Be sure not to miss the Opening Lecture by the legendary explorer Bertrand Piccard, who will deliver an inspiring message on resilience, drawing from his epic, solar-powered journey around the world.

This year, we've set a new record with the number of abstract submissions—over 4'200! We've handpicked the most groundbreaking research to be featured in the Late-Breaking News sessions, Free Communications, and our newly introduced ePoster showcase sessions.

Our Congress will continue to offer "Hands-on Workshops," a cherished tradition. And last but not least, "Subspecialty Sessions" will be held on Wednesday morning and Saturday early afternoon, with in-depth explorations of specific topics.

If you can't join us in person, you can still participate virtually, with live-streamed sessions available on our Congress online platform.

Join us in Amsterdam and help us make the 2024 EADV Congress an extraordinary and unforgettable experience!



Michel Gilliet

Chair of the Scientific Programming
Committee, EADV

EADV Scientific Programming Committee:

Michel Gilliet
Jo Lambert
Paola Pasquali
Lidia Rudnicka
Eli Sprecher
Thrasylvoulos Tzellos



The Academy

Founded in 1987, the European Academy of Dermatology and Venereology is a global community with the unifying goal of advancing excellence in patient care, promoting knowledge and expertise among healthcare professionals, as well as advocating on behalf of the specialty and patients.

EADV is a leading provider of education in dermatology-venereology through a unique blend of in-person and online courses, as well as digital learning tools including webinars and podcast episodes.

The Academy offers several scholarships, grants, and research funding opportunities, enriching networks and knowledge-sharing among future leaders in the specialty. EADV actively promotes better awareness of skin and venereal diseases by working closely with global and European policymakers on public health campaigns to tackle occupational skin diseases, melanoma, sexually transmitted infections, and other diseases.

The Journal of the European Academy of Dermatology and Venereology (JEADV), publishes a wide range of articles that focus on basic science, clinical and translational research in dermatology and venereology. With an Impact Factor of 8.4, it is now ranked 5th among the international dermatology journals. The JEADV Clinical Practice is the open-access peer-reviewed publication of EADV. It features cutting-edge educational and clinically orientated content, for aspiring researchers, to showcase the latest hands-on practices in clinics and innovative clinical and surgical skills.

Every year EADV holds a flagship Congress in the autumn and a smaller Symposium in the spring, which together attract over 18,000 delegates from around the world, exchanging ideas, experiences and projects to improve patient care.

Future EADV events

EADV Symposium

22-24 May 2025
Prague, Czech Republic

EADV Congress

17-20 September 2025
Paris, France



Continuing medical education – Continuing professional development (CME-CPD)

The EADV Congress 2024, Amsterdam, Netherlands, 25-28 September 2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **24.0 European CME credits (ECMEC®s)**. CME Credits Each medical specialist can claim only those hours of credit actually spent in the educational activity (as recorded by the scanning process or online access). Here below find the breakdown of credits per day:

- Wednesday 25 September 6 credits
- Thursday 26 September 6 credits
- Friday 27 September 6 credits
- Saturday 28 September 6 credits



The accreditation system is based on 1 ECMEC per hour.

No credits will be guaranteed by the EADV to delegates participating in the following sessions: industry sessions, subspecialty sessions, allied healthcare professionals workshop, ePoster showcases, Residents track and EADV Games.

Procedure to gain your credits

Scan your badge, complete the evaluation forms and download the CME-CPD Certificate.

The EADV offers individual CME-CPD participation through the scanning of the bar code and the speaker/session evaluation that will be available for a period of 3 months after the end of the Congress (until 31 December 2024).

1. Scan your badge as you pass through the entrance of each session hall (or access the session online, live or on-demand).
2. Complete the anonymous online evaluation form for each attended session. Access the evaluation system in the "My Congress" area on the online Congress platform.
3. Download your CME-CPD certificate and retain it for your personal records.

Evaluation data is essential to our statistics and is of considerable help in the choice of future topics and speakers. Your feedback and comments are greatly appreciated.

Conversion of credits

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at edhub.ama-assn.org/pages/applications

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Information regarding the conversion of EACCME®credits

Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at edhub.ama-assn.org/pages/applications to obtain the necessary paperwork and instructions. Physicians and other healthcare professionals will be required to pay a processing fee to the AMA.

For other countries, please contact the relevant national/regional accreditation authority



Abstract reviewers

EADV is grateful to the following reviewers who have given their time and expertise in reviewing the submitted abstracts:

- Ashraf Badawi
- Deepak Balak
- Ana Balato
- Zsuzsanna Bata Csorgo
- Johannes Bauer
- Asli Bilgiç, Svetlana Bobko
- Evelina Buinauskaite
- Piergiacomo Calzavara-Pinton
- Jose Manuel Carrascosa
- Romana Ceovic
- Pavel Chernyshov
- Renata Csoma
- Razvigor Darlenski
- Elke De Jong
- Clio Dessinioti
- Dario Didona
- Mateja Dolenc Voljc
- Nejib Doss
- Kossara Drenovska
- Andrew Finlay
- Christina Fotiadou
- Klaus Fritz
- Menno Gaastra
- Ana Maria Gimenez Arnau
- Maria-Angeliki Gkini
- Stamatis Gregoriou
- Jürg Hafner
- Cristina Has
- Claudia Heller-Vitouch
- Dirk Hijnen
- Barbara Horváth
- Matilde Iorizzo
- Sherief Janmohamed
- Veli-Matti Kahari
- Talia Kakourou
- Lidija Kandolf-Sekulovic
- Alexander Katoulis
- Jana Kazandjieva
- Katerina Kolyadenko
- Dimitra Koumaki
- Barbara Kunz
- Aikaterini Liakou
- Bohdan Lytvynenko
- Susanna Marini
- Vali Mateeva
- Brent Moody
- Dedee Murrell
- Luigi Naldi
- Arjen Fokko Nikkels
- Almudena Nuno Gonzalez
- Rodica Olteanu
- Katerina Patsatsi
- David Pesque
- Sandra Peternel
- Pawel Piotr Pietkiewicz
- Carlo Pincelli
- Svetlana Popadic
- Adam Reich
- Enrique Rodriguez-Lomba
- Matthias Schmuth
- Dusan Skiljevic
- Luis Soares de Almeida
- Efthymia Soura
- Sundaramoorthy Srinivasan
- Zsuzsanna Szalai
- Bing Thio
- Christian Vestergaard
- Norbert Wikonkal
- Savaş Yayli
- Alexander Zink
- Torsten Zuberbier



Subspecialty and international societies

The following societies develop and manage scientific sessions during the EADV Congress 2024 after approval from the EADV Scientific Programming Committee.

Each society has a specific focus on a dermatological topic and offers important insights into the latest developments in that field.

- EHSF - European Hidradenitis Suppurativa Foundation
- ENS - European Nail Society
- ESCAD - European Society for Cosmetics and Aesthetic Dermatology
- ESLD – European Society for Lasers and energy-based devices
- ESDaP – European Society for Dermatology and Psychiatry
- ESDP - European Society for Dermatopathology
- ESPD - European Society for Photodermatology
- ETFAD - European Task Force of Atopic Dermatitis
- Euromelanoma
- EURO-PDT - European Society for Photodynamic Therapy in Dermatology
- EWDVS - European Women Dermatological and Venereological Society
- GA²LEN - Global Allergy and Asthma European Network of Excellence
- GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
- IADVL – Indian Association of Dermatologists, Venereologists and Leprologists
- IDS - International Dermoscopy Society
- IEC - International Eczema Council
- IPC - International Psoriasis Council
- IPS – International Peeling Society
- ISD - International Society of Dermatology
- MEIDAM - Middle East International Dermatology and Aesthetic Medicine
- PALD - Pan Arab League of Dermatologists
- SPIN - Skin Inflammation & Psoriasis International Network
- SSDDS - Saudi Society of Dermatology and Dermatologic Surgery
- WDS - Women's Dermatologic Society



Scientific programme

The scientific programme has been organised on full or half-day tracks; each track has a specific topic and a structured programme. Entry will be made on a first-come, first-served basis.

Session formats

Sessions of different formats will cover the important fields of dermatology and venereology. Subjects will be treated with different approaches and from different perspectives. The following session types will be scheduled throughout the duration of the Congress and are available to all registered participants.

- **Plenary sessions:** Plenary lectures are EADV show-case sessions and include key-note lectures delivered by eminent scientists and doctors.
- **Focus on:** These sessions aim at providing comprehensive in-depth coverage of a certain topic in dermatology. The talks will be included in sessions on pathophysiology / epidemiology, clinical challenges, or practical aspects of disease management and will provide the latest cutting-edge information.
- **Updates:** These sessions will enable participants to update their knowledge on a specific topic and hear about the most relevant and recent developments, guidelines and practical knowledge from the past year. The talks will summarize the current understanding of the subject, followed by an update on the most recent novelties with their impact on clinical practice.
- **Controversies:** Controversial topics in dermatology will be discussed from different points of view in the form of a debate, giving delegates extensive insights into the latest findings.
- **Training and education:** These lectures focus on a specific disease and include basic information about epidemiology, pathophysiology, diagnosis, management and prognosis. The target audience of these sessions is young dermatology trainees and residents, as well as dermatologists that want to refresh their basic knowledge on specific topics.
- **Free communications:** Authors of the most highly ranked abstracts assessed by a selected panel of abstract reviewers are invited to provide a 10-minute oral presentation.
- **Miscellaneous:** The miscellaneous track includes sessions organised and delivered by groups, task forces and committees other than the EADV Committee, such as the Project Proposal Review Committee, the Ethics Committee or the JEADV.

Scientific programme

- **ePoster showcase:** A selection of the best ePosters made by the scientific programming committee will be orally presented in the ePoster Showcase sessions. In addition to submitting their ePosters, the authors will have the possibility to present their findings to the audience in the open stage area.
- **Residents track:** A full track will be dedicated to residents on the second part of the congress. Different subjects will be discussed by residents asking questions to the experts, with an interaction with the audience, involving them in the discussion.
- **Subspecialty sessions:** Subspecialty and International Society meetings are scientific sessions developed and managed by the individual societies after approval from the EADV Scientific Programming Committee.
- **EADV Games:** The EADV will host a quiz for residents during the congress, an event which will gather 18 European countries to compete against each other in a thrilling quiz focusing on various Dermatology topics.
- **Workshops*:** Workshops are a great opportunity to immediately implement newly learned skills, to gain practical experience and quickly acquire knowledge on the subject. Workshops also promote interaction between instructors and participants.
- **Allied healthcare professionals workshops:** A dedicated workshop series designed specifically for allied healthcare professionals. On Saturday, we will feature an entire track dedicated to Nurses, offering valuable insights, and opportunities for networking.

* All Workshops require a pre-registration and a pre-payment. Class sizes are limited to 35 places each and registrants are accepted on a first-paid, first-served basis. More info eadv.org/congress/scientific/workshops



Wednesday, 25 September 2024

Programme at a glance

Plenary lectures	12:00 – 13:00	17:45 – 19:00
Auditorium	Plenary Lecture A	Plenary session with keynote lecture

Sessions	08:30 – 11:45		14:15 – 15:45	16:00 – 17:30
Auditorium			Late breaking news	Late breaking news
Elicium	WDS - Women's Dermatologic Society		Focus on bullous diseases	Focus on bullous diseases
Room 3.1	ESCAD - European Society for Cosmetics and Aesthetic Dermatology		Psoriasis	Psoriasis
Forum	IDS - International Dermoscopy Society		Oral diseases	Pregnancy and skin diseases
Room 7.1	ENS – European Nail Society		Prevention and skin cancer screening	Actinic keratosis
Room 7.2	ETFAD – European Task Force of Atopic Dermatitis		New and emerging drugs	New and emerging drugs
Room 7.3	IPC – International Psoriasis Council		Dermatology in skin of colour patients	Dermatology in skin of colour patients
Room 7.4	EHSF – European Hidradenitis Suppurativa Foundation		Rosacea	Climate change and environmental dermatology
Room 7.5	ESLD – European Society for Lasers and energy-based devices		JAK inhibitors	Vitiligo
E107–E108	(08:30 – 10:00) SPIN - Skin Inflammation & Psoriasis International Network	(10:15 – 11:45) GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis	Acne and rosacea	Nail and hair disorders
E103-E104	Ga ² LEN – Global Allergy and Ashtma Excellence Network		Dermato-endocrinology	Vasculitis and vasculopathies
G102-G103		(9:45 – 11:30) Euromelanoma	Dermatopathology	Dermatopathology
G104-G105	ESPD – European Society for Photodermatology		Skin ageing and rejuvenation	Geriatric dermatology
E102	(08:30 – 10:00) EWDVS – European Women Dermatological and Venereological Society	(10:15 – 11:45) PALD – Pan Arab League of Dermatologists	History of dermatology	Skin diseases in Latin America
D202	Basics of ultrasound imaging in dermatology		Allergology: Skin environmental induced contact dermatitis	
D203	Laser treatment for beginners		STI diagnosis and treatment	
Open stage			ePoster showcase	ePoster showcase



Wednesday, 25 September 2024

PLENARY SESSION

⌚ 12:00 – 13:00 CEST

📍 AUDITORIUM

	Plenary lectures A Chairs: Martin Röcken (Tübingen, Germany) Manabu Fujimoto (Suita, Japan)
12:00	Neoadjuvant treatment in melanoma Christian Blank (Amsterdam, Netherlands)
12:20	Artificial intelligence: Friend or foe? Hans Peter Soyer (Brisbane, Australia)
12:40	STDs in 2024 Henry John Christiaan De Vries (Amsterdam, Netherlands)

PLENARY SESSION

⌚ 17:45 – 19:00 CEST

📍 AUDITORIUM

	Plenary session with keynote lecture Chairs: Martin Röcken (Tübingen, Germany) Michel Gilliet (Lausanne, Switzerland)
17:45	Introduction Martin Röcken (Tübingen, Germany)
17:55	Welcome Dirk Jan Hijnen (Rotterdam, Netherlands)
18:05	Keynote speaker introduction Michel Gilliet (Lausanne, Switzerland)
18:10	Renewable energy and clean technologies: the new medication for our world Bertrand Piccard (Lausanne, Switzerland)
18:45	Discussion, Q&A



D1T01.1		Late breaking news Chairs: Markus Vincent Starink (Amstelveen, Netherlands) Monika Arenbergerova (Prague, Czech Republic)
D1T01.1A	14:15	Durability of response to nemolizumab in patients with moderate-to-severe prurigo nodularis: Results from a randomised placebo-controlled withdrawal Phase 3b study Franz Legat (Graz, Austria)
D1T01.1B	14:30	ZL-1503, a bispecific, serum half-life extended antibody targeting both inflammatory and pruritogenic pathways for atopic dermatitis and other IL-13/IL-31 related diseases Linda Liu (Cambridge, United States)
D1T01.1C	14:45	Orismilast efficacy in adults with moderate-to-severe atopic dermatitis in a phase 2b trial: early impact on itch and patient-reported outcomes Eric Simpson (Portland, United States)
D1T01.1D	15:00	Nemolizumab long-term safety and efficacy up to 56 weeks in ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis Diamant Thaçi (Luebeck, Germany)
D1T01.1E	15:15	Deucravacitinib in the treatment of lichen planopilaris - interim analysis Aaron Mangold (Scottsdale, United States)
D1T01.1F	15:30	DELTA FORCE trial: A 24-week head-to-head phase 3 trial comparing the efficacy and safety of topical delgocitinib cream with oral alitretinoin capsules in adults with severe chronic hand eczema Ana Giménez-Arnau (Barcelona, Spain)



DIT01.2		Late breaking news Chairs: Paola Pasquali (Cambrils, Spain) Gudrun Ratzinger (Innsbruck, Austria)
DIT01.2A	16:00	Efficacy and safety of izokibep, a novel IL-17A inhibitor, in moderate-to-severe hidradenitis suppurativa: Week 12 results from a randomized, double-blind, placebo-controlled, multicenter, phase 3 study Kim A. Papp (Waterloo, ON, Canada)
DIT01.2B	16:15	Sexually transmitted diseases: An unprecedented global overview of their prevalence Charbel Skayem (Paris, France)
DIT01.2C	16:30	Tape-strips transcriptomic analysis from patients with moderate to severe atopic dermatitis treated with nemolizumab Emma Guttman-Yassky (New York, United States)
DIT01.2D	16:45	Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with chronic spontaneous urticaria Martin Metz (Berlin, Germany)
DIT01.2E	17:00	Efficacy and safety of lebrikizumab is maintained up to 3 years in patients with moderate-to-severe atopic dermatitis: ADvocate 1 and ADvocate 2 to ADjoin long-term extension trial Diamant Thaçi (Luebeck, Germany)
DIT01.2F	17:15	Impact of atopic dermatitis in adults depends on its age of onset: Results of the "Scars of Life" project Jonathan I. Silverberg (Washington, United States)



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 08:30 – 11:45 CEST

📍 ELICIUM

	WDS - Women's Dermatologic Society Chairs: Rashmi Sarkar (Noida, Uttar Pradesh, India) Aikaterini Patsatsi (Thessaloniki, Greece) Kossara Drenovska (Sofia, Bulgaria)
08:30	Introduction Rashmi Sarkar (Noida, Uttar Pradesh, India)
08:35	WDS and rose parade of cases Latanya Benjamin (Coral Springs, FL, United States)
08:45	Pearls from paediatric dermatology practice Latanya Benjamin (Coral Springs, FL, United States)
09:00	AIBD in women of childbearing age: Treatment challenges Aikaterini Patsatsi (Thessaloniki, Greece)
09:15	AIBD in children Kossara Drenovska (Sofia, Bulgaria)
09:30	Uncommon drug reactions to common drugs Vaishali Nahata (Nashik, India)
09:45	Vulval dermatoses – A clinic-histopathological correlation Mark Koh (Singapore, Singapore)
10:00	Break
10:15	A leadership program for academic dermatologists – The EADV example Carle Paul (Toulouse, France)
10:30	Gender equity in academic dermatology Dédée Murrell (Sydney, Australia)
10:45	Women dermatologists' leadership in India Rashmi Sarkar (Noida, Uttar Pradesh, India)
11:00	GLODERM: Launching leadership training for global health dermatologists Esther Freeman (Boston, United States)
11:15	Role of women dermatologist in the industry Delphine Kerob (Levallois Perret, France)
11:30	Gender disparities in inflammatory dermatoses Hitaishi Mehta (Chandigarh, India)
11:37	Female genital dermatoses other than STDs Anubha Dev (Chandigarh, India)



Wednesday, 25 September 2024

FOCUS ON

⌚ 14:15 – 15:45 CEST

📍 ELICIUM

DIT02.1		Focus on bullous diseases Chairs: Dédée Murrell (Sydney, Australia) Martin Laimer (Salzburg, Austria)
DIT02.1A	14:15	Inherited skin fragility diseases Cristina Has (Freiburg, Germany)
DIT02.1B	14:35	Epidermolysis bullosa Martin Laimer (Salzburg, Austria)
DIT02.1C	14:55	Drug repurposing in inherited bullous diseases Dédée Murrell (Sydney, Australia)
DIT02.1D	15:15	Inherited bullous diseases can be treated Peter van den Akker (Groningen, Netherlands)
DIT02.1E	15:35	Discussion, Q&A

FOCUS ON

⌚ 16:00 – 17:30 CEST

📍 ELICIUM

DIT02.2		Focus on bullous diseases Chairs: Luca Borradori (Bern, Switzerland) Barbara Horvath (Groningen, Netherlands)
DIT02.2A	16:00	Pemphigus: New paradigm Pascal Joly (Rouen, France)
DIT02.2B	16:20	Pemphigoid, an expanding spectrum of disorders Luca Borradori (Bern, Switzerland)
DIT02.2C	16:40	Other acquired bullous diseases Enno Schmidt (Lübeck, Germany)
DIT02.2D	17:00	Emerging treatments on the horizon Barbara Horvath (Groningen, Netherlands)
DIT02.2E	17:20	Discussion, Q&A



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 08:30 – 11:45 CEST

📍 ROOM 3.1

	ESCAD - European Society for Cosmetics and Aesthetic Dermatology Chairs: Peter Velthuis (Rotterdam, Netherlands)
08:30	Targeted toxin injections Hugues Cartier (Arras, France)
08:45	Scar remodelling with innovative combination strategies Susanna Marini (Trieste, Italy)
09:00	Optimal filler placement: What have we learned from ultrasound imaging Leonie Schelke (Amsterdam, Netherlands)
09:15	Facial skin ageing and related phenotypes: Main findings from a population-based study Luba Pardo (rotterdam, Netherlands)
09:30	Filler complication classification Marina Landau (Herzlia, Israel)
09:45	Research in cosmetic medicine Peter Velthuis (Rotterdam, Netherlands)
10:00	From subjective to objective facial assessment - personalized treatment plans using AI Klaus Fritz (Landau, Germany)
10:15	Change in fillers after time in situ Olga Liplavk (Amsterdam, Netherlands)
10:30	Management of keloids with local medication Vazula Bekkers (Rotterdam, Netherlands)
10:45	Cellular and tissue effects of HA fillers: From histology to imaging Ferial Fanian (ST CLOUD, France)
11:00	Hyaluronidase to dissolve HA filler Peter Arne Gerber (Düsseldorf, Germany)
11:15	Science bites 2024: Evidence-based updates in cosmetic dermatology Hema Sundaram (Rockville, United States)
11:30	Lasers for scars Keyvan Nouri (Miami, United States)



Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 3.1

D1T03.1		Psoriasis Chairs: Kilian Eyerich (Freiburg, Germany) Hok Bing Thio (Rotterdam, Netherlands)
D1T03.1A	14:15	Inflammatory memory and disease modification Kilian Eyerich (Freiburg, Germany)
D1T03.1B	14:35	Population differences in psoriasis Hok Bing Thio (Rotterdam, Netherlands)
D1T03.1C	14:55	Pustular psoriasis: is it really psoriasis? Hervé Bachelez (Paris, France)
D1T03.1D	15:15	Personalised medicine approaches for tailored treatments Satveer Mahil (London, United Kingdom)
D1T03.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 3.1

D1T03.2		Psoriasis Chairs: April W. Armstrong (Los Angeles, United States) Jo LW Lambert (Ghent, Belgium)
D1T03.2A	16:00	New topicals Diamant Thaçi (Luebeck, Germany)
D1T03.2B	16:20	Do we need oral treatment options? Richard B. Warren (Manchester, United Kingdom)
D1T03.2C	16:40	Therapeutic drug monitoring in your practice? Jo LW Lambert (Ghent, Belgium)
D1T03.2D	17:00	Does psoriasis treatment prevent the development of psoriatic arthritis? April W. Armstrong (Los Angeles, United States)
D1T03.2E	17:20	Discussion, Q&A



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 8:30 – 11:45 CEST

📍 FORUM

	IDS - International Dermoscopy Society Chairs: Caterina Longo (Modena, Italy) Zoe Apalla (Thessaloniki, Greece) John Paoli (Gothenburg, Sweden)
08:30	Cases with a teaching point Jelena Stojkovic-Filipovic (Belgrade, Serbia)
08:43	Cases with a teaching point Sebastian Podlipnik (Barcelona, Spain)
08:56	Cases with a teaching point Awatef Kelati (Casablanca, Morocco)
09:09	Cases with a teaching point Elvira Moscarella (Naples, Italy)
09:22	Common diseases in skin of colour Enzo Errichetti (Udine, Italy)
09:35	Cases with a teaching point Ruzica Jurakic Tonic (Zagreb, Croatia)
09:48	Cases with a teaching point Elisa Cinotti (Siena, Italy)
10:01	Cases with a teaching point Dimitrios Sgouros (Athens, Greece)
10:14	Cases with a teaching point Nisa Akay Bengu (Ankara, Türkiye)
10:27	Trichoscopy in alopecia areata, from diagnosis to treatment monitoring Michela Starace (Bologna, Italy)
10:40	Cases with a teaching point Raimonds Karls (Daugmale, Latvia)
10:53	Cases with a teaching point Ahmed Sadek (Cairo, Egypt)
11:06	Cases with a teaching point Claudio Conforti (Trieste, Italy)
11:19	Cases with a teaching point Cristian Navarrete-Dechent (Santiago, Chile)
11:32	Quiz Konstantinos Liopyris (Athens, Greece)

Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 FORUM

DIT014.1		Oral diseases Chairs: Raimonds Karls (Daugmale, Latvia) Mahtab Samimi (Tours, France)
DIT04.1A	14:15	Oral biology: from microbiome to immunity Speaker TBC
DIT04.1B	14:35	Mycoplasma-induced reactive mucositis Amna Elyas (Malmö, Sweden)
DIT04.1C	14:55	Oral lichen planus Mahtab Samimi (Tours, France)
DIT04.1D	15:15	Oncology of the oral cavity Raimonds Karls (Daugmale, Latvia)
DIT04.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 FORUM

DIT04.2		Pregnancy and skin diseases Chairs: Miklos Sardy (Budapest, Hungary) Jenny Murase (San Francisco, CA, United States)
DIT04.2A	16:00	Melanoma in pregnancy Gabriele Roccuzzo (Torino, Italy)
DIT04.2B	16:20	Clinical pearls from the pregnancy dermatology clinic Samantha Vaughan-Jones (Surrey, United Kingdom)
DIT04.2C	16:40	Consequences and treatment of STIs during pregnancy Miklos Sardy (Budapest, Hungary)
DIT04.2D	17:00	Update on safety of medications in pregnancy Jenny Murase (San Francisco, CA, United States)
DIT04.2E	17:20	Discussion, Q&A



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 8:30 – 11:45 CEST

📍 ROOM 7.1

	ENS - European Nail Society Chairs: Nilton Gioia Di Chiacchio (Sao Paulo, Brazil) Andre Lencastre (Alcabideche, Portugal) Bianca Maria Piraccini (Bologna, Italy)
08:30	Introduction Nilton Gioia Di Chiacchio (Sao Paulo, Brazil)
08:35	Saved by the nail plate: Adventures in nail unit dermatopathology. Beth Ruben (San Francisco, United States)
08:50	Clinical case Tomer Goldsmith (Tel Aviv, Israel)
08:57	Onychoscopy in longitudinal depression of the nail plate Michela Starace (Bologna, Italy)
09:12	Clinical case Andrea Sechi (Milan, Italy)
09:19	Diagnostic challenges related to the nail unit pigmented lesions Adam Rubin (Philadelphia, United States)
09:34	Clinical case Kendall Billick (Montreal, Canada)
09:41	Longitudinal Leukonychia - what's next? Marcel Pasch (Nijmegen, Netherlands)
09:56	Nailing systemic disorders Andre Lencastre (Alcabideche, Portugal)
10:11	Clinical Case Charlotte Arnal (Rodez, France)
10:18	Uncommon uses of common treatments for nail conditions Azzam Alkhalifah (Arrass, Saudi Arabia)
10:33	Clinical case Francesca Pampaloni (Bologna, Italy)
10:40	Longitudinal xantonychia Marisa Mathieu (Brussels, Belgium)
10:55	Clinical case Beatrice Verhamme (Leuven, Belgium)
11:02	Management of nail disorders due to anti-cancers from a dermatologist and podiatrist point of view Annemie Galimont-Collen (Kwadendamme, Netherlands)
11:17	Clinical Case Ioanna Triantafyllopoulou (Athens, Greece)
11:24	Nail unit tumors presenting as erythronychia: A case series Fatih Göktaş (Istanbul, Türkiye)
11:39	Conclusion/Announcements



Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.1

D1T05.1		Prevention and skin cancer screening Chairs: Henry W. Lim (Grosse Pointe, United States) Marlies Wakkee (Rotterdam, Netherlands)
D1T05.1A	14:15	Oral prevention Salvador González Rodríguez (Madrid, Spain)
D1T05.1B	14:35	Photoprotection Henry W. Lim (Grosse Pointe, United States)
D1T05.1C	14:55	Use of AI for screening Marlies Wakkee (Rotterdam, Netherlands)
D1T05.1D	15:15	Identifying risk groups Zoe Venables (Norwich, United Kingdom)
D1T05.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.1

D1T05.2		Actinic keratosis Chairs: Elena Campione (Rome, Italy) Günther Hofbauer (Wetzikon, Switzerland)
D1T05.2A	16:00	Management of field cancerization Lidija Kandolf-Sekulovic (Belgrade, Serbia)
D1T05.2B	16:20	Management of solitary AK Elena Campione (Rome, Italy)
D1T05.2	16:40	Genomic landscape Jason Thomson (London, United Kingdom)
D1T05.2D	17:00	How to manage AK in immuno-suppressed patients Günther Hofbauer (Wetzikon, Switzerland)
D1T05.2E	17:20	Discussion, Q&A

Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 8:30 – 11:45 CEST

📍 ROOM 7.2

	ETFAD - European Task Force of Atopic Dermatitis Chairs: Mette Sondergaard Deleuran (Aarhus, Denmark) Andreas Wollenberg (Munich, Germany) Magdalena Trzeciak (Gdansk, Poland)
08:30	Welcome
08:40	Serum proteomic changes in atopic dermatitis patient treated with cyclosporine Jill Olydam (Rotterdam, Netherlands)
08:55	Mapping between common AD severity scores to facilitate large-scale meta-analyses of omics data Matthias Hübenthal (Kiel, Germany)
09:10	T cell signatures are associated with S. aureus skin infection in pediatric atopic dermatitis Julianne Clowry (Dublin, Ireland)
09:25	Maternal supplementation with prebiotics during pregnancy regulates colonization of the microbiota of high-risk children, but does not prevent atopic dermatitis at one year of age. The PREGRALL multicenter randomized control trial Sébastien Barbarot (Nantes, France)
09:40	Educational attainment in individuals with high and low utilization of healthcare for atopic dermatitis Laura von Kobyletzki (Örebro, Sweden)
09:55	Variability in impact on quality -of-life from EASI score changes in paediatric and adult dermatitis: insights from the UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR) Michael Ardern-Jones (Southampton, United Kingdom)
10:10	Identification of factors that protect against anxiety and depression in patients with atopic dermatitis Elise Vandersichel (Gent, Belgium)
10:25	Contact allergy among atopic dermatitis patients Magdalena Trzeciak (Gdansk, Poland)
10:40	Investigating doctors ´ perspectives on skin conditions encountered in general practice in Denmark, with a special focus on atopic dermatitis Anne Sofie Frølund (Aarhus, Denmark)
10:55	Atopic dermatitis and eczema in the elderly population are distinct entities Susanne Radonjic (Bern, Switzerland)
11:10	Switching from Dupilumab to JAK inhibitors or Tralokinumab in case of facial or ocular adverse events: a real-life experience Delphine Staumont Salle (lille, France)
11:25	Risk of infections in atopic dermatitis patients treated with biologics and JAK inhibitors: Results from the BioDay registry Marjolein de Bruin-Weller (Utrecht, Netherlands)

Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.2

DIT06.1		New and emerging drugs Chairs: Thomas Bieber (Bonn, Germany) Antonio Costanzo (Milan, Italy)
DIT06.1A	14:15	Hidradenitis suppurativa James G. Krueger (New York, United States)
DIT06.1B	14:35	Atopic dermatitis Thomas Bieber (Bonn, Germany)
DIT06.1C	14:55	Alopecia areata and vitiligo Julien Seneschal (Bordeaux, France)
DIT06.1D	15:15	Psoriasis Antonio Costanzo (Milan, Italy)
DIT06.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.2

DIT06.2		New and emerging drugs Chairs: Frederic Caux (Bobigny, France) Margarida Gonçalves (Coimbra, Portugal)
DIT06.2A	16:00	Cutaneous lupus erythematosus Margarida Gonçalves (Coimbra, Portugal)
DIT06.2B	16:20	Blistering diseases Frederic Caux (Bobigny, France)
DIT06.2C	16:40	Melanoma Ana Ciurea (Houston, United States)
DIT06.2D	17:00	Non-melanoma skin cancer Lidija Kandolf-Sekulovic (Belgrade, Serbia)
DIT06.2E	17:20	Discussion, Q&A



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 8:30 – 11:45 CEST

📍 ROOM 7.3

	IPC - International Psoriasis Council Chairs:
08:30	PART I: CURRENT INSIGHTS and FUTURE DIRECTIONS
08:30	Welcome and Introduction Lone Skov (Hellerup, Denmark)
08:35	Big Data: Challenges and opportunities Tamar Nijsten (Rotterdam, Netherlands)
08:55	The role of AI in psoriasis care: A vision for the future Alexander Navarini (Basel, Switzerland)
09:15	Preventing psoriatic arthritis Frank Behrens (Frankfurt am Main, Germany)
09:35	Sustaining psoriasis remission Satveer Mahil (London, United Kingdom)
09:55	Panel Discussion
10:10	Break
10:25	PART II: SPOTLIGHT ON PEDIATRIC PSORIASIS
10:25	Introduction to part II Satveer Mahil (London, United Kingdom)
10:30	Recent treatment advances in paediatric psoriasis Amy Paller (Chicago, United States)
10:50	Recategorization of disease severity in paediatric psoriasis Marieke Seyger (Nijmegen, Netherlands)
11:10	PART III: CHALLENGING CLINICAL CASES
11:10	Challenging case with a focus on paediatrics Mona ElKalioby (Cairo, Egypt)
11:20	Challenging case with a focus on data driven care Ravi Ramessur (London, United Kingdom)
11:30	Panel discussion
11:40	Closing and adjourn Lone Skov (Hellerup, Denmark)



Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.3

D1T07.1		Dermatology in skin of colour patients Chairs: Ibrahima Traore (Conakry, Guinea) Andrew F. Alexis (New York, United States)
D1T07.1A	14:15	Challenges in recognising common inflammatory diseases Kouadio Celestin Ahogo (Abidjan, Côte d'Ivoire)
D1T07.1B	14:35	Vitiligo Laila Benzekri (Rabat, Morocco)
D1T07.1C	14:55	Infections Ibrahima Traore (Conakry, Guinea)
D1T07.1D	15:15	Acne Andrew F. Alexis (New York, United States)
D1T07.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.3

D1T07.2		Dermatology in skin of colour patients Chairs: Siham Dikhaye (Oujda, Morocco) Noureddine Litaïem (Tunis, Tunisia)
D1T07.2A	16:00	Skin whitening and management of hyperpigmentation Siham Dikhaye (Oujda, Morocco)
D1T07.2B	16:20	Challenges in detecting skin cancer Nazim Khaled Benmehidi (Algiers, Algeria)
D1T07.2C	16:40	Hair disorders Awatef Kelati (Casablanca, Morocco)
D1T07.2D	17:00	Keloids Noureddine Litaïem (Tunis, Tunisia)
D1T07.2E	17:20	Discussion, Q&A

Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 8:30 – 11:45 CEST

📍 ROOM 7.4

	EHSF - European Hidradenitis Suppurativa Foundation Chairs: Georgios Nikolakis (Dessau, Germany) Kelsey van Straalen (Rotterdam, Netherlands)
8:35	Moisture-Associated Skin Damage (MASD) in hidradenitis suppurativa: Mechanisms, clinical implications and targeted management strategies Alessandra Michelucci (Pisa, Italy)
8:47	Geriatric hidradenitis suppurativa: Retrospective evaluation of clinical features, disease course and treatment methods in a tertiary care hospital Yusuf Can Edek (Ankara, Türkiye)
8:59	Impaired QoL in Japanese patients with hidradenitis suppurativa Koremasa Hayama (Tokyo, Japan)
9:11	Invited lecture: Syndromic hidradenitis suppurativa Angelo Valerio Marzano (Milan, Italy)
9:25	Invited presentation: The 14th EHSF e.V. Conference, Feb. 12-14, 2025 in Vilnius Lithuania Ruta Ganceviciene (Vilnius, Lithuania)
9:34	Discussion
9:49	Administration of systemic isotretinoin can be a useful diagnostic test for differentiation of acne and acne-like hidradenitis suppurativa Anna Pirogova (Moscow, Russian Federation)
10:01	Ultrasonography of facial and submandibular hidradenitis suppurativa and concomitance with acne vulgaris at high-frequency and ultra-high-frequency Ximena Wortsman (Santiago, Chile)
10:13	Towards the development of upgrade-criteria for the use of biologics as first-line treatment in HS Georgios Nikolakis (Dessau, Germany)
10:25	Real-world efficacy and survival of biologic agents in the treatment of hidradenitis suppurativa in Greece Aikaterini Liakou (Athens, Greece)
10:37	Discussion
10:45	Six-month safety and effectiveness of upadacitinib in patients with moderate-to-severe hidradenitis suppurativa Elia Rosi (Florence, Italy)
10:57	Malignant transformation during anti-TNF treatment of hidradenitis suppurativa Gabija Rudzikaitė-Fergizė (Vilnius, Lithuania)
11:09	Assessment of clinician knowledge of hidradenitis suppurativa: Insights from a multidisciplinary survey study Klaudia Knecht-Gurwin (Wrocław, Poland)
11:21	Ultrasonography-guided MODES technique and mini graft combination in hidradenitis suppurativa surgery: A pilot study Yusuf Can Edek (Ankara, Türkiye)
11:33	Discussion and conclusion



Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.4

D1T08.1		Rosacea Chairs: Clio Dessinioti (Athens, Greece) Bernard Cribier (Strasbourg, France)
D1T08.1A	14:15	Update on patogenesis Martin Steinhoff (Doha, Qatar)
D1T08.1B	14:35	New classification of rosacea Jerry Tan (Ontario, Canada)
D1T08.1C	14:55	New therapeutic approach Bernard Cribier (Strasbourg, France)
D1T08.1D	15:15	Aggressive and difficult to treat rosacea Clio Dessinioti (Athens, Greece)
D1T08.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.4

D1T08.2		Climate change and environmental dermatology Chairs: Chris Callewaert (Gent, Belgium) Susana Puig (Barcelona, Spain)
D1T08.2A	16:00	Climate change and skin diseases Misha Rosenbach (Philadelphia, United States)
D1T08.2B	16:20	Influence of climate change on the microorganisms habitat Chris Callewaert (Gent, Belgium)
D1T08.2C	16:40	Indoor and outdoor pollution and effects on the skin Claudia Traidl-Hoffmann (Augsburg, Germany)
D1T08.2D	17:00	Are actinic keratoses an indicator for pollution? Susana Puig (Barcelona, Spain)
D1T08.2E	17:20	Discussion, Q&A



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 8:30 – 11:45 CEST

📍 ROOM 7.5

	ESLD - European Society for Lasers and energy based Devices Chairs: Ashraf Badawi (Oakville, Canada) Albert Wolkerstorfer (Amsterdam, Netherlands) Johan Snauwaert (Brussels, Belgium)
08:30	Challenges in treating pigmented lesions with lasers in dark skin Mukta Sachdev (Bangalore, India)
08:43	Tips and Tricks in laser physics and laser tissue interactions: Do we need photothermal or photomechanical effect to achieve your therapeutic goal? Leonardo Marini (Trieste, Italy)
08:56	Tips & Tricks in Laser treatment of benign pigmented lesions and tattoos Thierry Passeron (Nice, France)
09:09	Fractional Lasers versus Microneedling RF in Hair growth stimulation Rana Hilal (Egypt)
09:22	Tips & Tricks in laser treatment of some resistant skin problems Badea Jiryis (Haifa, Israel)
09:35	Tips & Tricks in Laser treatment of vascular lesions Albert Wolkerstorfer (Amsterdam, Netherlands)
09:48	Tips & Tricks in Laser Assisted Hair Reduction Hanan Nada (Cairo, Egypt)
10:01	Can we reduce the skin cancer burden with Lasers? Johan Snauwaert (Brussels, Belgium)
10:14	Tricks & Tricks in treating stretch marks with lasers Solwan El Samanoudy (Giza, Egypt)
10:27	Tips & Tricks in treating acne scars with lasers and microneedling RF Merete Haedersdal (Copenhagen, Denmark)
10:40	Energy based applications according the German Laser guidelines, What is new? Uwe Paasch (Leipzig, Germany)
10:53	Tips and Tricks in Laser applications in Dermatology by Prof. Pablo Boixeda Pablo Boixeda (Madrid, Spain)
11:06	Tips & Tricks in managing Dysmorphic concerns and reducing malpractice in laser clinics Cemre Turk (Boston, United States)
11:19	Tips & Tricks in marketing my Laser Practice NOUR ALTAJALI (Kuwait City, Kuwait)
11:32	Tips & Tricks in combination therapy for facial rejuvenation Ashraf Badawi (Oakville, Canada)

Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.5

DIT09.1		JAK inhibitors Chairs: Curdin Conrad (Lausanne, Switzerland) Andreas Wollenberg (Munich, Germany)
DIT09.1A	14:15	The expanding landscape of indications Curdin Conrad (Lausanne, Switzerland)
DIT09.1B	14:35	JAK selectivity: Is it relevant? Maryanne M. Senna (Winchester, United States)
DIT09.1C	14:55	Upcoming topical and systemic JAKs Kamran Ghoreschi (Berlin, Germany)
DIT09.1D	15:15	Safety and monitoring recommendations: MACE, thrombosis and cancer Andreas Wollenberg (Munich, Germany)
DIT09.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.5

DIT09.2		Vitiligo Chairs: Khaled Ezzedine (Créteil, France) Nanja van Geel (Gent, Belgium)
DIT09.2A	16:00	Update on vitiligo: New discoveries, new treatments, new hope John E. Harris (Worcester, United States)
DIT09.2B	16:20	New topical and systemic treatments Viktoria Eleftheriadou (Wolverhampton, United Kingdom)
DIT09.2C	16:40	Comorbidities in vitiligo: myths and reality Khaled Ezzedine (Créteil, France)
DIT09.2D	17:00	Physical interventions: triggers for vitiligo Nanja van Geel (Gent, Belgium)
DIT09.2E	17:20	Discussion, Q&A



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 8:30 – 10:00 CEST

📍 E107-E108

	SPIN - Skin Inflammation & Psoriasis International Network Chair: Wolf-Henning Boehncke (Geneva, Switzerland)
08:30	Introduction: SPIN – what is in there for me? Wolf-Henning Boehncke (Geneva, Switzerland)
08:40	The headline news - Alopecia areata Sergio Vaño-Galván (Madrid, Spain)
08:45	The headline news - Atopic dermatitis Tiago Torres (Porto, Portugal)
08:50	The headline news - Hidradenitis suppurativa Amit Garg (New York, United States)
08:55	The headline news - Psoriasis Curdin Conrad (Lausanne, Switzerland)
09:00	The headline news - Vitiligo Julien Seneschal (Bordeaux, France)
09:05	Round table - Revisiting patient-reported outcomes
09:18	Round table - Unravelling the disease: progress (and obstacles) in understanding the pathogenesis of IMIDs
09:30	Round table - Perspectives: disease modification, remission, and cure of IMIDs
09:43	Round table - Disease heterogeneity
09:55	Summary and conclusion Wolf-Henning Boehncke (Geneva, Switzerland)



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 10:15 – 11:45 CEST

📍 E107-E108

	GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Chairs: Joseph F. Merola (Boston, United States) April W. Armstrong (Studio City, United States) Laura Jane Savage (Leeds, United Kingdom)
10:15	PsA for the dermatologist: highlights from the updated PsA EULAR guidelines William Tillett (Bath, United Kingdom)
10:25	Patient preferences in psoriatic therapy: topical, oral, injectable Kenneth B. Gordon (Milwaukee, United States)
10:35	Combination therapy approaches to psoriatic disease treatment Joseph F. Merola (Boston, United States)
10:45	Is early disease intervention, remission and disease modification possible? The data in 2024 April W. Armstrong (Los Angeles, United States)
10:55	Shining a light on phototherapy: Results of the LITE study Joel Gelfand (Philadelphia, United States)
11:05	Y-Grappa updates Betul Macit (Istanbul, Türkiye)
11:15	Radiographic progression in PsA: What the dermatologist needs to know Frank Behrens (Frankfurt, Germany)
11:25	Novel treatment approaches to complex cases Alice B. Gottlieb (New York, United States)
10:15	PsA for the dermatologist: highlights from the updated PsA EULAR guidelines William Tillett (Bath, United Kingdom)



Wednesday, 25 September 2024

TRAINING AND EDUCATION

⌚ 14:15 – 15:45 CEST

📍 E107-108

DIT10.1		Acne and rosacea Chairs: Falk Ochsendorf (Frankfurt, Germany) Hugues Cartier (Arras, France)
DIT10.1A	14:15	Pathophysiology of acne and rosacea Falk Ochsendorf (Frankfurt, Germany)
DIT10.1B	14:35	Management of acne Lucero Noguera (Madrid, Spain)
DIT10.1C	14:55	Management of rosacea Dae Hun Suh (Seoul, South Korea)
DIT10.1D	15:15	Procedural therapies for acne and rosacea Hugues Cartier (Arras, France)
DIT10.1E	15:35	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 16:00 – 17:30 CEST

📍 E107-108

DIT10.2		Nail and hair disorders Chairs: David Saceda Corralo (Madrid, Spain) Bianca Maria Piraccini (Bologna, Italy)
DIT10.2A	16:00	Alopecia areata David Saceda Corralo (Madrid, Spain)
DIT10.2B	16:20	Dissecting cellulitis Bianca Maria Piraccini (Bologna, Italy)
DIT10.2C	16:40	Longitudinal melanonychia Michał Sobjanek (Gdansk, Poland)
DIT10.2D	17:00	Onychomatricoma Andre Lencastre (Alcabideche, Portugal)
DIT10.2E	17:20	Discussion, Q&A



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 08:30 – 11:45 CEST

📍 E103-E104

	GA²LEN - Global Allergy and Asthma Excellence Network Chairs:
08:30	Who is Ga²Len Torsten Zuberbier (Berlin, Germany)
08:40	Importance of GA²LEN in EADV Torsten Zuberbier (Berlin, Germany)
08:50	Updates on urticaria from GA²LEN UCARE Emek Kocatürk Göncü (Istanbul, Türkiye)
09:30	Q&A
09:40	ADCARE - Itch and pain in atopic dermatitis Manuel Pereira (Berlin, Germany)
10:00	Q&A
10:10	Updates on atopic dermatitis from ADCARE Torsten Zuberbier (Berlin, Germany)
10:50	Q&A



Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 E103-104

D1T11.1		Dermato-endocrinology Chairs: Ralf Paus (Miami, United States) Christos C. Zouboulis (Dessau, Germany)
D1T11.1A	14:15	Insuline resistance and the skin Christos C. Zouboulis (Dessau, Germany)
D1T11.1B	14:35	Thyroid-skin connection Ralf Paus (Miami, United States)
D1T11.1C	14:55	Menopause and the skin Claudia De Giovanni (Brighton, United Kingdom)
D1T11.1D	15:15	Skin problems in the transgender population Ayelet Rishpon (Tel Aviv, Israel)
D1T11.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 E103-104

D1T11.2		Vasculitis and vasculopathies Chairs: Robert Micheletti (Philadelphia, United States) Angelo Valerio Marzano (Milan, Italy)
D1T11.2A	16:00	New treatments of refractory livedoid vasculopathies Soyun Cho (Seoul, South Korea)
D1T11.2B	16:20	Targeted treatments for vasculitis Angelo Valerio Marzano (Milan, Italy)
D1T11.2C	16:40	Calciophylaxis Cornelia Erfurt-Berge (Erlangen, Germany)
D1T11.2D	17:00	ANCA-associated vasculitis Robert Micheletti (Philadelphia, United States)
D1T11.2E	17:20	Discussion, Q&A

Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 09:45 – 11:35 CEST

📍 G102-G103

	Euromelanoma Chairs: Veronique del Marmol (Brussels, Belgium) Mariano Suppa (Brussels, Belgium)
09:45	Welcome and introduction Mariano Suppa (Brussels, Belgium)
10:05	Chemoprevention of skin cancer: an update Carmen Orte Cano (Bruxelles, Belgium)
10:20	What's new in the field of AK Thomas Dirschka (Wuppertal, Germany)
10:40	EUSCAP: Risk factors for high frequency BCC Katharina Wunderlicht (Brussels, Belgium)
10:55	EUSCAP: SUNTRAC risk stratification in kidney OTR Wiam Al Bouzidi (Brussels, Belgium)
11:10	Euromelanoma 2025: A new campaign Philippe Pendaries (Tunbridge Wells, United Kingdom)
11:25	Final conclusions Mariano Suppa (Brussels, Belgium)

Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 G102-G103

D1T12.1		Dermatopathology Chairs: Mohamad Goldust (New Haven, United States) Jivko Kamarachev (Zurich, Switzerland)
D1T12.1A	14:15	What's new in histopathological techniques? Jivko Kamarachev (Zurich, Switzerland)
D1T12.1B	14:35	What's new in digital pathology? Speaker TBC
D1T12.1C	14:55	What's new in molecular pathology? Michael Tetzlaff (San Francisco, United States)
D1T12.1D	15:15	What's new in AI-driven dermatopathology? Mohamad Goldust (New Haven, United States)
D1T12.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 G102-G103

D1T12.2		Dermatopathology Chairs: Helmut Beltraminelli (CH Bellinzona, Switzerland) Eduardo Jaime Calonje (London, United Kingdom)
D1T12.2A	16:00	What's new in melanocytic tumors ? Arnaud De la Fourchardière (Lyon, France)
D1T12.2B	16:20	What's new in cutaneous lymphomas ? Helmut Beltraminelli (Bellinzona, Switzerland)
D1T12.2C	16:40	What's new in inflammatory dermatoses ? Franco Rongioletti (Milan, Italy)
D1T12.2D	17:00	What's new in panniculitis ? Eduardo Jaime Calonje (London, United Kingdom)
D1T12.2E	17:20	Discussion, Q&A

Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 08:30 – 11:45 CEST

📍 G104-G105

	ESPD - European Society for Photodermatology Chairs: Piergiacomo Calzavara-Pinton (Brescia, Italy) Yolanda Gilaberte (Zaragoza, Spain) Dilek Seckin (Istanbul, Türkiye) Serena Lembo (Italy) Thomas Haarmann-Stemmann (Germany) Marina Venturini (Brescia, Italy)
08:30	Photosensitivity and photodiagnostics - an evolving story Sally Helen Ibbotson (Dundee, United Kingdom)
09:30	Photoprotection according to skin phototypes Yolanda Gilaberte (Zaragoza, Spain)
09:45	UVA and UVB interactions in skin carcinogenesis Thomas Haarmann-Stemmann (Germany)
10:00	Digital photoprotection Piergiacomo Calzavara-Pinton (Brescia, Italy)
10:15	In vivo and ex vivo comparative study of NBUVB, methotrexate and apremilast in psoriasis patients Serena Lembo (Italy)
10:30	What's new in oral photoprotection Salvador González Rodríguez (Madrid, Spain)
10:45	Skin microbiome and photodermatoses Peter Wolf (Graz, Austria)



Wednesday, 25 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 G104-G105

D1T13.1		Skin ageing and rejuvenation Chairs: Hassan Galadari (Dubai, United Arab Emirates) Karin Scharffetter-Kochanek (Ulm, Germany)
D1T13.1A	14:15	Molecular mechanisms of skin ageing Hassan Galadari (Dubai, United Arab Emirates)
D1T13.1B	14:35	New molecules in anti-ageing medicine Karin Scharffetter-Kochanek (Ulm, Germany)
D1T13.1C	14:55	Are skin rejuvenation procedures evidence-based? Hassan Galadari (Dubai, United Arab Emirates)
D1T13.1D	15:15	Dysmorphic disorders in aesthetic dermatology Claudia Borelli (Tübingen, Germany)
D1T13.1E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 G104-G105

D1T13.2		Geriatric dermatology Chairs: Jürg Hafner (Zurich, Switzerland) Elke Weisshaar (Heidelberg, Germany)
D1T13.2A	16:00	Tailored treatments for skin cancer Isabelle Hoorens (Ghent, Belgium)
D1T13.2B	16:20	Managing itch in the elderly Elke Weisshaar (Heidelberg, Germany)
D1T13.2C	16:40	Leg ulcers Jürg Hafner (Zurich, Switzerland)
D1T13.2D	17:00	Hair and nail in the elderly Megan Mowbray (Dunfermline, United Kingdom)
D1T13.2E	17:20	Discussion, Q&A



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 08:30 – 10:00 CEST

📍 E102

	EWDVS - European Women Dermatological and Venereological Society Chairs: Carmen Rodríguez Cerdeira (Vigo, Spain) Brunilda Bardhi (Tirana, Albania) Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Republic)
08:30	Women's health promotion Carmen Rodríguez Cerdeira (Vigo, Spain)
08:40	Face rejuvenation in modern time Brunilda Bardhi (Tirana, Albania)
08:50	Different perspectives on cutaneous pathologies in dark skin Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Republic)
09:00	Hidradenitis Suppurativa. What's new? Monika Fida (Tirana, Albania)
09:10	Melasma: An update May Elsamahy (Cairo, Egypt)
09:20	Clinical and microbiological aspects of skin-related neglected tropical diseases. Experience in a developing country José Guillermo Pereira-Brunelli (San Lorenzo, Paraguay)
09:30	Psychological condition in dermatological patients Adriana López-Bárcenas (Morelia, Mexico)
09:40	New topical anti-inflammatory drugs Nayera Moftah (Cairo, Egypt)
09:50	Questions and answers



Wednesday, 25 September 2024

SUBSPECIALTY SESSION

⌚ 08:30 – 10:00 CEST

📍 E102

	PALD - European Women Dermatological and Venereological Society Chairs: Riad Mashal (Ramallah, Palestine) Gamal Elduweb (Benghazi, Libya) Mohamed Bengazil (Tripoli, Libya)
10:15	Exosome in regenerative medicine Roxanna Sadoughifar (Iran)
10:25	Intralesional cryosurgery for the treatment of keloid scars Amal Chamli (Tunis, Tunisia)
10:35	Difficult clinical cases in lasers Mohammed Rachid Hamlaoui (Oran, Algeria)
10:45	Biosimilars in the treatment of psoriasis in Libyan patients Ibrahim Almukahal (Benghazi, Libya)
10:55	Alternating and coexisting diseases. Is it a true concept ? Khalil Ismail Mohammed Alhamdi (Iraq)
11:05	Jak inhibitors in the treatment of skin Inflammatory skin diseases Riad Mashal (Ramallah, Palestine)
11:15	Therapeutic options of Lifa disease Muhsin Al Dhalimi (Najaf, Iraq)
11:25	Recurrent dermatophytosis: New treatment modality Dooha Alhamdi (Basra, Iraq)
11:35	Pruritis with diabetes Aymen Alshami (Yemen)

Wednesday, 25 September 2024

MISCELLANEOUS

⌚ 14:15 – 15:45 CEST

📍 E102

DIT14.3		History of dermatology Chairs: Michael Lukas Geiges (Kloten, Switzerland) Lawrence Chukwudi Nwabudike (Bucharest, Romania)
DIT14.3A	14:15	Our heritage in dermatology is naturopathic, what will our legacy be? Lawrence Chukwudi Nwabudike (Bucharest, Romania)
DIT14.3B	14:35	Guy de Chauliac: one of the first dermatologists? Christian Diehl (Cordoba, Argentina)
DIT14.3C	14:55	The history of leprosy told by bones: a systematic review on human remains findings Patricia Deps (Vitoria, Brazil)
DIT14.3D	15:15	Women in the history of dermatology: Test subjects in dermatological-venereological research Michael Lukas Geiges (Kloten, Switzerland)
DIT14.3E	15:30	Report on the founding meeting of the International Working Group for Wax Moulages Michael Lukas Geiges (Kloten, Switzerland)
DIT14.3F	15:35	Discussion, Q&A

MISCELLANEOUS

⌚ 14:15 – 15:45 CEST


📍 E102

DIT14.4		Skin diseases in Latin America Chairs: Jose Luis Lopez-Estebanz (Madrid, Spain) Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Rep.)
DIT14.4A	16:00	Cats and sporothricosis: the perfect storm Omar Lupi (Rio De Janeiro, Brazil)
DIT14.4B	16:10	Leishmaniasis: an update José Manuel Ríos-Yuil (Ciudad de Panama, Panama)
DIT14.4C	16:20	Scurvy, an emerging disease Judith Dominguez-Cherit (Ciudad de Mexico, Mexico)
DIT14.4E	16:30	Ivermectin in dermatology Jose Luis Lopez-Estebanz (Madrid, Spain)
DIT14.4F	16:40	Challenges in differential diagnosis of tropical dermatology Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Republic)
DIT14.4G	16:50	Subincisions in Mexican patients: Is there any difference? Rosa María Ponce Olivera (México, Mexico)
DIT14.4H	17:00	Discussion, Q&A

D1T14.4A	16:00	Cats and sporothricosis: the perfect storm Omar Lupi (Rio De Janeiro, Brazil)
----------	-------	---

Wednesday, 25 September 2024

ePOSTER SHOWCASE

 **14:15 – 15:45 CEST**

 **OPEN STAGE**

EPS01		ePoster showcase
EPS01.01	14:15	Beyond the surface: Exploring dupilumab's efficacy in palmoplantar pustulosis and the critical role of Th2 inflammation Yuxin Zheng (Hangzhou, China)
EPS01.02	14:25	Anti-IL-15 neutralizing antibody counteracts vitiligo in a humanized mouse model Ela Elyada (Netanya, Israel)
EPS01.03	14:35	Dysregulation of the IL-33/sST2 pathway in prurigo nodularis Lai San Wong (Kaohsiung, Taiwan)
EPS01.04	14:45	Patient characteristics and comorbidities in moderate-to-severe CHE: Results from the RWEAL study Maria Concetta Fargnoli (Aquila, Italy)
EPS01.05	14:55	EPS01.05: Early serum markers for Immune checkpoint inhibitor induced hypophysitis in melanoma patients Fouad Mitri (Biel, Switzerland)
EPS01.06	15:05	EPS01.06: Global Delphi consensus on treatment goals for generalised pustular psoriasis (GPP) Diamant Thaçi (Luebeck, Germany)
EPS01.07	15:15	Serological biomarkers of immune-cell activity and tissue destruction are associated with disease severity in patients with prurigo nodularis Signe Holm Nielsen (Herlev, Denmark)
EPS01.08	15:25	Sensory symptoms as an early manifestation of active vitiligo: a case control clinical and molecular study Hagar El Sayed (Cairo, Egypt)
EPS01.09	15:35	Dupilumab breaks the “itch-scratch cycle” in chronic prurigo João Teixeira (Coimbra, Portugal)

Wednesday, 25 September 2024

ePOSTER SHOWCASE

⌚ 16:00 – 17:30 CEST

📍 OPEN STAGE

EPS02		ePoster showcase
EPS02.01	16:00	Aquaporin 1, 8 and 9 expression: possible correlation with prognosis and clinical outcome on malignant melanoma Lara Camillo (Novara, Italy)
EPS02.02	16:10	Advanced basal cell carcinoma: clinical and histological predictors of tumor recurrence after complete response on hedgehog inhibitors Maria Mannino (Catania, Italy)
EPS02.03	16:20	Biomarkers of the tumor immune micro-environment for management of anal pre-cancers Fernando Dias Goncalves Lima (Amsterdam, Netherlands)
EPS02.04	16:30	Fatigue and Pain in Patients With Psoriasis and Oligoarticular Psoriatic Arthritis and Improvements on Apremilast Treatment: 48-Week Data From FOREMOST
EPS02.05	16:40	Tackling self-stigma in chronic skin disease – Development and evaluation of the SkinCompass Online Programme Rachel Sommer (Hamburg, Germany)
EPS02.06	16:50	From patients' needs to a digital, personalised melanoma survivorship care plan Nadia Kamminga (Rotterdam, Netherlands)
EPS02.07	17:00	International survey on training of dermatology residents in supportive oncodermatology: the RESCUE study Ariadna Ortiz (Toulouse, France)
EPS02.08	17:10	Drug supply for psoriasis in transition: 15 years of experience in the German Psoriasis Registry PsoBest Matthias Augustin (Hamburg, Germany)
EPS02.09	17:20	Therapeutic management of infantile hemangiomas with beta-blockers Himeur Zoulikha (TLEMCEEN, Algeria)

Scientific Programme

Thursday, 26 September 2024

Programme at a glance

Plenary lecture	12:00 – 13:00
Auditorium	Plenary Lectures B

Sessions	08:30 – 10:00	10:15 – 11:45	14:15 – 15:45	16:00 – 17:30
Auditorium	Focus on hidradenitis suppurativa	Focus on hidradenitis suppurativa	Late breaking news	Late breaking news
Elicium	Atopic dermatitis	Atopic dermatitis	Sclerotic skin diseases	Genital diseases
Room 3.1	Paediatric dermatology: Infectious diseases	Paediatric dermatology: Inflammatory diseases	Paediatric dermatology: Congenital malformations	Paediatric dermatology: Dermato-oncology
Forum	Melanoma	Melanoma	Genetics of common diseases	Genetics of rare diseases
Room 7.1	Immediate type allergies	Contact eczema	Chronic urticaria	Drug eruptions
Room 7.2	Dermatosurgery (Part 1)	Dermatosurgery (Part 2)	Mohs surgery	Management of inoperable skin cancer
Room 7.3	Hair disorders	Hair disorders	Alopecia areata	Nail disorders
Room 7.4	Controversies I	Controversies II	Controversies III	Controversies IV
Room 7.5	Basal cell carcinoma	Squamous cell carcinoma	Melanoma	Melanoma
E107-E108	Atopic dermatitis	Non atopic eczema	Drug reactions	Vasculitis
E103-E104	Fillers I, Basics	Botulinum toxin I, Basics	Lasers and energy-based devices. Practical aspects of basics	Patient selection and practice management
G102-G103	STI screening	STI prevention	HIV	Scabies
G104-G105	Free Communications 1	Free Communications 2	Free Communications 3	Free Communications 4
E102	Collaborating in novel ways to elevate dermatology research	EADV research funding and fellowships	Ethics, diversity and inclusion	Best of Dermatology papers 2024: a panoramic view
D202	Dermoscopy – Practical and conceptual		Chemical peelings	
D203	Medical photography in dermatology		Playing with AI in dermatology	
Open stage	ePoster showcase	ePoster showcase	ePoster showcase	ePoster showcase

Thursday, 26 September 2024

PLENARY SESSION

⌚ 12:00 – 13:00 CEST

📍 AUDITORIUM

	Plenary lectures B Chairs: Michel Gilliet (Lausanne, Switzerland) Branka Marinovic (Zagreb, Croatia)
12:00	Do big data make us bigger? Tamar Nijsten (Rotterdam, Netherlands)
12:20	Pustular psoriasis: clinical continuum or separate entity? Jonathan Barker (London, United Kingdom)
12:40	Climate change, pollution and skin cancer Susana Puig (Barcelona, Spain)

Thursday, 26 September 2024

FOCUS ON

⌚ 08:30 – 10:00 CEST

📍 AUDITORIUM

D2T01.1		Focus on hidradenitis suppurativa Chairs: Thrasyvoulos Tzellos (Bodø, Norway) Kelsey R. van Straalen (Rotterdam, Netherlands)
D2T01.1A	08:30	Novel aspects in pathogenesis Errol Prens (Rotterdam, Netherlands)
D2T01.1B	08:50	Comorbidities: How to screen and take them into account Kelsey R. van Straalen (Rotterdam, Netherlands)
D2T01.1C	09:10	A multidisciplinary approach: Improving the patient journey Gregor Borut Jemec (Roskilde, Denmark)
D2T01.1D	09:30	New evidence-based guidelines Thrasyvoulos Tzellos (Bodø, Norway)
D2T01.1E	09:50	Discussion, Q&A

FOCUS ON

⌚ 10:15 – 11:45 CEST

📍 AUDITORIUM

D2T01.2		Focus on hidradenitis suppurativa Chairs: Robert Emil Hunger (Bern, Switzerland) Francesca Prignano (Florence, Italy)
D2T01.2A	10:15	Novel outcome measures for your daily clinical practice Francesca Prignano (Florence, Italy)
D2T01.2B	10:35	Endotypes-directed treatment Hessel van der Zee (Rotterdam, Netherlands)
D2T01.2C	10:55	Surgery and combination treatments Antonio Martorell Calatayud (Valencia, Spain)
D2T01.2D	11:15	New and emerging treatments Robert Emil Hunger (Bern, Switzerland)
D2T01.2E	11:35	Discussion, Q&A

D2T01.3		Late breaking news Chairs: Michel Gilliet (Lausanne, Switzerland) Yolanda Gilaberte Calzada (Zaragoza, Spain)
D2T01.3A	14:15	Targeting IL-22RA1 with temtokibart in patients with moderate to severe atopic dermatitis induces fast clinical and molecular responses, distinct from dupilumab Christine Bangert (Vienna, Austria)
D2T01.3B	14:30	Cardiovascular effects of JAK inhibitors in atopic dermatitis: A retrospective cohort study Amina El Ayadi (Galveston, United States)
D2T01.3C	14:45	Secreted phosphoprotein 1-CD44 axis downregulation promotes melanocyte senescence through ROS generation Yul Hee Kim (Yeongtong-gu, Suwon-si, South Korea)
D2T01.3D	15:00	Ruxolitinib cream for mild-to-moderate hidradenitis suppurativa: 32-week data from a randomized phase 2 study Martina L Porter (Boston, United States)
D2T01.3E	15:15	Impact of treatment duration on response durability: A post hoc analysis of the TRuE-V long-term extension study of ruxolitinib cream in vitiligo David Rosmarin (Indianapolis, United States)
D2T01.3F	15:30	Efficacy and safety of oral povorcitinib in patients with prurigo nodularis: 40-week results from a randomized, double-blind, placebo-controlled phase 2 study Shawn Kwatra (Baltimore, United States)



Thursday, 26 September 2024

LATE BREAKING NEWS

⌚ 16:00 – 17:30 CEST

📍 AUDITORIUM

D2T01.4		Late breaking news Chairs: Margarida Gonçalo (Coimbra, Portugal) Lidia Rudnicka (Warsaw, Poland)
D2T01.4A	16:00	52-week safety and disease control with ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from the phase 3 TRuE-AD3 study Amy Paller (Chicago, IL, United States)
D2T01.4B	16:15	Development of a staphylococcus epidermidis strain for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity Mary Clare Spellman (San Francisco, United States)
D2T01.4C	16:30	Phase I study results of a novel immunomodulatory peptide, TCP-25, for treatment of dystrophic epidermolysis bullosa Artur Schmidtchen (Lund, Sweden)
D2T01.4D	16:45	Growth analysis in children aged 6 to 11 years with severe atopic dermatitis and impact of 16 weeks of dupilumab treatment on height Alan Irvine (Dublin, Ireland)
D2T01.4E	17:00	Efficacy and safety of the oral interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor zabedoseritib in adult patients with moderate-to-severe atopic dermatitis – Results of the phase 2a DAMASK study Stefan Jodl (Berlin, Germany)
D2T01.4F	17:15	Randomized controlled investigator-blinded comparative study of the efficacy and tolerability of a new 2-MNG containing serum versus Cysteamine 5% in the treatment of melasma Mukta Sachdev (Bangalore, India)

Thursday, 26 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ELICIUM

D2T02.1		Atopic dermatitis Chairs: Giovanni Damiani (Milan, Italy) Lisa Beck (Rochester, United States)
D2T02.1A	08:30	The role of <i>S. Aureus</i> Lisa Beck (Rochester, United States)
D2T02.1B	08:50	Immune mechanisms, biomarkers and novel therapeutic targets Christoph Schlapbach (Bern, Switzerland)
D2T02.1C	09:10	Environmental exposure as driver of allergic disease Marc Vocanson (Lyon, France)
D2T02.1D	09:30	Systemic comorbidities in AD Giovanni Damiani (Milan, Italy)
D2T02.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ELICIUM

D2T02.2		Atopic dermatitis Chair: Tilo Biedermann (Munich, Germany) Emma Guttman-Yassky (New York, United States)
D2T02.2A	10:15	Adult-onset AD: What is it? Emma Guttman-Yassky (New York, United States)
D2T02.2B	10:35	Microbiome modulation: Prevention or treatment of AD? Tilo Biedermann (Munich, Germany)
D2T02.2C	10:55	Hard to identify and treat AD Phyllis I. Spuls (Amstelveen, Netherlands)
D2T02.2D	11:15	New topical and systemic treatments Robert Bissonnette (Montreal, Canada)
D2T02.2E	11:35	Discussion, Q&A



Thursday, 26 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ELICIUM

D2T02.3		Sclerotic skin diseases Chairs: Pia Moinzadeh (Cologne, Germany) Franco Rongioletti (Milan, Italy)
D2T02.3A	14:15	Pathomechanisms of skin fibrosis and novel therapeutic targets Veli-Matti Kähäri (Turku, Finland)
D2T02.3B	14:35	Eosinophilic fasciitis Franco Rongioletti (Milan, Italy)
D2T02.3C	14:55	Localized Scleroderma Hirotsugu Oda (Cologne, Germany)
D2T02.3D	15:15	Systemic sclerosis Pia Moinzadeh (Cologne, Germany)
D2T02.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ELICIUM

D2T02.4		Genital diseases Chairs: Gudula Kirtschig (Tübingen, Germany) Giuseppe Argenziano (Naples, Italy)
D2T02.4A	16:00	Preventing STDs Derek Freedman (Dublin, Ireland)
D2T02.4B	16:20	Lichen sclerosus genitalis Gudula Kirtschig (Tübingen, Germany)
D2T02.4C	16:40	Dermoscopy of mucosal lesions Giuseppe Argenziano (Naples, Italy)
D2T02.4D	17:00	Non-infectious balanitis Sarah Edwards (Bury St Edmunds, United Kingdom)
D2T02.4E	17:20	Discussion, Q&A



Thursday, 26 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 3.1

D2T03.1		Paediatric dermatology: Infectious diseases Chairs: Martin Theiler (Zurich, Switzerland) Regina Fölster-Holst (Kiel, Germany)
D2T03.1A	08:30	The skin microbiome in children Yuval Ramot (Jerusalem, Israel)
D2T03.1B	08:50	Viral diseases in children Martin Theiler (Zurich, Switzerland)
D2T03.1C	09:10	Bacterial diseases in children Regina Fölster-Holst (Kiel, Germany)
D2T03.1D	09:30	Cutaneous leishmaniasis in children Francesco Borgia (Messina, Italy)
D2T03.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 3.1

D2T03.2		Paediatric dermatology: Inflammatory diseases Chairs: Marieke Seyger (Nijmegen, Netherlands) Amy Paller (Chicago, United States)
D2T03.2A	10:15	Psoriasis in children Marieke Seyger (Nijmegen, Netherlands)
D2T03.2B	10:35	Atopic dermatitis in children Amy Paller (Chicago, United States)
D2T03.2C	10:55	Hidradenitis suppurativa in children Joan Garcia Ladaría (Palma, Spain)
D2T03.2D	11:15	Acne and related disorders in pre-pubertal children Peter Hoeger (Hamburg, Germany)
D2T03.2E	11:35	Discussion, Q&A



Thursday, 26 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 3.1

D2T03.3		Paediatric dermatology: Congenital malformations Chairs: Andrea Diociaiuti (Roma, Italy) Lisa Weibel (Zurich, Switzerland)
D2T03.3A	14:15	Vascular malformations: pathogenesis Miikka Vikkula (Brussels, Belgium)
D2T03.3B	14:35	Vascular malformations: diagnostic and therapeutic approaches Eulàlia Baselga (Barcelona, Spain)
D2T03.3C	14:55	Non vascular congenital malformations: pathogenesis Andrea Diociaiuti (Roma, Italy)
D2T03.3D	15:15	Non vascular congenital malformations: diagnostic and therapeutic approaches Lisa Weibel (Zurich, Switzerland)
D2T03.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 3.1

D2T03.4		Paediatric dermatology: Dermato-oncology Chairs: Antonio Torrelo (Madrid, Spain) Iris Wohlmuth-Wieser (Salzburg, Austria)
D2T03.4A	16:00	Mastocytosis Antonio Torrelo (Madrid, Spain)
D2T03.4B	16:20	Pediatric malignant mesenchymal tumors Sylvie Fraitag (Paris, France)
D2T03.4C	16:40	Lymphoproliferative diseases Iris Wohlmuth-Wieser (Salzburg, Austria)
D2T03.4D	17:00	Melanoma in children Riccardo Pampena (Milan, Italy)
D2T03.4E	17:20	Discussion, Q&A



Thursday, 26 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 FORUM

D2T04.1		Melanoma Chairs: Yannick Elshot (Amsterdam, Netherlands) Josep Malvehy (Barcelona, Spain)
D2T04.1A	08:30	Prevention and epidemiology Dagmar Whitacker (Cape Town, South Africa)
D2T04.1B	08:50	Imaging techniques in melanoma Josep Malvehy (Barcelona, Spain)
D2T04.1C	09:10	Classification Yannick Elshot (Amsterdam, Netherlands)
D2T04.1D	09:30	Uveal, mucosal and acral melanoma Christoph Hoeller (Wien, Austria)
D2T04.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 FORUM

D2T04.2		Melanoma Chairs: Martin Röcken (Tübingen, Germany) Simone Ribero (Torino, Italy)
D2T04.2A	10:15	Biopsy excision margins and second excision Eduardo Nagore (Valencia, Spain)
D2T04.2B	10:35	Can we cure our patients with adjuvant treatment? Christian Posch (Wien, Austria)
D2T04.2C	10:55	The role of neoadjuvant treatment Simone Ribero (Torino, Italy)
D2T04.2D	11:15	Biomarker-based treatment of melanoma Martin Röcken (Tübingen, Germany)
D2T04.2E	11:35	Discussion, Q&A

Thursday, 26 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 FORUM

D2T04.3		Genetics of common diseases Chairs: Michael Simpson (London, United Kingdom) Yuval Ramot (Jerusalem, Israel)
D2T04.3A	14:15	Somatic mutations driving inflammatory diseases Yuval Ramot (Jerusalem, Israel)
D2T04.3B	14:35	Genetics-driven drug discovery Johann Bauer (Salzburg, Austria)
D2T04.3C	14:55	Genetic determinants of host response to infections Vinod Kumar (Nijmegen, Netherlands)
D2T04.3D	15:15	GWAS: highs and lows Michael Simpson (London, United Kingdom)
D2T04.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 FORUM

D2T04.4		Genetics of rare diseases Chairs: Veronica Kinsler (London, United Kingdom) Pierre Vabres (Dijon, France)
D2T04.4A	16:00	Gene therapy Alain Hovnanian (Paris, France)
D2T04.4B	16:20	Advanced cell therapy Su Lwin (London, United Kingdom)
D2T04.4C	16:40	New genetic skin diseases Pierre Vabres (Dijon, France)
D2T04.4D	17:00	What can rare diseases teach us about common skin disorders Veronica Kinsler (London, United Kingdom)
D2T04.4E	17:20	Discussion, Q&A

Thursday, 26 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.1

D2T05.1		Immediate type allergies Chairs: Ana Giménez-Arnau (Barcelona, Spain) Dagmar Simon (Bern, Switzerland)
D2T05.1A	08:30	Food allergies Torsten Zuberbier (Berlin, Germany)
D2T05.1B	08:50	Aero-allergens and atopic dermatitis: What is the link? Dagmar Simon (Bern, Switzerland)
D2T05.1C	09:10	Immediate contact hypersensitivity reactions: From contact urticaria to protein contact dermatitis Ana Giménez-Arnau (Barcelona, Spain)
D2T05.1D	09:30	Drug anaphylaxis Johannes Ring (Munich, Germany)
D2T05.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 14:15 CEST

📍 ROOM 7.1

D2T05.2		Contact eczema Chairs: Thomas Rustemeyer (Amsterdam, Netherlands) Marie-Louise Schuttelaar (Groningen, Netherlands)
D2T05.2A	10:15	Update on pathophysiology Thomas Rustemeyer (Amsterdam, Netherlands)
D2T05.2B	10:35	New allergens in 2024 Jeanne Duus Johansen (Hellerup, Denmark)
D2T05.2C	10:55	Allergic contact dermatitis to medical devices Ann Goossens (Leuven, Belgium)
D2T05.2D	11:15	Phenotype-directed treatment of hand eczema Marie-Louise Schuttelaar (Groningen, Netherlands)
D2T05.2E	11:35	Discussion, Q&A

Thursday, 26 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.1

D2T05.3		Chronic urticaria Chairs: Christian Vestergaard (Aarhus N, Denmark) Martin Metz (Berlin, Germany)
D2T05.3A	14:15	From pathophysiology to phenotypes Martin Metz (Berlin, Germany)
D2T05.3B	14:35	Difficult to treat chronic urticaria Christian Vestergaard (Aarhus N, Denmark)
D2T05.3C	14:55	New treatments in the pipeline Emek Kocatürk Göncü (Istanbul, Türkiye)
D2T05.3D	15:15	Recognising different types of angioedema Thomas Buttgereit (Berlin, Germany)
D2T05.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.1

D2T05.4		Drug eruptions Chairs: Annick Barbaud (Paris, France) Maja Mockenhaupt (Freiburg, Germany)
D2T05.4A	16:00	Pathogenesis of severe drug eruptions Wen-hung Chung (Taoyuan, Taiwan)
D2T05.4B	16:20	Diagnostic workup of severe drug eruptions Wolfram Hoetzenecker (Linz, Austria)
D2T05.4C	16:40	AGEP versus GPP: what is the difference? Annick Barbaud (Paris, France)
D2T05.4D	17:00	Managing SJS/TEN Maja Mockenhaupt (Freiburg, Germany)
D2T05.4E	17:20	Discussion, Q&A

Thursday, 26 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.2

D2T06.1		Dermatosurgery (Part 1) Chairs: Severin Läuchli (Zurich, Switzerland) John Paoli (Gothenburg, Sweden)
D2T06.1A	08:30	Perioperative antibiotic prophylaxis in skin surgery Daniela Hartmann (Munich, Germany)
D2T06.1B	08:50	Imaging techniques for tumor location and demarcation prior to Mohs surgery Cristian Navarrete-Dechent (Santiago, Chile)
D2T06.1C	09:10	Risk factors for needing ≥3 stages during Mohs surgery Asa Ingvar (Lund, Sweden)
D2T06.1D	09:30	Surgical margins for lentigo maligna - a critical review John Paoli (Gothenburg, Sweden)
D2T06.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.2

D2T06.2		Dermatosurgery (Part 2) Chairs: John Paoli (Gothenburg, Sweden) Severin Läuchli (Zurich, Switzerland)
D2T06.2A	10:15	Reconstructions: nose 1 Severin Läuchli (Zurich, Switzerland)
D2T06.2B	10:25	Reconstructions: nose 2 Ally-Khan Somani (Indianapolis, United States)
D2T06.2C	10:35	Reconstructions: perioral 1 Michael Muhlstadt (Geneva, Switzerland)
D2T06.2D	10:45	Reconstructions: perioral 2 Goran van Rooijen (Haarlem, Netherlands)
D2T06.2E	10:55	Reconstructions: periocular 1 Tri Nguyen (Spring, United States)
D2T06.2F	11:05	Reconstructions: periocular 2 Jean-Michel Amici (Bordeaux, France)
D2T06.2G	11:15	Reconstructions: trunk and extremities 1 Joseph Alcalay (Tel Aviv, Israel)
D2T06.2H	11:25	Reconstructions: trunk and extremities 2 Aleksandar Krunic (Chicago, United States)
D2T06.2I	11:35	Discussion, Q&A

Thursday, 26 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.2

D2T06.3		Mohs surgery Chairs: Aleksandar Kronic (Chicago, United States) Annika Van Rengen (Dordrecht, Netherlands)
D2T06.3A	14:15	Neoadjuvant therapy in locally advanced cancer Aleksandar Kronic (Chicago, United States)
D2T06.3B	14:35	The role of in-vivo and ex-vivo confocal microscopy Javier Perez-Anker (Barcelona, Spain)
D2T06.3C	14:55	Use of mohs surgery in non-keratinocytic tumours Mihaela Leventer (Bucharest, Romania)
D2T06.3D	15:15	Tips and tricks for multi-stage Mohs procedures Annika Van Rengen (Dordrecht, Netherlands)
D2T06.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.2

D2T06.4		Management of inoperable skin cancer Chairs: Azael Freites Martinez (Madrid, Spain) Alexander Stratigos (Athens, Greece)
D2T06.4A	16:00	Radiotherapy Meritxell Arenas (Tarragona, Spain)
D2T06.4B	16:20	Topical and systemic treatments Alexander Stratigos (Athens, Greece)
D2T06.4C	16:40	Combination treatments Azael Freites Martinez (Madrid, Spain)
D2T06.4D	17:00	Palliative care Mor Miodovnik (Tel Aviv, Israel)
D2T06.4E	17:20	Discussion, Q&A

Thursday, 26 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.3

D2T07.1		Hair disorders Chairs: Bianca Maria Piraccini (Bologna, Italy) Marta Sar-Pomian (Warsaw, Poland)
D2T07.1A	08:30	Hair follicle microenvironment Ralf Paus (Miami, United States)
D2T07.1B	08:50	Trichoscopy and imaging techniques Marta Sar-Pomian (Warsaw, Poland)
D2T07.1C	09:10	Female androgenetic alopecia Bianca Maria Piraccini (Bologna, Italy)
D2T07.1D	09:30	Male androgenetic alopecia Dimitrios Ioannides (Thessaaloniki, Greece)
D2T07.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.3

D2T07.2		Hair disorders Chairs: Alexander Katoulis (Athens, Greece) Ralph Trüeb (Zürich, Switzerland)
D2T07.2A	10:15	Workup for telogen effluvium Ralph Trüeb (Zürich, Switzerland)
D2T07.2B	10:35	Scarring alopecia Alexander Katoulis (Athens, Greece)
D2T07.2C	10:55	Infectious alopecia Nino Lortkipanidze (Tbilisi, Georgia)
D2T07.2D	11:15	Hair transplantation Nina Otberg (Potsdam, Germany)
D2T07.2E	11:35	Discussion, Q&A

Thursday, 26 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.3

D2T07.3		Alopecia areata Chairs: Monika Arenbergerova (Prague, Czech Republic) Lidia Rudnicka (Warsaw, Poland)
D2T07.3A	14:15	Pathophysiology of alopecia areata Jerry Shapiro (New York, United States)
D2T07.3B	14:35	Paediatric alopecia areata Ramon Grimalt (Terrassa, Spain)
D2T07.3C	14:55	Late onset alopecia areata Monika Arenbergerova (Prague, Czech Republic)
D2T07.3D	15:15	Managing alopecia areata in the era of JAK inhibitors Lidia Rudnicka (Warsaw, Poland)
D2T07.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.3

D2T07.4		Nail disorders Chairs: Bertrand Richert (Brussels, Belgium) Matilde Iorizzo (Lugano, Switzerland)
D2T07.4A	16:00	Ultrasound of the nail apparatus Ximena Wortsman (Santiago, Chile)
D2T07.4B	16:20	Infections of the nail Michela Starace (Bologna, Italy)
D2T07.4C	16:40	Psoriasis and lichen planus in nails Matilde Iorizzo (Lugano, Switzerland)
D2T07.4D	17:00	Nail tumours Bertrand Richert (Brussels, Belgium)
D2T07.4E	17:20	Discussion, Q&A



Thursday, 26 September 2024

CONTROVERSIES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.4

D2T08.1		Controversies I Chairs: Monika Arenbergerova (Prague, Czech Republic) Brigitte Dréno (Nantes, France)
D2T08.1A	08:30	Introduction Monika Arenbergerova (Prague, Czech Republic)
D2T08.1B	08:35	Should Oral minoxidil be our first choice for alopecia? YES Sergio Vaño-Galván (Madrid, Spain)
D2T08.1C	08:50	Should Oral minoxidil be our first choice for alopecia? NO Ralph Trüeb (Zürich, Switzerland)
D2T08.1D	09:05	Discussion, Q&A
D2T08.1E	09:15	Introduction Brigitte Dréno (Nantes, France)
D2T08.1F	09:20	Should we stick to reaching the cumulative dose of isotretinoin in acne: Yes Vincenzo Bettoli (Ferrara, Italy)
D2T08.1G	09:35	Should we stick to reaching the cumulative dose of isotretinoin in acne: NO Alison Layton (York, United Kingdom)
D2T08.1H	09:50	Discussion, Q&A

CONTROVERSIES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.4

D2T08.2		Controversies II Chairs: Jo LW Lambert (Ghent, Belgium) Hok Bing Thio (Rotterdam, Netherlands)
D2T08.2A	10:15	Introduction Jo LW Lambert (Ghent, Belgium)
D2T08.2B	10:20	Nutritional supplements in dermatology. Is there evidence? YES Apostolos Pappas (Branchburg, United States)
D2T08.2C	10:35	Nutritional supplements in dermatology. Is there evidence? NO Charlotte Näslund Koch (Hellerup, Copenhagen, Denmark)
D2T08.2D	10:50	Discussion, Q&A
D2T08.2E	11:00	Introduction Hok Bing Thio (Rotterdam, Netherlands)
D2T08.2F	11:05	Diet for acne patients. Is it beneficial? YES Rieke Driessen (Nijmegen, Netherlands)
D2T08.2G	11:20	Diet for acne patients. Is it beneficial? NO Jerry Tan (Ontario, Canada)
D2T08.2H	11:35	Discussion, Q&A



Thursday, 26 September 2024

CONTROVERSIES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.4

D2T08.3		Controversies III Chairs: Paola Pasquali (Cambrils, Spain) Alexander Navarini (Basel, Switzerland)
D2T08.3A	14:15	Introduction Alexander Navarini (Basel, Switzerland)
D2T08.3B	14:20	Is teledermatology ready to replace face to face consultations? Yes Jonathan Shapiro (Ramat Hasharon, Israel)
D2T08.3C	14:35	Is teledermatology ready to replace face to face consultations? NO Paola Pasquali (Cambrils, Spain)
D2T08.3D	14:50	Discussion, Q&A
D2T08.3E	14:55	Introduction Paola Pasquali (Cambrils, Spain)
D2T08.3F	15:00	Are imaging techniques really needed in dermatology? YES Elisa Cinotti (Siena, Italy)
D2T08.3G	15:15	Are imaging techniques really needed in dermatology? NO Nellie Konnikov (Boston, United States)
D2T08.3H	15:30	Discussion, Q&A

CONTROVERSIES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.4

D2T08.4		Controversies IV Chairs: Barbara Horvath (Groningen, Netherlands) Jan Gutermuth (Brussels, Belgium)
D2T08.4A	16:00	Introduction Barbara Horvath (Groningen, Netherlands)
D2T08.4B	16:05	Malignancy in Bullous pemphigoid: do we need to screen? YES Nisha Suyien Chandran (Singapore, Singapore)
D2T08.4C	16:20	Malignancy in Bullous pemphigoid: do we need to screen? No Aikaterini Patsatsi (Thessaloniki, Greece)
D2T08.4D	16:35	Discussion, Q&A
D2T08.4E	16:45	Introduction Jan Gutermuth (Brussels, Belgium)
D2T08.4F	16:50	Do we need in-patient beds for dermatology care? Yes Matthias Schmuth (Innsbruck, Austria)
D2T08.4G	17:05	Do we need in-patient beds for dermatology care? No Claus Zachariae (Hellerup, Denmark)
D2T08.4H	17:20	Discussion, Q&A

Thursday, 26 September 2024

TRAINING AND EDUCATION

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.5

D2T09.1		Basal cell carcinoma Chairs: Ignasi Martí-Martí (Barcelona, Spain) Tamar Nijsten (Rotterdam, Netherlands)
D2T09.1A	08:30	Epidemiology and prognostic factors Tamar Nijsten (Rotterdam, Netherlands)
D2T09.1B	08:50	Imaging diagnosis Linda Tognetti (Siena, Italy)
D2T09.1C	09:10	Surgical management Ignasi Martí-Martí (Barcelona, Spain)
D2T09.1D	09:30	Non surgical options Eva Backman (Goteborg, Sweden)
D2T09.1E	09:50	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.5

D2T09.2		Squamous cell carcinoma Chairs: Nicole Basset-Seguín (Paris, France) Iris Zalaudek (Trieste, Italy)
D2T09.2A	10:15	Epidemiology and prognostic factors Nicole Basset-Seguín (Paris, France)
D2T09.2B	10:35	Imaging diagnosis Iris Zalaudek (Trieste, Italy)
D2T09.2C	10:55	Surgical management Visha A Patel (Washington, United States)
D2T09.2D	11:15	Non surgical options Carla Ferrandiz Pulido (Barcelona, Spain)
D2T09.2E	11:35	Discussion, Q&A



Thursday, 26 September 2024

TRAINING AND EDUCATION

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.5

D2T09.3		Melanoma Chairs: Petr Arenberger (Prague, Czech Republic) Veronique Bataille (Hemel Hempstead, United Kingdom)
D2T09.3A	14:15	Melanoma Veronique Bataille (Hemel Hempstead, United Kingdom)
D2T09.3B	14:35	Dermoscopy of melanoma Olivier Gaide (Lausanne, Switzerland)
D2T09.3C	14:55	The role of sentinel lymph node biopsy Marek Pásek (Praha, Czech Republic)
D2T09.3D	15:15	Follow up of melanoma patients Petr Arenberger (Prague, Czech Republic)
D2T09.3E	15:35	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.5

D2T09.4		Melanoma Chairs: Maria Concetta Fagnoli (Aquila, Italy) Christian Posch (Wien, Austria)
D2T09.4A	16:00	Targeted treatment Maria Concetta Fagnoli (Aquila, Italy)
D2T09.4B	16:20	Immunotherapy - adjuvant, neoadjuvant and advanced Omar Hasan Ali (Zurich, Switzerland)
D2T09.4C	16:40	mRNA vaccines Christian Posch (Wien, Austria)
D2T09.4D	17:00	Role of intralesional treatment Christoph Hoeller (Wien, Austria)
D2T09.4E	17:20	Discussion, Q&A



Thursday, 26 September 2024

TRAINING AND EDUCATION

⌚ 08:30 – 10:00 CEST

📍 E107 – E108

D2T10.1		Atopic dermatitis Chair: Marjolein de Bruin-Weller (Utrecht, Netherlands) Anna Di Nardo (San Diego, United States)
D2T10.1A	08:30	Pathophysiology Melinda Gooderham (Peterborough, Canada)
D2T10.1B	08:50	Comorbidities Anna Di Nardo (San Diego, United States)
D2T10.1C	09:10	Conventional systemic treatment Marjolein de Bruin-Weller (Utrecht, Netherlands)
D2T10.1D	09:30	Biologics and JAK inhibitors Jonathan I. Silverberg (Washington, United States)
D2T10.1E	09:50	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 10:15 – 11:45 CEST

📍 E107 – E108

D2T10.2		Non atopic eczema Chairs: Jana Kazandjieva (Sofia, Bulgaria) Suzana Ljubojevic Hadzavdic (Zagreb, Croatia)
D2T10.2A	10:15	Irritant versus allergic contact dermatitis David Pesqué (Barcelona, Spain)
D2T10.2B	10:35	Contact dermatitis from cosmetic ingredients and non-cosmetic culprits Annarita Antelmi (Malmö, Sweden)
D2T10.2C	10:55	Systemic contact dermatitis Suzana Ljubojevic Hadzavdic (Zagreb, Croatia)
D2T10.2D	11:15	Photoallergic contact dermatitis Jana Kazandjieva (Sofia, Bulgaria)
D2T10.2E	11:35	Discussion, Q&A



Thursday, 26 September 2024

TRAINING AND EDUCATION

⌚ 14:15 – 15:45 CEST

📍 E107 – E108

D2T10.3		Drug reactions Chairs: Wolfram Hoetzenecker (Linz, Austria) Lars E. French (Munich, Germany)
D2T10.3A	14:15	Classification and pathophysiology Vincent Descamps (Paris, France)
D2T10.3B	14:35	Early recognition of severe drug reactions Saskia Oro (Créteil, France)
D2T10.3C	14:55	Diagnostic work-up of drug eruptions Wolfram Hoetzenecker (Linz, Austria)
D2T10.3D	15:15	Management of severe drug eruptions Lars E. French (Munich, Germany)
D2T10.3E	15:35	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 16:00 – 17:30 CEST

📍 E107 – E108

D2T10.4		Vasculitis Chairs: Deepak Balak (Leiden, Netherlands) Hilde Beele (Gent, Belgium)
D2T10.4A	16:00	Classification Deepak Balak (Leiden, Netherlands)
D2T10.4B	16:20	Urticarial vasculitis Suzana Ljubojevic Hadzavdic (Zagreb, Croatia)
D2T10.4C	16:40	Calciphylaxis Hilde Beele (Gent, Belgium)
D2T10.4D	17:00	Correct use of systemic steroids and steroid sparing drugs for vasculitis Erkan Alpsoy (Antalya, Türkiye)
D2T10.4E	17:20	Discussion, Q&A



Thursday, 26 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 E103-E104

D2T11.1		Fillers I, Basics Chair: Berthold Rzany (Wien, Austria)
D2T11.1A	08:30	How to inject safely Berthold Rzany (Wien, Austria)
D2T11.1B	08:50	How to make a patient happy with 1 to 2 ml of filler Daisy Kopera (Graz, Austria)
D2T11.1C	09:10	How to make a patient happy with 3 and more ml of filler Luis Uva (lisbon, Portugal)
D2T11.1D	09:30	To inject superficially – on skin boosters Hans-Joachim Laubach (Geneva, Switzerland)
D2T11.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 E103-E104

D2T11.2		Botulinum Toxin I, Basics Chairs: Andreas Katsambas (Athens, Greece)
D2T11.2A	10:15	The role of botulinum toxin in preventing and treating scars Leonardo Marini (Trieste, Italy)
D2T11.2B	10:35	Glabella botulinum toxin: cookbook or bespoke? Christopher Rowland Payne (London, United Kingdom)
D2T12.2C	10:55	Botulinum toxin - Upper face Ines Verner Rashkovsky (Savyon, Israel)
D2T11.2D	10:55	Botulinum toxin - Pitfalls and complications Andreas Katsambas (Athens, Greece)
D2T11.2E	11:15	Discussion, Q&A

Thursday, 26 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 E103-E104

D2T11.3		Lasers and energy-based devices, Practical aspects of basics Chairs: Moshe Lapidoth (Ramat-Gan, Israel)
D2T11.3A	14:15	Approach for vascular lesions Milton Waner (New York, United States)
D2T11.3B	14:35	Treating pigmented lesions Assi Levi (Mevaseret Zion, Israel)
D2T11.3C	14:55	Current options for ablative and non ablative skin rejuvenation Daniel Brualla Palazón (Barcelona, Spain)
D2T11.3D	15:15	Future trends for lasers end energy based devices Mukta Sachdev (Bangalore, India)
D2T11.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 E103-E104

D2T11.4		Patient selection and practice management Chairs: Christopher Rowland Payne (London, United Kingdom)
D2T11.4A	16:00	Patient selection by psychological diagnosis. How the dermatologist should treat psychologically before aesthetically Christopher Rowland Payne (London, United Kingdom)
D2T11.4B	16:20	Patient selection: when it may be better to say no Eckart Prof Haneke (Freiburg im Breisgau, Germany)
D2T11.4C	16:40	Patient selection and treatment by facial morphotype Liliana Sytnyk (Kyiv, Ukraine)
D2T11.4D	17:00	Staff management and motivation: Boss vs.employees Svetlana Larkin (Odessa, Ukraine) Oleksandra Seletska (London, United Kingdom)
D2T11.4E	17:20	Discussion, Q&A



Thursday, 26 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 G102-G103

D2T12.1		STI Screening Chairs: Nicolas Dupin (Paris, France) Clarissa Vergunst (Amsterdam, Netherlands)
D2T12.1A	08:30	Mycoplasma genitalium infections Clarissa Vergunst (Amsterdam, Netherlands)
D2T12.1B	08:50	Chlamydia infections Marja Oldhoff (Paterswolde, Netherlands)
D2T12.1C	09:10	Upsurge in syphilis and neurosyphilis Nicolas Dupin (Paris, France)
D2T12.1D	09:30	Mpox Alba Catala (Barcelona, Spain)
D2T12.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 G102-G103

D2T12.2		STI prevention Chairs: Mihael Skerlev (Zagreb, Croatia)
DT12.2A	10:15	Vaccination against STI Georg Sary (Vienna, Austria)
D2T12.2B	10:35	HPV vaccination: can we do more? Mihael Skerlev (Zagreb, Croatia)
D2T12.2C	10:55	Can pre or post exposure antibiotics prevent STIs? Henry John Christiaan De Vries (Amsterdam, Netherlands)
D2T12.2D	11:15	Pre-exposure prophylaxis (PrEP) to prevent HIV infection Laurence Toutous-Trellu (Geneva, Switzerland)
D2T12.2E	11:35	Discussion, Q&A



Thursday, 26 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 G102-G103

D2T12.3		HIV Chairs: Elske Hoornenborg (Amsterdam, Netherlands) Peter Greenhouse (Bristol, United Kingdom)
D2T12.3A	14:15	2024 epidemiological trends Peter Greenhouse (Bristol, United Kingdom)
D2T12.3B	14:35	Indicator skin diseases George Sorin Tiplica (Bucharest, Romania)
D2T12.3C	14:55	Current and emerging therapies to control HIV Elske Hoornenborg (Amsterdam, Netherlands)
D2T12.3D	15:15	How safe are biologics in HIV patients? Giuseppe Pantaleo (Lausanne, Switzerland)
D2T12.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 G102-G103

D2T12.4		Scabies Chairs: Carmen Maria Salavastru (Bucharest, Romania) Kenneth Tomecki (Cleveland, United States)
D2T12.4A	16:00	Managing scabies outbreaks in Europe Claire Dewsnap (Sheffield, United Kingdom)
D2T12.4B	16:20	Scabies, a public challenge in the developing world Wendemagen Enbiale (Wageningen, Netherlands)
D2T12.4C	16:40	Evidence-based treatment of scabies in adults and children Carmen Maria Salavastru (Bucharest, Romania)
D2T12.4D	17:00	Crusted Scabies Kenneth Tomecki (Cleveland, United States)
D2T12.4E	17:20	Discussion, Q&A



FC01		Free Communications 1 Chairs: Asja Prohić (Sarajevo, Bosnia and Herzegovina) Dimitra Koumaki (Heraklion, Crete, Greece)
FC01.01	08:30	Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF-α blockade Chun-Bing Chen (Taoyuan, Taiwan)
FC01.02	08:40	Assessment of serum level of IL-6, D-dimer and CRP in patients with urticaria Hanan Rabeeh Nada (Cairo, Egypt)
FC01.03	08:50	Inflammatory filler complications revisited: Controversies, literature review, and case presentations Hussein Ghanem (Cairo, Egypt)
FC01.04	09:00	Hair regrowth enhancer or hair shedding? A comparative study for the treatment of female androgenic alopecia using Fractional Carbon dioxide versus Fractional Microneedling Radiofrequency. Rana Hilal (Egypt)
FC01.05	09:10	Targeting IL-1 controls refractory Pityriasis rubra pilaris Antonios G. A. Kolios
FC01.06	09:20	Multiparameter analysis of panniculitis reveals three clusters of patients Joy Assaf (Paris, France)
FC01.07	09:30	Results from the BEACON Trial: A Phase 2, Randomized, Open-label Trial of Bitopertin in Erythropoietic Protoporphyria George Mensing (Watertown, United States)
FC01.08	09:40	Prevalence of hidradenitis suppurativa in The Netherlands, a cross sectional study as part of the Global Hidradenitis Suppurativa Atlas (GHISA) Johanna van Huijstee (Rotterdam, Netherlands)
FC01.09	09:50	Topical treatment with active ingredients that regulate key pathophysiology signaling pathways in melasma Sebastian Podlipnik (Barcelona, Spain)



FC02		Free Communications 2 Chairs: Jose-Manuel Carrascosa (Badalona, Spain) Zsanett Renáta Csoma (Szeged, Hungary)
FC02.01	10:15	Cultural practices and dermatophytosis: Investigating ethnic variations in Tinea prevalence - A cross-sectional study Swathi Nagabushan (Mangalore, India)
FC02.02	10:25	Epidemiological insights into infections by Trichophyton mentagrophytes species complex in France Arnaud Jabet (Paris, France)
FC02.03	10:35	Recurrent erythema necroticans: A reminiscent of rpob gene mutation-induced rifampicin resistance Hiloni Chokshi (Maharashtra, India)
FC02.04	10:45	Barriers to Effective Cellulitis Management in a Primary Care Setting: An Audit Report Yan Ching Chow (Preston, United Kingdom)
FC02.05	10:55	Itch intensity assessment in atopic dermatitis with different itch instruments and time frames - are there differences? Felix Witte (Münster, Germany)
FC02.06	11:05	Pruritus and its association with malignancy and mortality in patients with dermatomyositis and polymyositis between 2000 and 2021: a nationwide matched cohort study Der-Jr Huang (New Taipei City, Taiwan)
FC02.07	11:15	CLE-400: Topical α2-adrenergic agonist being developed as a novel mechanism for treating chronic pruritus associated with notalgia paresthetica Orna Goren (Petach Tikva, Israel)
FC02.08	11:25	Exploring long-term sequelae following epidemic Mpox reveals a high frequency of scarring David Chromy (Vienna, Austria)
FC02.09	11:35	Diagnostic accuracy of non-invasive markers for biopsy-proven high-grade anal dysplasia David Chromy (Vienna, Austria)

FC03		Free Communications 3 Chairs: Piergiacomo Calzavara-Pinton (Brescia, Italy) Aleksandra Lesiak (Lodz, Poland)
FC03.01	14:15	Atypical fibroxanthoma and pleomorphic dermal sarcoma - A 10-year retrospective study Joana Vieitez Frade (Lisbon, Portugal)
FC03.02	14:25	Prospective analysis of reflectance confocal microscopy in 1285 dermatological lesions: Experience in a University Hospital setting Sebastián González-Valdés (Santiago, Chile)
FC03.03	14:35	Time interval between Sentinel Lymph Node Biopsy and Excision of Primary Melanoma does not impact long term outcomes in a large UK cohort Georgios Kounidas (Cambridge, United Kingdom)
FC03.04	14:45	Combining automated lesion risk and change assessment improves melanoma detection: A study applying Artificial Intelligence to multi-modal imaging. Chantal Rutjes (Brisbane, Australia)
FC03.05	14:55	Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS) Michael Migden (Houston, TX, United States)
FC03.06	15:05	Primary radiotherapy in older adults with basal cell carcinoma: results of the prospective, multicenter BATO cohort study on treatment burden, short-term outcomes and a comparison with surgically treated patients Josephine Emma Mangnus (Nijmegen, Netherlands)
FC03.07	15:15	Early detection of melanomas using circulating tumour-specific antibodies Cristina Vico-Alonso (Melbourne, Australia)
FC03.08	15:25	Pathologist consensus is crucial for the development of Artificial Intelligence training data in Dermatology Nicholas Muller (Brisbane, Australia)

FC04		Free Communications 4 Chairs: Francesca Prignano (Florence, Italy) David Pesqué (Barcelona, Spain)
FC04.01	16:00	Telogen and trichodynia: The approach of physical therapy Michela Starace (Bologna, Italy)
FC04.02	16:10	A retrospective study on tofacitinib in pediatric alopecia areata totalis and alopecia universalis Shreya Kempegowda (Delhi, India)
FC04.03	16:20	Use of botulinum toxin for the androgenetic alopecia: a prospective study of 50 patients Jay Modha (Rajkot, India)
FC04.04	16:30	Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials Paradi Mirmirani (Orinda, United States)
FC04.05	16:40	The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: A blinded randomized clinical trial Alireza Jafarzadeh (Tehran, Iran)
FC04.06	16:50	Treatment with USPlus Derm prolongs anagen through positive modulation of dermal papilla inductivity and reinforces the hair follicle stem cell niche in organ cultured, occipital healthy male scalp hair follicles Janin Edelkamp (Münster, Germany)
FC04.07	17:00	Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: efficacy and safety results of a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP) Mark Lebwohl (New York, United States)
FC04.08	17:10	Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies Ana Giménez-Arnau (Barcelona, Spain)
FC04.09	17:20	Using comparative transcriptomic profiling ex vivo to identify novel, potential targets for acute and chronic wound healing Marta Bertolini (Muenster, Germany)



Thursday, 26 September 2024

MISCELLANEOUS

⌚ 08:30 – 10:00 CEST

📍 E102

D2T14.1		Collaborating in Novel Ways to Elevate Dermatology Research Chairs: Catherine van Montfrans (Rotterdam, Netherlands) Aleksandra Lesiak (Lodz, Poland) Visnja Zaborski-Breton (Ottawa, Canada)
D2T14.1A	08:30	Welcome Visnja Zaborski-Breton (Ottawa, Canada)
D2T14.1B	08:35	Best practices of partnering with patient organizations in dermatology research Marc Yale (Roseville, United States)
	08:40	Presentations on collaborative research projects with dermatology patients
D2T14.1C	08:40	Quality of life of alopecia areata patients Aleksandra Lesiak (Lodz, Poland) Agata Nina Bura (Warszawa, Poland)
D2T14.1D	09:00	Launching a novel measure in dermatology – Patient Reported Impact of Dermatological Diseases (PRIDD) Jennifer Austin (Ottawa, Canada) Matthias Augustin (Hamburg, Germany)
D2T14.1E	09:20	Cannabis oil for chronic pain in Epidermolysis Bullosa Nicholas Schröder (groningen, Netherlands) Janet Schokker (Apeldoorn, Netherlands)
D2T14.1F	09:40	Collaboration between Industry and patient organizations in research Tiago R Matos (Amsterdam, Netherlands)
D2T14.1G	10:00	Closing remarks Visnja Zaborski-Breton (Ottawa, Canada)

D2T14.1		EADV Research funding and Fellowships Chairs: Veronique del Marmol (Brussels, Belgium) Ruggero Moro (València, Spain) Cristina Has (Freiburg, Germany)
D2T14.2A	10:15	Introduction Veronique del Marmol (Brussels, Belgium)
D2T14.2B	10:25	Unveiling the Pathomechanism of Behçet's Disease Secil Vural (Istanbul, Türkiye)
D2T14.2C	10:40	Transcriptome-based tumour stratification to better identify cutaneous squamous cell carcinomas at risk for metastases in organ transplant recipients Jan Nico Bouwes Bavink (Lisse, Netherlands)
D2T14.2D	10:55	Skin and sexually transmitted infections KAP (knowledge, attitude, and practice) survey and health promotion strategy using mobile and digital technologies in migrant populations in Malta and Lebanon Valeska Padovese (Msida, Malta)
D2T14.2E	11:10	Improving the Safety and Efficacy of Port Wine Birthmark Treatment Using Novel Approaches to Selective Photothermolysis Cemre Busra Turk (Boston, United States)
D2T14.2E	11:20	Mohs fellowship at the Fundación Instituto Valenciano de Oncología Anna Bota Llorca (Sevilla, Spain)
D2T14.2F	11:30	Clinical aspects for the diagnostic process and treatment of cutaneous lymphomas Niina Korhonen (Tampere, Finland)
D2T14.2G	11:35	Exploring the Wound Healing Field: An inspiring clinical fellowship journey in Spain Iulia-Elena Negulet (Bucharest, Romania)
D2T14.2H	11:40	Discussion, Q&A

Thursday, 26 September 2024

MISCELLANEOUS

⌚ 14:15 – 15:45 CEST

📍 E102

D1T14.3		Ethics, diversity and Inclusion Chairs: Cristina Bulai Livideanu (Toulouse, France) Elizabeth Lazaridou (Thessaloniki, Greece) Dimitra Koumaki (Heraklion, Crete, Greece)
D2T14.3A	14:15	Common outpatient paediatric skin conditions stratified by race and ethnicity Bisola Laguda (London, United Kingdom)
D2T14.3B	14:35	Dermatology facing skin lightening Antoine David Petit (Paris, France)
D2T14.3C	14:55	Erasing Inequities: Strategies for Addressing Bias in Dermatology Jui Vyas (Cardiff, United Kingdom)
D2T14.3D	15:15	Psoriasis and ethical aspects Vanda Bondare-Ansberga (Marupe, Latvia)
D2T14.3E	15:35	Discussion, Q&A

MISCELLANEOUS

⌚ 16:00 – 17:30 CEST

📍 E102

D2T14.4		Best of Dermatology papers 2024: a panoramic view Chairs: Carle Paul (Toulouse, France) Erwin Tschachler (Vienna, Austria)
D2T14.4A	16:00	Welcome and introduction Carle Paul (Toulouse, France)
D2T14.4B	16:05	Best papers of the year from JAAD Dirk Elston (Charleston, United States)
D2T14.4C	16:25	Best papers of the year from JID Erwin Tschachler (Vienna, Austria)
D2T14.4D	16:45	Best papers of the year from BJD John McGrath (London, United Kingdom)
D2T14.4E	17:05	Best papers of the year from JEADV Carle Paul (Toulouse, France)
D2T14.4F	17:25	Discussion, Q&A



EPS03		ePoster showcase
EPS03.01	08:30	Driving response in hidradenitis suppurativa: Therapeutic targeting of plasma cells by upadacitinib Kumar Krishnaswamy (Worcester, United States)
EPS03.02	08:40	Evidence of a role for IL-17F in the inflammatory mechanisms underlying hidradenitis suppurativa (HS), including in deep dermal tunnels Kristian Reich (Zug, Switzerland)
EPS03.03	08:50	Inflammatory lesion resolution with the IL-17A- and IL-17F-inhibiting Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the global, randomized, double-blind, placebo-controlled Phase 2 MIRA trial Martina L Porter (Boston, United States)
EPS03.04	09:00	The IL-17A- and IL-17F-inhibiting nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 International Hidradenitis Suppurativa Severity Score System (IHS4) results from the Phase 2 MIRA trial Brian Kirby (Dublin, Ireland)
EPS03.05	09:10	Association between air pollutant exposure and acne severity in a multiethnic adolescent cohort in the south-west of The Netherlands Willemijn Witkam (Rotterdam, Netherlands)
EPS03.06	09:20	Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II Jacek Szepietowski (Wroclaw, Poland)
EPS03.07	09:30	Sexuality and the desire for parenthood: The invisible burden of hidradenitis suppurativa in a nationwide French study
EPS03.08	09:40	NLRP3 inhibition reduces pathogenic IL1-family signalling in Hidradenitis Suppurativa skin Alessio Mylonas (Lausanne, Switzerland)
EPS03.09	09:50	Depth of the efficacy response to lutikizumab treatment in moderate-to-severe hidradenitis suppurativa (HS) Antonio Martorell Calatayud (Valencia, Spain)

EPS04		ePoster showcase
EPS04.01	10:15	Predictive factors for cardiovascular disease in dermatomyositis: A comprehensive exploration Dea Metko (Hamilton, Canada)
EPS04.02	10:25	Predictive factors for interstitial lung disease in dermatomyositis Dea Metko (Hamilton, Canada)
EPS04.03	10:35	Improvement in cutaneous manifestations with deucravacitinib in systemic lupus erythematosus: impact of baseline patient demographics and disease activity on CLASI-50 responses in the phase 2 PAISLEY trial Joseph Merola (Boston, United States)
EPS04.04	10:45	Predictive factors for concurrent infection in patients with adult-onset immunodeficiency syndrome associated with anti-interferon gamma autoantibodies presenting with reactive dermatoses Chudapa Sereephinan (Bangkok, Thailand)
EPS04.05	10:55	Medical care of mucosal lichen planus patients in Germany: a multicenter cross-sectional study of the patient's journey from diagnosis to therapy Neda Cramer (Germany)
EPS04.06	11:05	Topline results of the AURORA Trial: A phase 2, randomized, double-blind, placebo-controlled trial of bitopertin in erythropoietic protoporphyria George Mensing (Watertown, United States)
EPS04.07	11:15	Effect of Triterpene Extract on Skin Cohesion in Epidermolysis Bullosa Alexander Nyström (Freiburg, Germany)
EPS04.08	11:25	Five cases of Mycoplasma Pneumoniae-Induced Rash and Mucositis (MIRM): Clinical features and outcomes among a case series in 2023/2024 Oliver Johnson (Liverpool, United Kingdom)
EPS04.09	11:35	EPS04.09: Multimorbidity in adults with atopic dermatitis in the Dutch general population Leon Miltner (Groningen, Netherlands)



EPS05		ePoster showcase
EPS05.01	14:15	Dupilumab provides rapid and continuous improvement in prurigo nodularis signs and symptoms over time: results from PRIME/PRIME2 Sonja Ständer (Münster, Germany)
EPS05.02	14:25	Comprehensive safety data in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOSTAD multinational prospective observational study Anne-Claire Fougerousse (Saint Mandé, France)
EPS05.03	14:35	Stapokibart improves patient-reported outcomes in adults with moderate-to-severe atopic dermatitis over 52 weeks: a post-hoc analysis of a pivotal phase 3 trial Jianzhong Zhang (Beijing, China)
EPS05.04	14:45	Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis including over 7000 patient-years of exposure Christopher Bunick (New Haven, CT, United States)
EPS05.05	14:55	Integrated analysis examining safety of abrocitinib in adolescents with moderate to severe atopic dermatitis with up to 4.6 years of exposure and efficacy at 112 weeks of treatment Amy Paller (Chicago, United States)
EPS05.06	15:05	Topical pan-JAK inhibition with delgocitinib restores the molecular signature of lesional skin in patients with chronic hand eczema Sonja Molin (Kingston, Canada)
EPS05.07	15:15	Phase 4 analyses: Trifarotene reduces atrophic acne scars across all skin types with greater effect in subjects with higher baseline acne and acne scarring severity Jerry Tan (Ontario, Canada)
EPS05.08	15:25	Study design of phase 3 trials evaluating rocatinlimab efficacy and safety in moderate-to-severe atopic dermatitis: the ROCKET program Emma Guttman-Yassky (New York, United States)
EPS05.09	15:35	ANB032, a BTLA checkpoint agonist antibody, attenuates dendritic cell (DC) maturation and function: A novel mechanism addressing atopic dermatitis pathophysiology Martin Dahl (San Diego, United States)

EPS06		ePoster showcase
EPS06.01	16:00	Appropriate treatment escalation improves disease control in patients with chronic spontaneous urticaria: Results from the Chronic Urticaria Registry (CURE) Emek Kocatürk Göncü (Istanbul, Türkiye)
EPS06.02	16:10	Psychosocial impacts of autoimmune blistering diseases: results from a large cross-sectional survey Marney White (New Haven, United States)
EPS06.03	16:20	ALPHA-STAR, a Phase 1b/2 clinical trial of single and multiple doses of STAR-0215 in patients with hereditary angioedema: initial safety and efficacy outcomes Raffi Tachdjian (Santa Monica, United States)
EPS06.04	16:30	Laboratory safety of nemolizumab in prurigo nodularis: Results from two phase 3 trials and one open-label extension study Martin Metz (Berlin, Germany)
EPS06.05	16:40	Imsidolimab, an IL-36 receptor antagonist, was effective and well tolerated for treatment and prevention of flares in patients with generalized pustular psoriasis: results from the phase 3 trials, GEMINI-1 and GEMINI-2 Adam Reich (Rzeszów, Poland)
EPS06.06	16:50	Pembrolizumab cutaneous toxicities in 131 patients with metastatic melanoma: Incidence, management, clinical implications and relationship with survival Amritpreet Singh (Auckland, New Zealand)
EPS06.07	17:00	Epidemiology and burden of generalised pustular psoriasis: A comprehensive literature review Anna Pagotto (London, United Kingdom)
EPS06.08	17:10	Generalised pustular psoriasis (GPP) in Germany: Insights from the non-interventional SCRIPTOR study Georgios Kokolakis (Berlin, Germany)
EPS06.09	17:20	Comparative analysis of vitamin D3 levels and the impact of vitamin D3 supplementation on disease severity in chronic spontaneous urticaria patients: A randomized controlled trial Disha Chakraborty (kolkata, India)



Scientific Programme

Friday, 27 September 2024

Programme at a glance

Sessions	08:30 – 10:00	10:15 – 11:45	14:15 – 15:45	16:00 – 17:30
Auditorium	Focus on cutaneous lymphomas	Focus on cutaneous lymphomas	Late breaking news	Late breaking news
Elicium	Dermoscopy pigmented lesions	Dermoscopy non pigmented lesions	Nair and hair dermoscopy	Dermoscopy in inflammatory disorders
Room 3.1	Basal cell carcinoma	Squamous cell carcinoma	Merkel cell carcinoma and cutaneous sarcomas	Targeted and immuno-therapies in dermatology-oncology
Forum	Preventing skin diseases	Social media and dermatology	Cutaneous lupus erythematosus	Connective tissue diseases
Room 7.1	Tattoos and piercings		Adverse events in new anti-cancer therapy	Granulomatous diseases
Room 7.2	Top advances in 2024 presented by ESDR	Photodermatology	Best of European and American dermatology	Best of European and American dermatology
Room 7.3	Fillers II, Advanced	Botulinum toxin II, Advanced	Lasers and energy-based devices II: Advanced, including complications management	Energy based-devices: Body contouring and tightening
Room 7.4	Controversies V	Controversies VI	Controversies VII	Controversies VIII
Room 7.5	Understanding genetics for dermatologists	Genetics in translation	Psoriasis	Autoimmune disorders
E107-E108	Bullous diseases	Surgical therapy	Office management	
E103-E104	Scars	Wound healing	Neutrophilic diseases	Occupational dermatology
G102-G103	Bacterial skin infections	Viral skin infections	Fungal skin infections	Proctology for dermatologists
G104-G105	Free Communications 5	Free Communications 6	Free Communications 7	Free Communications 8
D202	Phlebology for beginners		Conquer your audience: Perfect your presentation skills	
D203	Dermal fillers		Use of botulinum toxin in cosmetics and medical dermatology	
Open stage	[8:30 – 12:15] Residents Track		[14:00 – 15:30] Residents track	
Emerald				EADV Games

Friday, 27 September 2024

FOCUS ON

⌚ 08:30 – 10:00 CEST

📍 AUDITORIUM

D3T01.1		Focus on cutaneous lymphomas Chairs: Adele de Masson (Paris, France) Shamir Geller (New York, United States)
D3T01.1A	08:30	Immuno-phenotyping for the novice Shamir Geller (New York, United States)
D3T01.1B	08:50	Primary B-cell lymphoma Adele de Masson (Paris, France)
D3T01.1C	09:10	Identifying the mimickers of B-cell lymphoma Nicolas Ortonne (Creteil, France)
D3T01.1D	09:30	Treating B-cell lymphoma: A practical approach Evangelia Papadavid (Athens, Greece)
D3T01.1E	09:50	Discussion, Q&A

FOCUS ON

⌚ 10:15 – 11:45 CEST

📍 AUDITORIUM

D3T01.2		Focus on cutaneous lymphomas Chairs: Emmanuella Guenova (Lausanne, Switzerland) Maarten Vermeer (Leiden, Netherlands)
D3T01.2A	10:15	Mycosis fungoides: new insights on an old disease Emmanuella Guenova (Lausanne, Switzerland)
D3T01.2B	10:35	Do drugs induce cutaneous lymphomas? Evangelia Papadavid (Athens, Greece)
D3T01.2C	10:55	Sézary and other life-threatening cutaneous lymphomas Maarten Vermeer (Leiden, Netherlands)
D3T01.2D	11:15	Innovative approaches to treatment of CTCL Björn Thomas (London, United Kingdom)
D3T01.2E	11:35	Discussion, Q&A



D3T01.3		Late breaking news Chairs: Brigitte Dréno (Nantes, France) Manabu Fujimoto (Osaka, Japan)
D3T01.3A	14:15	Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT Christos C. Zouboulis (Dessau, Germany)
D3T01.3B	14:30	A phase 3, randomized controlled trial of topical patidegib gel 2% in patients with Gorlin syndrome Ervin Epstein (Orinda, United States)
D3T01.3C	14:45	Real-world effectiveness of tralokinumab in adults with atopic dermatitis: Interim data on improvements in patients with head and neck atopic dermatitis after up to 9 months of treatment in the TRACE study April W. Armstrong (Los Angeles, United States)
D3T01.3D	15:00	Efficacy and safety of ESK-001, a highly selective oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis: Phase 2 results through week 28 Andrew Blauvelt (Portland, United States)
D3T01.3E	15:15	Differentiating early responders, late responders, and nonresponders during real life dupilumab treatment using a personalized biomarker approach Ester Del Duca (Rome, Italy)
D3T01.3F	15:30	Familial occurrence of hidradenitis suppurativa is associated with increased risk of metabolic syndrome Suzan Al-Gburi (Cologne, Germany)



Friday, 27 September 2024

UPDATES

⌚ 16:00 – 17:30 CEST

📍 AUDITORIUM

D3T01.4		Late breaking news Chairs: Jo LW Lambert (Ghent, Belgium) Menno de Rie (Breukelen, Netherlands)
D3T01.4A	16:00	Efficacy and safety of HS-10374 in patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 trial Yan Zhou (China)
D3T01.4B	16:15	Matching-adjusted indirect comparison of the efficacy of delgocitinib and dupilumab in the treatment of moderate to severe atopic hand eczema April W. Armstrong (Los Angeles, United States)
D3T01.4C	16:30	Efficacy and safety of ruxolitinib cream in patients with cutaneous lichen planus: Results from a phase 2, randomized, vehicle-controlled study Aaron Mangold (Scottsdale, United States)
D3T01.4D	16:45	Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: 52-week results from a phase 3, randomized, placebo-controlled study Yukari Okubo (Tokyo, Japan)
D3T01.4E	17:00	Allogeneic CD19-targeted CAR-T therapy for refractory systemic lupus erythematosus (SLE) Biao Zheng (Shanghai, China)
D3T01.4F	17:15	Randomized vehicle-controlled clinical trial with the topical JAK inhibitor delgocitinib in patients with frontal fibrosing alopecia demonstrates biomarker and clinical efficacy Maryanne M. Senna (Winchester, United States)

Friday, 27 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ELICIUM

D3T02.1		Dermoscopy pigmented lesions Chairs: Aimilios Lallas (Thessaloniki, Greece) Caterina Longo (Modena, Italy)
D3T02.1A	08:30	Naevi Monika Arenbergerova (Prague, Czech Republic)
D3T02.1B	08:50	Early melanoma Aimilios Lallas (Thessaloniki, Greece)
D3T02.1C	09:10	Challenges in dark skin Giovanni Pellacani (Rome, Italy)
D3T02.1D	09:30	Facial lesions Danica Todorovic (Nis, Serbia)
D3T02.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ELICIUM

D3T02.2		Dermoscopy non pigmented lesions Chairs: Giuseppe Argenziano (Naples, Italy) Susana Puig (Barcelona, Spain)
D3T02.2A	10:15	Actinic keratosis and squamous cell carcinoma Nisa Akay Bengu (Ankara, Türkiye)
D3T02.2B	10:35	Basal cell carcinoma Susana Puig (Barcelona, Spain)
D3T02.2C	10:55	Pink tumours Roberta Giuffrida (Messina, Italy)
D3T02.2D	11:15	Rare skin tumours Giuseppe Argenziano (Naples, Italy)
D3T02.2E	11:35	Discussion, Q&A

Friday, 27 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ELICIUM

D3T02.3		Nail and hair dermoscopy Chairs: Luc Thomas (Pierre Bénite, France) Sergio Vaño-Galván (Madrid, Spain)
D3T02.3A	14:15	Pigmented nail bands Aleksandr Litus (Kyiv, Ukraine)
D3T02.3B	14:35	Nail tumours Luc Thomas (Pierre Bénite, France)
D3T02.3C	14:55	Alopecia areata Adriana Rakowska (Warsaw, Poland)
D3T02.3D	15:15	Scarring alopecia Sergio Vaño-Galván (Madrid, Spain)
D3T02.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ELICIUM

D3T02.4		Dermoscopy in inflammatory disorders Chairs: Zoe Apalla (Thessaloniki, Greece) Enzo Errichetti (Udine, Italy)
D3T02.4A	16:00	Can inflammoscopy replace histology? Enzo Errichetti (Udine, Italy)
D3T02.4B	16:20	Connective tissue diseases Zoe Apalla (Thessaloniki, Greece)
D3T02.4C	16:40	Capillaroscopy Luis Perez (Rotterdam, Netherlands)
D3T02.4D	17:00	Infections and infestations Claudio Conforti (Trieste, Italy)
D3T02.4E	17:20	Discussion, Q&A



Friday, 27 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 3.1

D3T03.1		Basal cell carcinoma Chairs: Ketty Peris (Rome, Italy) Julia Welzel (Augsburg, Germany)
D3T03.1A	08:30	The role of the tumour micro-environment Philippe Lefrancois (Montreal, Canada)
D3T03.1B	08:50	How to manage positive margins Julia Welzel (Augsburg, Germany)
D3T03.1C	09:10	Monitoring after BCC diagnosis Sebastian Podlipnik (Barcelona, Spain)
D3T03.1D	09:30	Combination treatments Ketty Peris (Rome, Italy)
D3T03.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 3.1

D3T03.2		Squamous cell carcinoma Chairs: Thomas Meyer (Bochum, Germany) Emily Ruiz (Boston, United States)
D3T03.2A	10:15	The role of HPV in SCC Thomas Meyer (Bochum, Germany)
D3T03.2B	10:35	New prognostic factors in SCC beyond staging Ketty Peris (Rome, Italy)
D3T03.2C	10:55	Adjuvant radiotherapy Javier Canueto (Salamanca, Spain)
D3T03.2D	11:15	Staging and follow-up of high risk SCC Emily Ruiz (Boston, United States)
D3T03.2E	11:35	Discussion, Q&A



Friday, 27 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 3.1

D3T03.3		Merkel cell carcinoma and cutaneous sarcomas Chairs: Ana-Maria Forsea (Bucharest, Romania) Thomas Vogt (Homburg, Germany)
D3T03.3A	14:15	Management of advanced Merkel cell carcinoma Ana-Maria Forsea (Bucharest, Romania)
D3T03.3B	14:35	The role of polyoma virus in Merkel cell carcinoma Marek Pásek (Praha 10, Czech Republic)
D3T03.3C	14:55	Management of dermatofibrosarcoma protuberans W. V. Houdt (Amsterdam, Netherlands)
D3T03.3D	15:15	Angiosarcoma Thomas Vogt (Homburg, Germany)
D3T03.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 3.1

D3T03.4		Targeted and immuno-therapies in dermato-oncology Chairs: Caroline Gaudy-Marqueste (Marseille, France) Orit Markowitz (New York, United States)
D3T03.4A	16:00	Follow-up of BCC patients on hedgehog inhibitors Egle Ramelyte (Zurich, Switzerland)
D3T03.4B	16:20	BRAF in the adjuvant setting of Melanoma: a cure on the horizon? Caroline Gaudy-Marqueste (Marseille, France)
D3T03.4C	16:40	Emerging therapies for melanoma Omar Hasan Ali (Zurich, Switzerland)
D3T03.4D	17:00	Emerging therapies for non-melanoma skin cancer Orit Markowitz (New York, United States)
D3T03.4E	17:20	Discussion, Q&A



Friday, 27 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 FORUM

D3T04.1		Preventing skin diseases Chairs: Thomas Luger (Münster, Germany) Peter Wolf (Graz, Austria)
D3T04.1A	08:30	Oral supplements for skin health: What is the evidence? Apostolos Pappas (Branchburg, United States)
D3T04.1B	08:50	Emollients for the prevention of the atopic march Thomas Luger (Münster, Germany)
D3T04.1C	09:10	Vaccines for infectious disease prevention Stephen Tying (Webster, United States)
D3T04.1D	09:30	Microbiome modulation Peter Wolf (Graz, Austria)
D3T04.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 FORUM

D3T04.2		Social media and dermatology Chairs: Ana Maria Molina Ruiz (Madrid, Spain) Sarah Walsh (London, United Kingdom)
D3T04.2A	10:15	How to be a derm influencer Karlijn Clarysse (Paris, France)
D3T04.2B	10:35	Practical tips for social media Ana Maria Molina Ruiz (Madrid, Spain)
D3T04.2C	10:55	Podcasts Sarah Walsh (London, United Kingdom)
D3T04.2D	11:15	The don'ts in social media Ornella Sacré (Brussels, Belgium)
D3T04.2E	11:35	Discussion, Q&A



Friday, 27 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 FORUM

D3T04.3		Cutaneous lupus erythematosus Chairs: Branka Marinovic (Zagreb, Croatia) Claudia Günther (Dresden, Germany)
D3T04.3A	14:15	Pathogenesis Miloš Nikolić (Belgrade, Serbia)
D3T04.3B	14:35	Monitoring progression Jörg Wenzel (Bonn, Germany)
D3T04.3C	14:55	Current treatment algorithm Branka Marinovic (Zagreb, Croatia)
D3T04.3D	15:15	Targeting interferons, plasmacytoid dendritic cells and B-cells Claudia Günther (Dresden, Germany)
D3T04.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 FORUM

D3T04.4		Connective tissue diseases Chairs: Aveen Connolly (London, United Kingdom) Scott Elman (Miami, United States)
D3T04.4A	16:00	Dermatomyositis: clinical spectrum, autoantibodies and management Aveen Connolly (London, United Kingdom)
D3T04.4B	16:20	Blue fingers: from Raynaud to chilblains Scott Elman (Miami, United States)
D3T04.4C	16:40	Mucosal involvement in connective tissue diseases Speaker TBC
D3T04.4D	17:00	New insights into mechanisms of fibrosis in systemic sclerosis Johann Gudjonsson (Ann Arbor, United States)
D3T04.4E	17:20	Discussion, Q&A



Friday, 27 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.1

D3T05.1		Tattoos and piercings Chairs: Christa de Cuyper (Bruges, Belgium) Sebastiaan Alain Servé van der Bent (Leiden, Netherlands)
D3T05.1A	08:30	Challenges in monitoring moles in tattoos Nicolas Kluger (Helsinki, Finland)
D3T05.1B	08:50	Tattoos complications Aneta Szczerkowska Dobosz (Gdansk, Poland)
D3T05.1C	09:10	Complications of tongue, lip, and genital piercings Christa de Cuyper (Bruges, Belgium)
D3T05.1D	09:30	Tattoo removal Sebastiaan Alain Servé van der Bent (Leiden, Netherlands)
D3T05.1E	09:50	Discussion, Q&A



Friday, 27 September 2024

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.1

D3T05.3		Adverse events in new anti-cancer therapy Chairs: Lucie Heinzerling (Munich, Germany) Lidija Kandolf-Sekulovic (Belgrade, Serbia)
D3T05.3A	14:15	Immune related cutaneous adverse events Eszter Baltas (Szeged, Hungary)
D3T05.3B	14:35	Immune related non-cutaneous adverse events Lucie Heinzerling (Munich, Germany)
D3T05.3C	14:55	Adverse events in targeted therapy Lidija Kandolf-Sekulovic (Belgrade, Serbia)
D3T05.3D	15:15	Management of adverse events in EGFR inhibitors Jan Ricar (Pilsen, Czech Republic)
D3T05.3E	15:35	Discussion, Q&A

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.1

D3T05.4		Granulomatous diseases Chairs: Ayse Serap Karadag (Istanbul, Türkiye) Wioletta Baranska-Rybak (Gdansk, Poland)
D3T05.4A	16:00	Sarcoidosis Elizabeth Arkema (Stockholm, Sweden)
D3T05.4B	16:20	Diagnosing non-infectious granuloma correctly Ayse Serap Karadag (Istanbul, Türkiye)
D3T05.4C	16:40	Emerging therapies for granuloma annulare Wioletta Baranska-Rybak (Gdansk, Poland)
D3T05.4D	17:00	Emerging therapies for necrobiosis lipoidica Jeffrey Callen (Louisville, United States)
D3T05.4E	17:20	Discussion, Q&A



Friday, 27 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.2

D3T06.1		Top advances in 2024 presented by ESDR Chairs: Neil Rajan (United Kingdom) Enikő Sonkoly (Uppsala, Sweden)
D3T06.1A	08:30	Skin microbiome manipulations to solve body odor Chris Callewaert (Gent, Belgium)
D3T06.1B	08:50	Peering beneath the surface: Deciphering skin mycobiome through proteomics analysis Beatrice Dyring-Andersen (Gentofte, Denmark)
D3T06.1C	09:10	Regulatory T-Cells: Navigating inflammatory diseases, immune regulation & therapies Tiago R Matos (Amsterdam, Netherlands)
D3T06.1D	09:30	New avenue to treat rare skin diseases: Precision therapeutic gene correction using DNA editing Joanna Jacków-Malinowska (London, United Kingdom)
D3T06.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.2

D3T06.2		Photodermatology Chairs: Margarida Gonçalo (Coimbra, Portugal) Piergiacomo Calzavara-Pinton (Brescia, Italy)
D3T06.2A	10:15	Photosensitivity and skin diseases Lesley Rhodes (Manchester, United Kingdom)
D3T06.2B	10:35	Drug photosensitivity enhancing skin cancer Eva Remenyik (Debrecen, Hungary)
D3T06.2C	10:55	Photo-patch testing Margarida Gonçalo (Coimbra, Portugal)
D3T06.2D	11:15	Photodynamic therapy: New indications Piergiacomo Calzavara-Pinton (Brescia, Italy)
D3T06.2E	11:35	Discussion, Q&A



Friday, 27 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.2

D3T06.3		Best of European and American Dermatology Chairs: Michel Gilliet (Lausanne, Switzerland) Jeffrey Callen (Louisville, United States)
D3T06.3A	14:15	The Truth about Acne Emmy Graber (Boston, United States)
D3T06.3B	14:40	Vitiligo Thierry Passeron (Nice, France)
D3T06.3C	15:05	Screening and early detection of skin cancer – Is melanoma over diagnosed? Daniel Bennett (Madison, United States)
D3T06.3D	15:30	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.2

D3T06.4		Best of European and American Dermatology Chairs: Michel Gilliet (Lausanne, Switzerland) Jeffrey Callen (Louisville, United States)
D3T06.4A	16:00	Trichoscopy for hair disorders Lidia Rudnicka (Warsaw, Poland)
D3T06.4B	16:25	Wound healing in the 21st century Robert Kirsner (Miami, United States)
D3T06.4C	16:50	Rosacea Martin Steinhoff (Doha, Qatar)
D3T06.4D	17:15	Discussion, Q&A

Friday, 27 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.3

D3T07.1		Fillers II, Advanced Chairs: Pierre Andre (Paris, France)
D3T07.1A	08:30	Dangerous anatomic areas, interest of the new technique of ultrasonography Hugues Cartier (Arras, France)
D3T07.1B	08:50	Injection of the periocular area Marina Landau (Herzlia, Israel)
D3T07.1C	09:10	Complications of HA injections, except vascular compromise Pierre Andre (Paris, France)
D3T07.1D	09:30	What to do in case of vascular compromise? Jonathan A. Kadouch (Amstelveen, Netherlands)
D3T07.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.3

D3T07.2		Botulinum toxin II, Advanced Chairs: Hans-Joachim Laubach (Geneva, Switzerland)
D3T07.2A	10:15	Botulinum toxine and laser/light therapy - how to get the best results from a combination therapy Hans-Joachim Laubach (Geneva, Switzerland)
D3T07.2B	10:35	Botulinum toxine and hyaluronic acid - when, where and how to inject both - an advanced guide Christopher Rowland Payne (London, United Kingdom)
D3T07.2C	10:55	Botulinom toxine and the fibroblast - what is the evidence for scar treatment? Sadaf Sanii (Genève, Switzerland)
D3T07.2D	11:15	Addressing Facial Asymmetries and Anatomical Variations in Detail with Botulinum Toxin Emanuel Carvalheiro Marques (Prague, Czech Republic)
D3T07.2E	11:35	Discussion, Q&A

Friday, 27 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.3

D3T07.3		Lasers and energy-based devices II: Advanced, including complications management Chair: Ashraf Badawi (Oakville, Canada)
D3T07.3A	14:15	Laser assisted scar treatment, practical considerations Ahmed Sadek (Cairo, Egypt)
D3T07.3B	14:35	Non ablative Rejuvenation Expectations, too good to be true? Ashraf Badawi (Oakville, Canada)
D3T07.3C	14:55	Fractional Q Switched Lasers, is it really a break through in the laser field? Hagar El Sayed (Cairo, Egypt)
D3T07.3D	15:15	Updates on laser treatment of vascular lesions Pablo Boixeda (Madrid, Spain)
D3T07.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.3

D3T07.4		Energy based-devices: Body contouring and tightening Chairs: Ines Verner Rashkovsky (Savyon, Israel)
D3T07.4A	16:00	Body Contouring & Skin Tightening: What is Hot? Ines Verner Rashkovsky (Savyon, Israel)
D3T07.4B	16:15	Blades, Sound waves & Light: The latest treatment of cellulite Martin Kassir (Dallas, United States)
D3T07.4C	16:30	Cryolipolysis Present & Future Lillit Garibyan (Boston, United States)
D3T07.4D	16:45	ExoRF or endoRF, type of cooking: Medium, well-cooked or blue? Hugues Cartier (Arras, France)
D3T07.4E	17:00	The Science Behind Exosomes Todd Schlesinger (Charleston, United States)
D3T07.4E	17:15	Discussion, Q&A



Friday, 27 September 2024

CONTROVERSIES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.4

D3T08.1		Controversies V Chairs: Henry John Christiaan De Vries (Amsterdam, Netherlands) Margarida Gonalo (Coimbra, Portugal)
D3T08.1A	08:30	Introduction Henry John Christiaan De Vries (Amsterdam, Netherlands)
D3T08.1B	08:35	Can HPV vaccination treat genital warts? Yes Errol Prens (Rotterdam, Netherlands)
D3T08.1C	08:50	Can HPV vaccination treat genital warts? NO Maarten Schim van der Loeff (Amsterdam, Netherlands)
D3T08.1D	09:05	Discussion, Q&A
D3T08.1E	09:15	Introduction Margarida Gonalo (Coimbra, Portugal)
D3T08.1F	09:20	Is patch testing before metal-prosthesis beneficial? Yes Thomas Rustemeyer (Amsterdam, Netherlands)
D3T08.1G	09:35	Is patch testing before metal-prosthesis beneficial? No Peter Thomas (Munich, Germany)
D3T08.1G	09:50	Discussion, Q&A

CONTROVERSIES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.4

D3T08.2		Controversies VI Chairs: Eduardo Nagore (Valencia, Spain) Myrto-Georgia Trakatelli (Thessaloniki, Greece)
D3T08.2A	10:15	Introduction Eduardo Nagore (Valencia, Spain)
D3T08.2B	10:20	Lentigo maligna surgery. YES Ruggero Moro (València, Spain)
D3T08.2C	10:35	Lentigo maligna surgery. NO Aimilios Lallas (Thessaloniki, Greece)
D3T08.2D	10:50	Discussion, Q&A
D3T08.2E	11:00	Introduction Myrto-Georgia Trakatelli (Thessaloniki, Greece)
D3T08.2F	11:05	Should we be more interventional on actinic cheilitis ? YES Roland Kaufmann (Frankfurt, Germany)
D3T08.2G	11:20	Should we be more interventional on actinic cheilitis ? NO Styliani Siskou (Greece)
D3T08.2H	11:35	Discussion, Q&A



Friday, 27 September 2024

CONTROVERSIES

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.4

D3T08.3		Controversies VII Chairs: Eli Sprecher (Tel Aviv, Israel) Lajos Kemény (Szeged, Hungary)
D3T08.3A	14:15	Introduction Eli Sprecher (Tel Aviv, Israel)
D3T08.3B	14:20	Pharmacogenomics, delivering the promises ? YES Carlo Pincelli (Modena, Italy)
D3T08.3C	14:35	Pharmacogenomics, delivering the promises ? NO Hervé Bachelez (Paris, France)
D3T08.3D	14:50	Discussion, Q&A
D3T08.3E	15:00	Introduction Lajos Kemény (Szeged, Hungary)
D3T08.3F	15:05	Do we still need phototherapy in the era of biologics ? YES Rolland Gyulai (Pécs, Hungary)
D2T08.3G	15:20	Do we still need phototherapy in the era of biologics ? NO Jan Gutermuth (Brussels, Belgium)
D3T08.3H	15:35	Discussion, Q&A

CONTROVERSIES

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.4

D3T08.4		Controversies VIII Chairs: Lidiya Todorova (Plovdiv, Bulgaria) Paolo Gisondi (Verona, Italy)
D3T08.4A	16:00	Introduction Lidiya Todorova (Plovdiv, Bulgaria)
D3T08.4B	16:05	Is there evidence for cell-based therapy in skin rejuvenation? YES Evgenia Makrantonaki (Wildeshausen, Germany)
D3T08.4C	16:20	Is there evidence for cell-based therapy in skin rejuvenation? NO Brunilda Bardhi (Tirana, Albania)
D3T08.4D	16:35	Discussion, Q&A
D3T08.4E	16:45	Introduction Paolo Gisondi (Verona, Italy)
D3T08.4F	16:50	Are cardiometabolic comorbidities a disease manifestation of AD? YES Carmen Maria Salavastru (Bucharest, Romania)
D3T08.4G	17:05	Are cardiometabolic comorbidities a disease manifestation of AD? NO Andreas Wollenberg (Munich, Germany)
D3T08.4H	17:20	Discussion, Q&A

Friday, 27 September 2024

TRAINING AND EDUCATION

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.5

D3T09.1		Understanding genetics for dermatologists Chairs: Antoni Gostynski (Maastricht, Netherlands) Josefina Piñón Hofbauer (Salzburg, Austria)
D3T09.1A	08:30	Basic technologies Antoni Gostynski (Maastricht, Netherlands)
D3T09.1B	08:50	Advanced technologies Jeremy Di Domizio (Lausanne, Switzerland)
D3T09.1C	09:10	New layers of complexity in genetics Josefina Piñón Hofbauer (Salzburg, Austria)
D3T09.1D	09:30	New approaches to genetic counseling Edel O'Toole (London, United Kingdom)
D3T09.1E	09:50	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.5

D3T09.2		Genetics in translation Chair: Judith Fischer (Freiburg, Germany) Yuval Ramot (Jerusalem, Israel)
D3T09.2A	10:15	From rare to common diseases Matthias Schmuth (Innsbruck, Austria)
D3T09.2B	10:35	Preventing genetic diseases Judith Fischer (Freiburg, Germany)
D3T09.2C	10:55	Drug repurposing in genetic skin diseases Alain Hovnanian (Paris, France)
D3T09.2D	11:15	Guiding treatment choices through genetics Yuval Ramot (Jerusalem, Israel)
D3T09.2E	11:35	Discussion, Q&A

Friday, 27 September 2024

TRAINING AND EDUCATION

⌚ 14:15 – 15:45 CEST

📍 ROOM 7.5

D3T09.3		Psoriasis Chairs: Lluís Puig (Barcelona, Spain) Catherine Smith (London, United Kingdom)
D3T09.3A	14:15	Pathogenesis and the therapeutic landscape Tiago Torres (Porto, Portugal)
D3T09.3B	14:35	Comorbidities and their management Catherine Smith (London, United Kingdom)
D3T09.3C	14:55	Which drug for which patient? Reinhart Speeckaert (Gent, Belgium)
D3T09.3D	15:15	Subtypes and their management Lluís Puig (Barcelona, Spain)
D3T09.3E	15:35	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 16:00 – 17:30 CEST

📍 ROOM 7.5

D3T09.4		Autoimmune disorders Chairs: Luca Borradori (Bern, Switzerland) Enno Schmidt (Lübeck, Germany)
D3T09.4A	16:00	Rheumatology for the dermatologist Luis Perez (Rotterdam , Netherlands)
D3T09.4B	16:20	Polymorphic light eruption Marjan Garmyn (Leuven, Belgium)
D3T09.4C	16:40	Bullous pemphigoid Enno Schmidt (Lübeck, Germany)
D3T09.4D	17:00	Chronic oral erosions: practical diagnostic algorithm Luca Borradori (Bern, Switzerland)
D3T09.4E	17:20	Discussion, Q&A

Friday, 27 September 2024

TRAINING AND EDUCATION

⌚ 08:30 – 10:00 CEST

📍 E107 – E108

D3T10.1		Bullous diseases Chairs: Michael Hertl (Marburg, Germany) Aikaterini Patsatsi (Thessaloniki, Greece)
D3T10.1A	08:30	Inherited epidermolysis bullosa Jemima Mellerio (London, United Kingdom)
D3T10.1B	08:50	Pemphigus Michael Hertl (Marburg, Germany)
D3T10.1C	09:10	Bullous Pemphigoid Aikaterini Patsatsi (Thessaloniki, Greece)
D3T10.1D	09:30	Other acquired bullous diseases Joost Meijer (Groningen, Netherlands)
D3T10.1E	09:50	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 10:15 – 11:45 CEST

📍 E107 – E108

D3T10.2		Surgical therapy Chairs: Paola Pasquali (Cambrils, Spain) Michał Sobjanek (Gdansk, Poland)
D3T10.2A	10:15	Paediatric surgery Emanuel Carvalheiro Marques (Prague, Czech Republic)
D3T10.2B	10:35	Cryosurgery Paola Pasquali (Cambrils, Spain)
D3T10.2C	10:55	Biopsy techniques Michał Sobjanek (Gdansk, Poland)
D3T10.2D	11:15	Nail surgery Severin Läuchli (Zurich, Switzerland)
D3T10.2E	11:35	Discussion, Q&A

Friday, 27 September 2024

MISCELLANEOUS

⌚ 14:15 – 15:45 CEST

📍 E107 – E108

D3T10.3		Office management Chairs: Rolf Ostendorf (Monchengladbach, Germany) Monika Gniadecka (Herlev, Denmark)
D3T10.3A	14:15	Integrated dermatology practice in multidisciplinary team Konstantine Buxtorf Friedli (Sezegnin, Switzerland)
D3T10.3B	14:30	New ways cooperation between private office and hospital Menno Gaastra (Alkmaar, Netherlands)
D3T10.3C	14:45	How to change a solo office to a successful dermatologic center or hospital solo practice cooperating together Kristin Thorisdottir (Gardabaer, Iceland) Rolf Ostendorf / (Monchengladbach, Germany)
D3T10.3D	15:00	Changing patients demands Monika Gniadecka (Herlev, Denmark)
D3T10.3E	15:15	Integrated centers for skin emergencies and other skin diseases Georges Reuter (Strasbourg, France)
D3T10.3F	15:30	Discussion, Q&A

EADV GAMES

⌚ 16:00 – 17:30 CEST

📍 EMERALD

D3T10.4		EADV Games Chairs: Frederic Caux (Bobigny, France) Dedee Murrell (Sydney, Australia)
---------	--	---

The EADV Congress 2024 will host the first edition of the EADV Games, where 18 European countries will compete against each other in a thrilling quiz focusing on different dermatology topics.

18 Participating countries



Belgium



Czech Rep.



Denmark



Estonia



Finland



France



Germany



Hungary



Italy



Latvia



Netherlands



Poland



Portugal



Romania



Spain



Switzerland



Türkiye



UK

The participants of the winning team will get free registration to the next EADV Congress

More info eadv.org/congress/scientific/eadv-games/



Friday, 27 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 E103-E104

D3T11.1		Scars Chair: Vincenzo Bettoli (Ferrara, Italy) Klaus Fritz (Landau, Germany)
D3T11.1A	08:30	Is prevention of abnormal scar formation possible? Vincenzo Bettoli (Ferrara, Italy)
D3T11.1B	08:50	Pharmacological treatment of scars Øystein Grimstad (Tromsø, Norway)
D3T11.1C	09:10	Evidence based laser use for scar treatment Klaus Fritz (Landau, Germany)
D3T11.1D	09:30	Surgery and radiotherapy for scars Klaus Eisendle (Bolzano, Italy)
D3T11.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 E103-E104

D3T11.2		Wound healing Chairs: Elena Conde (Madrid, Spain) Catherine van Montfrans (Rotterdam, Netherlands)
D3T11.2A	10:15	Pathophysiology of wound healing Sabine Eming (Cologne, Germany)
D3T11.2B	10:35	Wound healing in chronic ulcer Ariela Hafner (Ramat Gan, Israel)
D3T11.2C	10:55	Dermatologist and the diabetic foot management Elena Conde (Madrid, Spain)
D3T11.2D	11:15	Advanced wound healing treatments Catherine van Montfrans (Rotterdam, Netherlands)
D3T11.2E	11:35	Discussion, Q&A

Friday, 27 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 E103-E104

D3T11.3		Neutrophilic diseases Chairs: Erkan Alpsoy (Antalya, Türkiye) Alex Ortega Loayza (Portland, United States)
D3T11.3A	14:15	Vexas syndrome Thibault Mahevas (Paris, France)
D3T11.3B	14:35	Behçet's disease Erkan Alpsoy (Antalya, Türkiye)
D3T11.3C	14:55	Pyoderma gangrenosum Alex Ortega Loayza (Portland, United States)
D3T11.3D	15:15	Inherited neutrophilic dermatoses Laurence Feldmeyer (Bern, Switzerland)
D3T11.3E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 E103-E104

D3T11.4		Occupational dermatology Chairs: Angelo Valerio Marzano (Milan, Italy) Sven Malte John (Osnabrück, Germany)
D3T11.4A	16:00	Treatments of hand eczema Claus Zachariae (Hellerup, Denmark)
D3T11.4B	16:20	New allergens in the occupational settings Thomas Rustemeyer (Amsterdam, Netherlands)
D3T11.4C	16:40	Managing atopic dermatitis in occupational settings Angelo Valerio Marzano (Milan, Italy)
D3T11.4D	17:00	Occupational skin cancer Sven Malte John (Osnabrück, Germany)
D3T11.4E	17:20	Discussion, Q&A

Friday, 27 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 G102-G103

D3T12.1		Bacterial skin infections Chairs: Emma Haentjens (Gent, Belgium) Jana Tresnak Hercogova (Prague, Czech Republic)
D3T12.1A	08:30	The rise of Mycoplasma Pneumoniae infections: what are skin signs? Emma Haentjens (Gent, Belgium)
D3T12.1B	08:50	Infectious complications following cosmetic procedures Rashmi Sarkar (Noida ,Uttar Pradesh, India)
D3T12.1C	09:10	Phage therapy of wound-associated infections Mateja Dolenc Voljc (Ljubljana, Slovenia)
D3T12.1D	09:30	Epidemiology of skin bacterial infections in Europe Jana Tresnak Hercogova (Prague, Czech Republic)
D3T12.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 G102-G103

D3T12.2		Viral skin infections Chairs: Kieron Leslie (San Francisco, United States) Peter Friedman (New City, United States)
D3T12.2A	10:15	Viruses and skin cancer Vincent Piguet (Toronto, Canada)
D3T12.2B	10:35	HHV8 and Kaposi sarcoma Nicolas Dupin (Paris, France)
D3T12.2C	10:55	HIV as a chronic disease Kieron Leslie (San Francisco, United States)
D3T12.2D	11:15	Warts: new treatment options Peter Friedman (New City, United States)
D3T12.2E	11:35	Discussion, Q&A

Friday, 27 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 G102-G103

D3T12.3		Fungal skin infections Chairs: Emmanuella Guenova (Lausanne, Switzerland) Roderick James Hay (London, United Kingdom)
D3T12.3A	14:15	Terbinafine resistance in dermatophytic nail and skin infections Emmanuella Guenova (Lausanne, Switzerland)
D3T12.3B	14:35	Deep cutaneous fungal infections Carmen Rodríguez Cerdeira (Vigo, Spain)
D3T12.3C	14:55	Changes in epidemiology of dermatophytes Ditte Marie Saunte (Virum, Denmark)
D3T12.3D	15:15	Novel diagnostic procedures Roderick James Hay (London, United Kingdom)
D3T12.2E	15:35	Discussion, Q&A

UPDATES

⌚ 16:00 – 17:30 CEST

📍 G102-G103

D3T12.4		Proctology for dermatologists Chairs: Giovanni Paolino (Milan, Italy) Matthijs Siegenbeek van Heukelom (Amsterdam, Netherlands)
D3T12.4A	16:00	Hemorrhoids Jacqueline van Laarhoven (Netherlands)
D3T12.4B	16:20	Perianal fistular diseases Jacqueline van Laarhoven (Netherlands)
D3T12.4C	16:40	Anal cancer and precursor lesions Matthijs Siegenbeek van Heukelom (Amsterdam, Netherlands)
D3T12.4D	17:00	Anal melanoma: how different is it? Giovanni Paolino (Milan, Italy)
D3T12.4E	17:20	Discussion, Q&A

Friday, 27 September 2024

FREE COMMUNICATIONS

⌚ 08:30 – 10:00 CEST

📍 G104-G105

FC05		Free Communications 5 Chairs: Adam Reich (Rzeszow, Poland) Christina Fotiadou (Thessaloniki, Greece)
FC05.01	08:30	Efficacy and safety of vunakizumab in moderate-to-severe psoriasis across different BMI classifications Linfeng Li (Beijing, China)
FC05.02	08:40	TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, elicits early skin responses and minimal disease activity in patients with active psoriatic arthritis: results from a randomized phase 2b study Alice B. Gottlieb (New York, United States)
FC05.03	08:50	Artificial Intelligence-based identification of generalized pustular psoriasis: Early diagnosis to potentiate timely treatment Marta Van Beek (Iowa City, United States)
FC05.04	09:00	International consensus definition and diagnostic criteria for generalized pustular psoriasis from the International Psoriasis Council Siew Eng Choon (Johor Bahru, Malaysia)
FC05.05	09:10	Healthcare resource utilisation of patients with generalised pustular psoriasis in Germany Bhargav Lakshminarasimhan (Ingelheim am Rhein, Germany)
FC05.06	09:20	Insights into generalised pustular psoriasis (GPP) in the United Kingdom: Findings from the SCRIPTOR study Marie Li (Bracknell, United Kingdom)
FC05.07	09:30	Sutterella wadsworthensis as a hallmark of the gut microbiome in patients with severe psoriasis Sueli Coelho Da Silva Carneiro (Rio De Janeiro, Brazil)
FC05.08	09:40	Identifying super responders who remain treatment free for more than 2 years after guselkumab withdrawal: data from the Phase 3b GUIDE trial in psoriasis Kilian Eyerich (Freiburg, Germany)
FC05.09	09:50	Psoriatic lesions in human skin xenotransplants in vivo are triggered by perceived stress and can be suppressed by the neurokinin-1 receptor antagonist aprepitant Ralf Paus (Miami, United States)

FC06		Free Communications 6 Chairs: Christian Vestergaard (Aarhus N, Denmark) Cristina Has (Freiburg, Germany)
FC06.01	10:15	Current status, patient profiles and impact on health care through the German Psoriasis Registry PsoBest Matthias Augustin (Hamburg, Germany)
FC06.02	10:25	GUIDE trial (part 3): Following guselkumab withdrawal and a long treatment-free period, disease control is rapidly regained upon re-treatment in psoriasis super-responders Khusru Asadullah (Berlin, Germany)
FC06.03	10:35	Longitudinal evaluation of neutrophil-to-lymphocyte ratio in guselkumab-treated patients with psoriatic disease and levels of systemic inflammation associated with elevated cardiovascular risk: post hoc analysis of 4 phase 3, randomized, controlled studies Joseph Merola (Boston, United States)
FC06.04	10:45	ESK-001, an allosteric TYK2 inhibitor, modulates disease and TYK2-related pathway transcriptomic biomarkers in Psoriasis STRIDE trial patients Mera Tilley
FC06.05	10:55	Apremilast in patients with moderate to severe genital psoriasis: Week 32 Results from the phase 3 DISCREET study Joseph Merola (Boston, United States)
FC06.06	11:05	Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK 2) inhibitor, in patients with moderate to severe scalp psoriasis: patient-reported outcomes at Week 16 of a phase 3b/4 multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP) Diamant Thaçi (Luebeck, Germany)
FC06.07	11:15	Risankizumab differentially modifies psoriatic pathogenetic T-cells populations based on patient's autoreactivity status. Paola Facheris (New York, United States)
FC06.08	11:25	Bimekizumab treatment in plaque psoriasis resulted in a rapid and deep normalisation of molecular signatures associated with PASI sub-components, that preceded clinical skin clearance Ioana Cutcutache (Slough, United Kingdom)
FC06.09	11:35	Early and durable improvements in patient-reported symptoms and signs of moderate-to-severe psoriasis with JNJ-77242113: 1-year results from FRONTIER 1 & 2 April Armstrong (Los Angeles, United States)



FC07		Free Communications 7 Chairs: Mateja Dolenc Voljc (Ljubljana, Slovenia) Deepak Balak (Leiden, Netherlands)
FC07.01	14:15	Clinical characteristics and treatment patterns of psoriasis in Asia and Switzerland: results of the multicentre Global Healthcare Study on Psoriasis (GHSP) Chong Yao Ho (Singapore, Singapore)
FC07.02	14:25	The dermatologist's role in cardiovascular risk screening in moderate-to-severe psoriasis Péter Holló (Budapest, Hungary)
FC07.03	14:35	Clinical characteristics of generalized pustular psoriasis: A large retrospective cohort in China Zhiqiang Cao (Xi'an, China)
FC07.04	14:45	Treatment response of delgocitinib cream according to Chronic Hand Eczema (CHE) subtypes in adults with moderate to severe CHE: results from the Phase 3 DELTA 1, DELTA 2, and DELTA 3 trials Robert Bissonnette (Montreal, Canada)
FC07.05	14:55	Safety of Baricitinib for the treatment of atopic dermatitis over a median of 1.6 and up to 4.6 years treatment: Final integrated analysis of 8 clinical trials Antonio Costanzo (Milan, Italy)
FC07.06	15:05	ATTO-1310: A first-in-class anti-IL31 Attobody® for atopic dermatitis and other pruritic diseases David Bellovin (Fremont, United States)
FC07.07	15:15	IL-1 targeting agents in Schnitzler syndrome: a multicenter, retrospective, real-world study from the international AIDA Network registry Laura Calabrese (Siena, Italy)
FC07.08	15:25	Unfolding dermatologic spectrum of adult onset Still disease: real-life data from the International AIDA Registry Laura Calabrese (Siena, Italy)
FC07.09	15:35	Two-year follow-up of dupilumab patients in routine care for atopic eczema: results from the German national registry TREATgermany Thomas Birkner (Dresden, Germany)

FC08		Free Communications 8 Chairs: Dusan Skiljevic (Belgrade, Serbia) Aikaterini Patsatsi (Thessaloniki, Greece)
FC08.01	16:00	68-week safety results of amlitelimab (an anti-OX40 Ligand antibody) in patients with moderate-to-severe atopic dermatitis from STREAM-AD Phase 2b dose-ranging and withdrawal study Stephan Weidinger (Kiel, Germany)
FC08.02	16:10	Stringent efficacy response of skin clearance and itch-free state with abrocitinib 100 mg versus dupilumab in patients with moderate-to-severe atopic dermatitis: A post hoc analysis of JADE COMPARE Stephan Weidinger (Kiel, Germany)
FC08.03	16:20	Sustained achievement of no or minimal patient-reported atopic dermatitis skin symptoms with long-term upadacitinib use: Week 140 results from phase 3 Measure Up 1 and Measure Up 2 clinical trials Raj Chovatiya (Chicago, United States)
FC08.04	16:30	Efficacy and safety of upadacitinib vs dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: Results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up) Kilian Eyerich (Freiburg, Germany)
FC08.05	16:40	Characterization of atopic dermatitis medication use before and during pregnancy in the United States Andrea Marcus (Tarrytown, NY, United States)
FC08.06	16:50	Real-world effectiveness of risankizumab in biologic-naïve and biologic-experienced patients with psoriasis at 2 years of treatment: an interim analysis from VALUE, a multicountry, postmarketing observational study Diamant Thaçi (Luebeck, Germany)
FC08.07	17:00	Investigation of dynamics in skin barrier function of atopic dermatitis following targeted therapy Fang Wang (Guangzhou, China)
FC08.08	17:10	Efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SHR-1819 in patients with moderate-to-severe atopic dermatitis (AD): a multicenter, randomized, double-blind, placebo-controlled phase 2 study Chaoying Gu (Shanghai, China)
FC08.09	17:20	Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study Emma Guttman-Yassky (New York, United States)

Friday, 27 September 2024

RESIDENTS TRACK

⌚ 08:30 – 12:15 CEST

📍 OPEN STAGE

D3T14.1		RESIDENTS TRACK Chairs: Hok Bing Thio (Rotterdam, Netherlands) Markus Vincent Starink (Amstelveen, Netherlands)
D3T14.1A	08:30	Dermatology training in Europe 2030: what are the challenges? Petr Arenberger (Prague, Czech Republic)
D3T14.1B	09:00	Can you train in an academic enviroment? Markus Vincent Starink (Amstelveen, Netherlands)
D3T14.1C	09:15	Can you train in a non-academic environment? Birgitte Visch (Arnhem, Netherlands)
	09:30	Break
D3T14.1D	09:45	Skin of colour in training Esther Lai-A-Fat (Paramaribo, Suriname)
D3T14.1E	10:15	Lifestyle in dermatology Deepak Balak (Leiden, Netherlands)
D3T14.1F	10:45	Break
D3T14.1G	11:00	Residents personal stories Miguel Jansen (Rotterdam, Netherlands)
D3T14.1H	11:10	Residents personal stories Amy Livesey (Portsmouth, United Kingdom)
D3T14.1I	11:20	Residents personal stories Luc Laumen (Maastricht, Netherlands)
D3T14.1L	11:30	Q&A session successful dermatologists Tiago R Matos (Amsterdam, Netherlands) Enikö Sonkoly (Uppsala, Sweden) Jo LW Lambert (Ghent, Belgium) Tiago R Matos (Amsterdam, Netherlands)

RESIDENTS TRACK

⌚ 14:00 – 15:30 CEST

📍 OPEN STAGE

D3T14.2		RESIDENTS TRACK Chairs: Hok Bing Thio (Rotterdam, Netherlands) Markus Vincent Starink (Amstelveen, Netherlands)
D3T14.2A	14:00	Targeted therapies: is it sustainable? YES Peter C.M. Van de Kerkhof (Eefde, Netherlands)
D3T14.2B	14:22	Targeted therapies: is it sustainable? NO Matthias Augustin (Hamburg, Germany)
D3T14.2C	14:45	Do you need to be a physician to perform dermatologist's task? Paola Pasquali (Cambrils (TA), Spain)

Scientific Programme

Saturday, 28 September 2024

Programme at a glance

Plenary lecture	12:00 – 13:00
Auditorium	Plenary Lectures C

Sessions	08:30 – 10:00	10:15 – 11:45	14:15 – 15:45	16:00 – 17:30
Auditorium	Acne	Acne	IEC - International Eczema Council	
Elicium	Pruritus	Chronic prurigo	Scars and wound healing	
Room 3.1	Hypopigmentation	Hyperpigmentation		
Forum	Varicose veins	Chronic leg ulcers	ISD – International society of Dermatology	
Room 7.1	International Society for Paediatric Dermatology: Challenging clinical cases	Hot topics in Dermatology selected by the EADV President		
Room 7.2	Peeling	Aesthetic dermatology for medical indications		
Room 7.3	Red flags and emergencies in dermatology	Psychodermatology		
Room 7.4	Paediatric dermatology: Pathogenesis	Paediatric dermatology: Management		
Room 7.5	Infectious diseases	Skin and systemic diseases		
E107-E108	Dermatopathology	Basics of dermatological technologies	IADVL – Indian Association of Dermatologists, Venereologists and Leprologists	
E103-E104		Dermatoses in challenging environmental conditions	SSDDS – Saudi society of dermatology and dermatologic surgery	
G102-G103	IPS - International Peeling Society		EURO-PDT – European Society for Photodynamic Therapy in Dermatology	
G104-G105		ESDP - European Society for Dermatopathology	ESDaP – European Society of Dermatology and Psychiatry	
E102			MEIDAM	
D202	Surgery - Basic		Surgery – Intermediate	
D203	Get your papers published: tips and tricks from the editors		Wound healing	
Open stage	[09:00 – 12:30] Residents track			
Emerald	Tools to aid consultation	Chronic inflammatory skin diseases - HS & AD	Caring for chronic inflammatory skin diseases	Nurse education & research

Saturday, 28 September 2024

PLENARY SESSION

⌚ 12:00 – 13:00 CEST

📍 AUDITORIUM

	Plenary lectures C Chairs: Menno de Rie (Breukelen, Netherlands) Carmen Maria Salavastru (Bucharest, Romania)
12:00	JAK inhibition: Quo vadis? Massimo Gadina (Bethesda, United States)
12:20	ESDR plenary lecture: "Insights on the skin barrier from severe ichthyosis" Edel O'Toole (London, United Kingdom)
12:40	René Touraine plenary lecture:" The role of dermatopathology in modern dermatology" Dieter Metze (Munster, Germany)



Saturday, 28 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 AUDITORIUM

D4T01.1		Acne Chairs: Brigitte Dréno (Nantes, France) José Luis López Estebarez (Madrid, Spain)
D4T01.1A	08:30	New guidelines in acne Alison Layton (York, United Kingdom)
D4T01.1B	08:50	Spironolactone: a place in the algorithm of adult female acne Brigitte Dréno (Nantes, France)
D4T01.1C	09:10	Acne scars: prevention and treatment Sewon Kang (Baltimore, United States)
D4T01.1D	09:30	Acne associated hyperpigmentation: dos and don'ts Jose Luis Lopez-Estebarez (Madrid, Spain)
D4T01.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 AUDITORIUM

D4T01.2		Acne Chairs: Vincenzo Bettoli (Ferrara, Italy) Lajos Kemény (Szeged, Hungary)
D4T01.2A	10:15	Management of acne in transgender patients Nicolas Kluger (Helsinki, Finland)
D4T01.2B	10:35	Is there a place for biologics in acne? Lajos Kemény (Szeged, Hungary)
D4T01.2C	10:55	Low doses of isotretinoin: risk/benefit ratio Vincenzo Bettoli (Ferrara, Italy)
D4T01.2D	11:15	Light and acne: myth or reality Margarita Larralde (Buenos Aires, Argentina)
D4T01.2E	11:35	Discussion, Q&A

Saturday, 28 September 2024

SUBSPECIALTY SESSION

⌚ 14:15 – 17:30 CEST

📍 AUDITORIUM

	IEC – International Eczema council Chairs: Robert Bissonnette (Montreal, Canada) Tove Agner (Copenhagen, Denmark)
14:15	Welcome and introduction from the International Eczema Council Alan Irvine (Dublin, Ireland)
14:25	Chronic hand eczema Tove Agner (Copenhagen, Denmark)
14:40	Are biomarkers helpful for identification of subtypes? Caroline Meyer Olesen (Copenhagen, Denmark)
14:55	What is the role of the microbiome in CHE and should we treat it? Line Brok Nørreslet (Denmark)
15:10	Frequent and important contact allergies in non-occupational CHE Margarida Gonçalo (Coimbra, Portugal)
15:25	How to prevent occupational hand eczema: Simple and novel solutions Sven Malte John (Osnabrück, Germany)
15:40	HE in childhood: How to treat and prevent progression Lawrence Eichenfield (San Diego, United States)
16:10	Traditional and novel topical treatments for CHE Sonja Molin (Kingston, Canada)
16:30	Systemic treatments: Which one should I choose? Marie-Louise Schuttelaar (Groningen, Netherlands)
16:50	Investigational treatments we may soon be able to add to our armamentarium Robert Bissonnette (Montreal, Canada)
17:10	Q & A: Presenter Panel Discussion

Saturday, 28 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ELICIUM

D4T02.1		Pruritus Chairs: Jacek Szepietowski (Wroclaw, Poland) Gil Yosipovitch (Miami, United States)
D4T02.1A	08:30	Neuroimmune regulation of itch Hongzhen Hu (New York, United States)
D4T02.1B	08:50	Hepatic and uremic itch Gil Yosipovitch (Miami, United States)
D4T02.1C	09:10	Paraneoplastic itch Jacek Szepietowski (Wroclaw, Poland)
D4T02.1D	09:30	Neuropathic itch Laurent Misery (Brest, France)
D4T02.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ELICIUM

D4T02.2		Chronic prurigo Chairs: Kenji Kabashima (Kyoto, Japan) Bernhard Homey (Düsseldorf, Germany)
D4T02.2A	10:15	Pathophysiology Kenji Kabashima (Kyoto, Japan)
D4T02.2B	10:35	Phenotypes and diagnostic workup Martin Metz (Berlin, Germany)
D4T02.2C	10:55	New therapies targeting immune dysregulation Bernhard Homey (Düsseldorf, Germany)
D4T02.2D	11:15	New therapies targeting neural dysregulation Sonja Ständer (Münster, Germany)
D4T02.2E	11:35	Discussion, Q&A

Saturday, 28 September 2024

UPDATES

⌚ 14:15 – 15:45 CEST

📍 ELICIUM

D4T02.3		Scars and wound healing Chairs: Keyvan Nouri (Miami, United States)
D4T02.3A	14:15	Lasers for Treatment of Scars Overview Christine Dierickx (Luxembourg, Luxembourg)
D4T02.3B	14:35	Treatment of Scars in Skin of Colour Mukta Sachdev (Bangalore, India)
D4T02.3C	14:55	Fractional Laser/Drug Delivery for Treatment of Scars Merete Haedersdal (Copenhagen, Denmark)
D4T02.3D	15:15	What's New for Treatment of Scars Brian Berman (Miami Beach, United States)
D4T02.3D	15:35	Discussion, Q&A

Saturday, 28 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 3.1

D4T03.1		Hypopigmentation Chairs: Nanja van Geel (Gent, Belgium) Jelena Stojkovic-Filipovic (Belgrade, Serbia)
D4T03.1A	08:30	Hypopigmentation as a clue for genetic diseases Nanja van Geel (Gent, Belgium)
D4T03.1B	08:50	Diagnostic algorithm for hypo- and de-pigmentation Albert Wolkerstorfer (Amsterdam, Netherlands)
D4T03.1C	09:10	Hypopigmentation in skin of colour Nkechi Anne Enechukwu (Nnewi, Nigeria)
D4T03.1D	09:30	Drug-induced hypo and hyperpigmentation Jelena Stojkovic-Filipovic (Belgrade, Serbia)
D4T03.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 3.1

D4T03.2		Hyperpigmentation Chairs: Jean Krutmann (Dusseldorf, Germany) Mauro Picardo (Rome, Italy)
D4T03.2A	10:15	Pathogenesis of melasma Mauro Picardo (Rome, Italy)
D4T03.2B	10:35	Prevention and treatment of melasma Robert Artur Dahmen (Zürich, Switzerland)
D4T03.2C	10:55	Post- inflammatory hyperpigmentation Marta Sar-Pomian (Warsaw, Poland)
D4T03.2D	11:15	Acquired pigmentary disorders Jean Krutmann (Dusseldorf, Germany)
D4T03.2E	11:35	Discussion, Q&A

Saturday, 28 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 FORUM

D4T04.1		Varicose veins Chairs: Felizitas Pannier (Bonn, Germany) Simone Van der Velden (Eindhoven, Netherlands)
D4T04.1A	08:30	Pathophysiology of venous insufficiency Tobias Gorge (Munster, Germany)
D4T04.1B	08:50	Advanced diagnostic techniques Felizitas Pannier (Bonn, Germany)
D4T04.1C	09:10	Current and emerging treatments Simone Van der Velden (Eindhoven, Netherlands)
D4T04.1D	09:30	Skin signs of venous insufficiency and their management Rutger Isaäc Frederik van der Waal (Hilversum, Netherlands)
D4T04.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 FORUM

D4T04.2		Chronic leg ulcers Chairs: Kirsi Isoherranen (Helsinki, Finland) Damien Pastor (Genève, Switzerland)
D4T04.2A	10:15	Vascular ulcers Kirsi Isoherranen (Helsinki, Finland)
D4T04.2B	10:35	Inflammatory ulcers Valentina Dini (Pisa, Italy)
D4T04.4C	10:55	Ulcers induced by physical insults Damien Pastor (Genève, Switzerland)
D4T04.4D	11:15	Neoplastic ulcers Pier Alessandro Fanti (Bologna, Italy)
D4T04.4E	11:35	Discussion, Q&A

Saturday, 28 September 2024

SUBSPECIALTY SESSION

⌚ 14:15 – 17:30 CEST

📍 FORUM

	ISD - International society of dermatology Chairs: Nellie Konnikov (Boston, United States) Leopoldo Santos (Sao Paulo, Brazil) Jacek Szepietowski (Wroclaw, Poland)
14:15	Introduction
14:20	Female androgenetic alopecia: Antiandrogenic treatment Rita Guedes (Vila Nova De Gaia, Portugal)
14:30	Alopecia areata: Treatment update Lidia Rudnicka (Warsaw, Poland)
14:45	Tinea capitis - how I treat Daniela Guzman (Guadalajara, Mexico)
14:55	How to avoid hair damage from hair care practice Awatef Kelati (Casablanca, Morocco)
15:05	Q&A
15:20	Therapeutic uses of botulinum toxin: A guide for a clinical dermatologist Hassan Galadari (Dubai, United Arab Emirates)
15:30	From residency to real world: My first 5 years practicing dermatology Samar Khalil (Sarba, Jounieh, Lebanon)
15:40	The trichoscopy of eyebrow Svjetlana Ponorac (Ljubljana, Slovenia)
15:50	Beyond borders: The ISD mentorship program Alejandra de la O Escamilla (Monterrey, Mexico)
16:00	Dermatological Life Quality assessment among patients afflicted by various cutaneous diseases Navlin Naidoo (Bloemfontein, South Africa)
16:10	Q&A
16:20	Atopic dermatitis - how we should approach our children? Silvia Soutto Mayor (Brazil, Brazil)
16:30	International consensus on the treatment of scars with energy-based devices Alexander Turkevych (Lviv, Ukraine)
16:40	Pharmaceutical Methuselahs: old but gold drugs Omid Zargari (Rasht, Iran)
16:50	Hand eczema - subjective symptoms revisited Adam Zalewski (Wrocław, Poland)
17:00	Q&A

Saturday, 28 September 2024

MISCELLANEOUS

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.1

D4T05.1		International Society for Paediatric Dermatology: Challenging clinical cases Chairs: Amy Paller (Chicago, United States)
D4T05.1A	08:30	Introduction Amy Paller (Chicago, United States)
D4T05.1B	08:35	Quiz 1 Christine Bodemer (Paris, France)
D4T05.1C	08:50	New genodermatoses Arti Nanda (Salmiya, Kuwait)
D4T05.1D	09:07	Skin of colour Mark Koh (Singapore, Singapore)
D4T05.1E	09:24	Quiz 2 Antonio Torrelo (Madrid, Spain)
D4T05.1F	09:39	Neonatal tumors Margarita Larralde (Buenos Aires, Argentina)
D4T05.1G	09:56	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.1

D4T05.2		Hot topics in dermatology selected by the EADV President Chairs: Martin Röcken (Tübingen, Germany) Branka Marinovic (Zagreb, Croatia) Alexander Stratigos (Athens, Greece)
D4T05.2A	10:15	From genetics to clinical care in dermatology: time to bring down the walls Eli Sprecher (Tel Aviv, Israel)
D4T05.2B	10:40	Skin signs of torture and trafficking Jan Gutermuth (Brussels, Belgium)
D4T05.2C	11:05	Genetics and skin cancer Susana Puig (Barcelona, Spain)
D4T05.2D	11:30	Discussion, Q&A

Saturday, 28 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.2

D4T06.1		Peeling Chair: Felipe Ribeiro (São Paulo, Brazil)
D4T06.1A	08:30	Peels for acne Felipe Ribeiro (São Paulo, Brazil)
D4T06.1B	08:50	What's new in peels in skin of colour ? Mukta Sachdev (Bangalore, India)
D4T06.1C	09:10	Lessons from croton-oil phenol peel Ediléia Bagatin (Sao Paulo, Brazil)
D4T06.1D	09:30	History on Chemical Peels Manal Bosseila (Cairo, Egypt)
D4T06.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.2

D4T06.2		Aesthetic dermatology for medical indications Chairs: Klaus Fritz (Landau, Germany)
D4T06.2A	10:15	Aesthetic procedures for post injury scar treatments Alexander Turkevych (Lviv, Ukraine)
D4T06.2B	10:35	Fractional approaches for drug delivery Merete Haedersdal (Copenhagen, Denmark)
D4T06.2C	10:55	Energy based devices for acne and acne scars Ines Verner Rashkovsky (Savyon, Israel)
D4T06.2D	11:15	The impact of diabetes in aesthetic dermatology and procedures Klaus Fritz (Landau, Germany)
D4T06.2E	11:35	Discussion, Q&A



Saturday, 28 September 2024

UPDATES

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.3

D4T07.1		Red flags and emergencies in dermatology Chairs: Olivier Chosidow (Créteil, France) Anusuya Kawsar (London, United Kingdom)
D4T07.1A	08:30	Skin toxicities associated with immune checkpoint inhibitors Anusuya Kawsar (London, United Kingdom)
D4T07.1B	08:50	Stings and bites Giovanni Paolino (Milano, Italy)
D4T07.1C	09:10	Necrotising fasciitis Olivier Chosidow (Créteil, France)
D4T07.1D	09:30	Toxic epidermal necrolisis and Staphylococcal Scalded Skin Syndrome Bayanne Olabi (Newcastle , United Kingdom)
D4T07.1E	09:50	Discussion, Q&A

UPDATES

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.3

D4T07.2		Psychodermatology Chairs: Francesca Sampogna (Rome, Italy) Andrea Maderal (Miami, United States)
D4T07.2A	10:15	Youngsters and social media induced skin diseases Sylvia van Beugen (Leiden, Netherlands)
D4T07.2B	10:35	Psychodermatology multidisciplinary services Francesca Sampogna (Rome, Italy)
D4T07.2C	10:55	Generalized and nonlocal dysesthesia Andrea Maderal (Miami, United States)
D4T07.2D	11:15	Isotretinoin and the risk for psychiatric events Speaker TBC
D4T07.2E	11:35	Discussion, Q&A

Saturday, 28 September 2024

TRAINING AND EDUCATION

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.4

D4T08.1		Paediatric dermatology: Pathogenesis Chairs: Michela Starace (Bologna, Italy) Antonio Torrelo (Madrid, Spain)
D4T08.1A	08:30	Autoinflammatory diseases in children Antonio Torrelo (Madrid, Spain)
D4T08.1B	08:50	Erythroderma in the newborn Iria Neri (Bologna, Italy)
D4T08.1C	09:10	Nail disorders in children Michela Starace (Bologna, Italy)
D4T08.1D	09:30	Haemangiomas Suzanne Pasmans (Rotterdam, Netherlands)
D4T08.1E	09:50	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.4

D4T08.2		Paediatric dermatology: Management Chairs: Ulrike Blume-Peytavi (Berlin, Germany) Michela Starace (Bologna, Italy)
D4T08.2A	10:15	Genodermatoses Edel O'Toole (London, United Kingdom)
D4T08.2B	10:35	Inflammatory diseases Karoline Krause (Berlin, Germany)
D4T08.2C	10:55	Hair disorders in children Ulrike Blume-Peytavi (Berlin, Germany)
D4T08.2D	11:15	Congenital melanocytic nevi Suzanne Pasmans (Rotterdam, Netherlands)
D4T08.2E	11:35	Discussion, Q&A

Saturday, 28 September 2024

TRAINING AND EDUCATION

⌚ 08:30 – 10:00 CEST

📍 ROOM 7.5

D4T09.1		Infectious diseases Chairs: Valeska Padovese (Msida, Malta) Ditte Marie Saunte (Virum, Denmark)
D4T09.1A	08:30	Scabies Hilde Lapeere (Gent, Belgium)
D4T09.1B	08:50	Traveller's diseases Valeska Padovese (Msida, Malta)
D4T09.1C	09:10	Cellulitis Cord Sunderkoetter (Halle, Germany)
D4T09.1D	09:30	Warts Ditte Marie Saunte (Virum, Denmark)
D4T09.1E	09:50	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 10:15 – 11:45 CEST

📍 ROOM 7.5

D4T09.2		Skin and systemic diseases Chairs: Selim Aractingi (Paris, France) Alexander Navarini (Basel, Switzerland)
D4T09.2A	10:15	Inflammatory bowel disease Alexander Navarini (Basel, Switzerland)
D4T09.2B	10:35	Paraneoplastic manifestations Marcia Ramos-e-Silva (Rio de Janeiro, Brazil)
D4T09.2C	10:55	Calciphylaxis Markus Böhm (Münster, Germany)
D4T09.2D	11:15	Endocrinopathies Selim Aractingi (Paris, France)
D4T09.2E	11:35	Discussion, Q&A

Saturday, 28 September 2024

TRAINING AND EDUCATION

⌚ 08:30 – 10:00 CEST

📍 E107-E108

D4T10.1		Dermatopathology Chairs: Gürkan Kaya (Geneva, Switzerland)
D4T10.1A	08:30	Systematic approach to inflammatory skin diseases Gürkan Kaya (Geneva, Switzerland)
D4T10.1B	08:50	Systematic approach to neoplastic skin diseases Jose Carlos Cardoso (Coimbra, Portugal)
D4T10.1C	09:10	How to order the right immuno-stain Helmut Beltraminelli (Bellinzona, Switzerland)
D4T10.1D	09:30	Immuno-fluorescence Ralf Ludwig (Lübeck, Germany)
D4T10.1E	09:50	Discussion, Q&A

TRAINING AND EDUCATION

⌚ 10:15 – 11:45 CEST

📍 E107-E108

D4T10.2		Basics of dermatological technologies Chairs: Yolanda Gilaberte Calzada (Zaragoza, Spain) Ralf Ludwig (Lübeck, Germany)
D4T10.2A	10:15	Lasers Laurence Imhof (Zürich, Switzerland)
D4T10.2B	10:35	Phototherapy and photodynamic therapy Yolanda Gilaberte Calzada (Zaragoza, Spain)
D4T10.2C	10:55	LC-OCT (Line-field confocal - optical coherence tomography) and ultrasound Mariano Suppa (Brussels, Belgium)
D4T10.2D	11:15	Total body photography Ashfaq Marghoob (Hauppauge, United States)
D4T10.2E	11:35	Discussion, Q&A

Saturday, 28 September 2024

SUBSPECIALTY SESSION

⌚ 14:15 – 17:30 CEST

📍 E107 – E108

	IADVL - Indian Association of Dermatologists, Venereologists and Leprologists Chairs: Manjunath Shenoy (Mangalore, India) Bhumeshkumar Katakam (Hyderabad, India) Shyam Verma (Vadodara, India) Rashmi Sarkar (Noida, Uttar Pradesh, India)
14:15	Microneedle radio frequency for acne scars: Patient and physician's perspective Meghna Sharma (Rajpura, India)
14:25	Management of lichen planus in pediatric age group Sudarshan Gaurkar (sangli, India)
14:35	Acanthosis nigricans: Insight about management and challenges Shraddha Ingole (Nagpur, India)
14:45	How I manage challenging cases in paediatric dermatoses Bhumeshkumar Katakam (Hyderabad, India)
14:55	Conventional and newer modalities for the management of neuralgia associated with herpes zoster Vanya Narayan (New Delhi, India)
15:05	Chronic dermatophytosis in coastal Karnataka (India) - an evaluation of clinical, conventional and molecular diagnosis Manjunath Shenoy (Mangalore, India)
15:15	Lepra reactions: What's known and what's new Kinnor Das (Silchar, India)
15:24	Clinico-serological spectrum of SLE Meghana Phiske (Navi Mumbai, India)
15:33	Clinicopathologic spectrum of cutaneous adnexal tumors Geeti Khullar (New Delhi, India)
15:42	Management of mycetoma: Actinomycetoma vs eumycetoma Parul Verma (Lucknow, India)
15:51	Management of ingrown toe nail with the best therapeutic and aesthetic outcome Raghunath Reddy (India)
16:00	Management of post surgical Non tubercular mycobacterial infections Sushruta Dash (New Delhi, India)
16:09	My tryst with targeted phototherapy in Dermatology Sujay Khandpur (New Delhi, India)
16:18	Updates in management of androgenetic alopecia Dinesh Kumar Devaraj (Chennai, India)
16:27	Therapeutic updates in acne management Rashmi Mittal (Dehradun, India)
16:36	What is new in the management of atopic dermatitis? Abhishek De (Kolkata, India)

16:45	Oral minoxidil in alopecia Kiran Vasant Godse (Navi Mumbai, India)
16:54	Treatment perspectives in female pattern alopecia Anuradha Kakkanatt Babu (Kochi, India)
17:03	Emerging animal pox: A professional hazard Anil Bhokare (Malegaon, India)
17:12	Dermal compartment in vitiligo and its therapeutic implications Vishal Thakur (Bathinda, India)
17:21	Recent advances in STIs Yogesh Marfatia (Vadodara, India)

Saturday, 28 September 2024

MISCELLANEOUS

⌚ 08:30 – 10:00 CEST

📍 E103-E104

D4T11.2		Dermatoses in challenging environmental conditions Chairs: Federica Dassoni (Milan, Italy) Aleksandr Litus (Kyiv, Ukraine)
D4T11.2A	10:15	Natural disasters Aleksandr Sumenko (Hamburg , Germany)
D4T11.2B	10:35	Street Medicine Marcel Roswora (Hamburg, Germany)
D4T11.2C	10:55	Combat-related skin injuries Aleksandr Litus (Kyiv, Ukraine)
D4T11.2D	11:15	Role of deployed dermatologist during humanitarian missions Federica Dassoni (Milan, Italy)
D4T11.2E	11:35	Discussion, Q&A

Saturday, 28 September 2024

SUBSPECIALTY SESSION

⌚ 14:15 – 17:30 CEST

📍 E103 – E104

	SSDDS – Saudi society of dermatology and dermatologic surgery Chairs: Abdullah Alakeel (Riyadh, Saudi Arabia) Afaf Alshiekh (Riyadh, Saudi Arabia) Maysa Tariq Eshmawi (Saudi Arabia)
14:15	Lichen planopilaris and its variants Ruaa Alharithy (Riyadh, Saudi Arabia)
14:30	Non responding peri-ungual warts! You have 10 other options Azzam Alkhalifah (Arrass, Saudi Arabia)
14:45	Chronic actinic dermatitis: Challenges in diagnosis and treatment options Dana Aleissa (Riyadh, Saudi Arabia)
15:00	Challenging cases from Riyadh Sultan Al-Khenaizan (Riyadh, Saudi Arabia)
15:15	What's new in topical acne treatment Rana Shahab (dhahran, Saudi Arabia)
15:30	Pearls in dermatology Mohammed AlJasser (Riyadh, Saudi Arabia)
15:45	Paradox in cosmetic dermatology Salma Albargawi (Riyadh, Saudi Arabia)
16:00	Updates from recent dermpath publications Faisal Al-Mohommedi (Mississauga, Canada)
16:15	Laser light: Illuminating new paths in scar Louai Salah (Jeddah, Saudi Arabia)
16:30	Collagen biostimulators - Evidence-based and our center experience Abdulhadi Jfri (Jeddah, Saudi Arabia)
16:45	Updates on non-surgical face lift Ghassan Niaz (Saudi Arabia)
17:00	Botulinum toxin off-label use in dermatology Bader Zimmo (Jeddah, Saudi Arabia)
17:15	Welcome to the new age: Skin health is the new wealth Lama Altawil (Riyadh, Saudi Arabia)

Saturday, 28 September 2024

SUBSPECIALTY SESSION

⌚ 08:30 – 11:45 CEST

📍 G102 – G103

	IPS - International Peeling Society Chair: Fotini Bageorgou (Athens, Greece) Marina Landau (Herzlia, Israel)
08:30	Short introduction of IPS Fotini Bageorgou (Athens, Greece)
08:35	Laser assisted delivery of peeling substance Peter Velthuis (Naarden, Netherlands)
08:50	Superficial chemical peels for melasma Rashmi Sarkar (Noida ,Uttar Pradesh, India)
09:05	To peel or not to peel: that is the question! Elena Rossi (Modena, Italy)
09:20	TBC Fatima-Zahra Belgnaoui (Saudi Arabia)
09:35	The role of chemical peels in the treatment of precancerous skin lesions and field carcinogenesis Christina Fotiadou (Thessaloniki, Greece)
09:50	Q&A
10:10	Want to become a “deep peeler” and do not know how to start? Lets start with segmental peels first Marina Landau (Herzlia, Israel)
10:25	Safety in deep peels Felipe Ribeiro (São Paulo, Brazil)
10:40	Peeling TCA, my favorite indications Maria Garcia Baldovi (Sueca, Spain)
10:55	Starting with Chemical Peeling Lidia Comba Pérez Pérez (Vigo, Spain)
11:10	Melanin rich skin and pigmentation - the peel challenge. What peels can and cannot do for pigmentation in darker skin types Mukta Sachdev (Bangalore, India)
11:25	Q&A

Saturday, 28 September 2024

SUBSPECIALTY SESSION

⌚ 14:15 – 17:30 CEST

📍 G102 – G103

	EURO-PDT – European Society for Photodynamic Therapy in Dermatology Chairs: Lasse R. Braathen (Oberhofen, Switzerland) Colin Morton (Perthshire, United Kingdom) Rolf-Markus Szeimies (Recklinghausen, Germany)
14:15	Welcome and introduction Lasse R. Braathen (Oberhofen, Switzerland)
14:20	Field cancerization - Diagnostic and therapeutic implications Lasse R. Braathen (Oberhofen, Switzerland)
14:40	The place of PDT in skin cancer practice in 2024 Colin Morton (Perthshire, United Kingdom)
15:00	Is there a place for general practitioners in the management of AK? Satish Lubeek (Nijmegen, Netherlands)
15:20	Combination-based strategies for the treatment of AK with PDT Stefano Piaserico (Padova, Italy)
15:40	Home PDT Sally Helen Ibbotson (Dundee, United Kingdom)
16:00	Artificial daylight PDT - Lessons learnt from the Artlight Study Rolf-Markus Szeimies (Recklinghausen, Germany)
16:20	Antimicrobial PDT Yolanda Gilaberte (Zaragoza, Spain)
16:40	PDT for acne Eleni Sotiriou (Thessaloniki, Greece)
17:00	Summary and closing remarks Lasse R. Braathen (Oberhofen, Switzerland)

Saturday, 28 September 2024

SUBSPECIALTY SESSION

⌚ 10:15 – 11:45 CEST

📍 G104 – G105

	ESDP - European Society for Dermatopathology Chairs: Gürkan Kaya (Geneva, Switzerland) Carlo Francesco Tomasini (Pavia, Italy)
10:15	European Society of Dermatopathology Gürkan Kaya (Geneva, Switzerland)
10:30	European Diploma of Dermatopathology Carlo Francesco Tomasini (Pavia, Italy)
10:45	Test Yourself - Dermatopathology Quiz Carlo Francesco Tomasini (Pavia, Italy)
11:15	Test Yourself - Dermatopathology Quiz Gürkan Kaya (Geneva, Switzerland)

Saturday, 28 September 2024

SUBSPECIALTY SESSION

⌚ 14:15 – 17:30 CEST

📍 G104 – G105

	ESDaP - European Society for Dermatology and Psychiatry Chairs: Francesca Sampogna (Rome, Italy) Florence Dalgard (Oslo, Norway) Francoise Poot (Bruxelles, Belgium)
14:20	What if a doctor can't find what's wrong with me? Ria Willemsen (Brussels, Belgium)
14:32	Crawling shadows: unraveling challenges in management of delusional infestation Khulood Almarzooqi (Abu Dhabi, United Arab Emirates)
14:44	Psychological interventions in the treatment of delusional infestations Mohammad Jafferany (Saginaw, United States)
14:56	Management of patients with delusional infestation across Europe Patrick Kemperman (Haarlem, Netherlands)
15:08	Body-focused repetitive behaviors: current and new treatment approaches Katlein Franca (Miami, United States)
15:20	Clinical case: Who should treat this? Rihab Shara (abu dhabi, United Arab Emirates)
15:32	The psychoneuroimmunology of atopic dermatitis Regina Havenith (Bonn, Germany)
15:44	Identification of protective factors for anxiety and depression in patients with atopic dermatitis Elise Vandersichel (Gent, Belgium)
15:56	Break
16:18	Psychodermatology of alopecia areata Maria-Angeliki Gkini (London, United Kingdom)
16:30	Psychodermatology in the aesthetic practice Razvigor Darlenski (Sofia, Bulgaria)
16:42	Screening for body dysmorphic disorder and the body image perception among pierced individuals Justyna Putek (Wrocław, Poland)
16:54	Use of DLQI as primary endpoint in clinical studies: the growing importance of psychosocial aspects of skin disease Faraz Mahmood Ali (Cardiff, United Kingdom)
17:06	Psychological and behavioural factors among hidradenitis suppurativa patients Marta García Bustínduy (Tenerife, Spain) Vania Alexandra Lukoviek Araya (San Cristóbal de La Laguna, Spain) Jezabel Bravo-Medina
17:18	Investigating anhedonia among patients with dermatological conditions Aleksandra Stefaniak (Wrocław, Poland)

Saturday, 28 September 2024

SUBSPECIALTY SESSION

⌚ 14:15 – 17:30 CEST

📍 E102

	MEIDAM Chairs: Khaled AlNuaimi (Dubai, United Arab Emirates) Saad Alsogair (Al Khobar, Saudi Arabia) Ruaa Alharithy (Riyadh, Saudi Arabia)
14:15	Opening note and welcome message Khaled AlNuaimi (Dubai, United Arab Emirates)
14:20	The impact of environmental aggressors on the skin Saad Alsogair (Al Khobar, Saudi Arabia)
14:35	Update in dermatophyte resistance Hussain Juma (Manama, Bahrain)
14:50	Unusual faces for psoriasis Manar Al Saqabi (Kuwait, Kuwait)
15:05	Acne scars fast and furious Abrar Bukhari (Riyadh, Saudi Arabia)
15:20	Early localized vitiligo - a medical emergency Samia Esmat (Cairo, Egypt)
15:35	Periocular pigmentation treatment Ruaa Alharithy (Riyadh, Saudi Arabia)
15:50	Demographic and clinical variants of lichen planus Fathi Elkasah (Sirte, Libya)
16:05	Dermoscopy of actinic lichen planus in skin of colour Awatef Kelati (Casablanca, Morocco)
16:20	Immunobullous diseases among the geriatric population in Lagos, Nigeria: Diagnostic challenges and management Adaeze Ikebudu (Iagos, Nigeria)
16:35	Fracture blister: An underdiscussed topic Sahar Dadkhahfar (Tehran, Iran)
16:50	Laser assisted transepidermal drug delivery in dermatology Muhsin Al Dhalimi (Najaf, Iraq)
17:05	Therapeutic education in atopic dermatitis: An observational study Samira Zobiri (Algiers, Algeria)
17:20	Primary cutaneous large B-Cell lymphoma on the scalp Ronak Saeed Ahmed (Sulaymaniyah, Iraq)

Saturday, 28 September 2024

RESIDENTS TRACK

⌚ 09:00 – 12:30 CEST

📍 OPEN STAGE

D4T14.1		RESIDENTS TRACK Chairs: Hok Bing Thio (Rotterdam, Netherlands) Markus Vincent Starink (Amstelveen, Netherlands)
D4T14.1A	09:00	Aesthetic dermatology and complications (cosmetics/tattoo/ethics) Peter Velthuis (Rotterdam, Netherlands)
D4T14.1B	09:30	Break
D4T14.1C	09:45	Green pharma Nicole Hunfeld (Rotterdam, Netherlands)
D4T14.1D	10:15	Influence of skinfluencers in social media Ana Maria Molina Ruiz (Madrid, Spain)
D4T14.1E	10:45	Break
D4T14.1F	11:00	When the machines come in to help Josep Malvehy (Barcelona, Spain)
D4T14.1G	11:30	How do we make a greener congress? Hok Bing Thio (Rotterdam, Netherlands)
	12:00	Closing Ceremony Miguel Jansen (Rotterdam, Netherlands) Joep Krom (Rotterdam, Netherlands)

ALLIED HCP WORKSHOPS

⌚ 08:30 – 10:00 CEST

📍 EMERALD

D4T17.01		Tools to aid consultation Chairs: Paola Pasquali (Cambrils, Spain) Kristine Kirkeby Fuskeland (Nittedal, Norway)
D4T17.1A	08:30	The power of outcome measurement in clinical practice: tools to improve care on all levels Emma Vyvey (Ghent, Belgium)
D4T17.1B	08:50	The use of photography to enhance the consultation Paola Pasquali (Cambrils, Spain)
D4T17.1C	09:10	Shared Decision Making Christine Bundy (Cardiff, United Kingdom)
D4T17.1D	09:30	Constructive conversation tools to aid nurse consultation Kristine Kirkeby Fuskeland (Nittedal, Norway)
D4T17.1E	09:50	Discussion, Q&A

ALLIED HCP WORKSHOPS

⌚ 10:15 – 11:45 CEST

📍 EMERALD

D4T17.02		Chronic inflammatory skin diseases - HS & AD Chairs: Luis Dias (Lisboa, Portugal) Alberto Barea (Kingston Upon Thames, United Kingdom)
D4T17.2A	10:15	Hidradenitis Suppurativa Hannah Wainman (Bristol, United Kingdom)
D4T17.2B	10:35	Wound Dressings in Hidradenitis Suppurativa Kelly Impey (Dublin, Ireland)
D4T17.2C	10:55	Nurse consultation in Atopic Dermatitis Luis Dias (Lisboa, Portugal)
D4T17.2D	11:15	Patient Management in Atopic Dermatitis and comorbidities Alberto Barea (Kingston Upon Thames, United Kingdom)
D4T17.2E	11:35	Discussion, Q&A

D4T17.03		Caring for chronic inflammatory skin diseases Chairs: Elfie Deprez (Sint-Denijs-Westrem, Belgium) Jo LW Lambert (Ghent, Belgium)
D4T17.3A	14:15	Lifestyle factors in inflammatory skin diseases Brian Kirby (Dublin, Ireland)
D4T17.3B	14:35	Value based healthcare for psoriasis; a team approach Jo LW Lambert (Ghent, Belgium)
D4T17.3C	14:55	Bridging Gaps in care for Chronic Inflammatory Skin Disease: Nurse-Led Strategies Elfie Deprez (Sint-Denijs-Westrem, Belgium)
D4T17.3D	15:15	Lived experience of psoriasis Ilse van Ee (Leusden, Netherlands)
D4T17.3E	15:35	Discussion, Q&A

D4T17.04		Nurse education & research Chairs: Julia Schofield (Hatfield , United Kingdom) Alberto Barea (Kingston Upon Thames, United Kingdom)
D4T17.4A	16:00	Preparing Dermatology Nurses for the future Julia Schofield (Hatfield , United Kingdom)
D4T17.4B	16:20	Leading research: Nurse role as a principal investigator Alberto Barea (Kingston Upon Thames, United Kingdom)
D4T17.4C	16:40	Nursing research to improve access to dermatological advice for individuals with suspicious skin lesions Speaker TBC
D4T17.4D	17:00	Nurse as Research Lead: my journey in identifying the psychological needs of patients with SJS/TEN Pauline Siobhan O'Reilly (Limerick, Ireland)
D4T17.4E	17:20	Discussion, Q&A


Practical workshops

All workshops require a pre-registration and a pre-payment. Class sizes are limited to 35 places each and registrants are accepted on a first-paid, first-served basis.

More info eadv.org/congress/scientific/workshops

References to brands: Commercial names of medical devices/software/equipment may appear in this content because they are linked to specific medical procedures, which are the focus of this training material. Other products in the market can be used to perform the aforementioned medical procedures. The educational provider does not endorse any particular product.

Wednesday 25 September 2024



Room D202 8:30 – 11:45

Basics of ultrasound imaging in dermatology

Chair: Fernando Alfageme (ES)

This workshop is designed for dermatologists seeking to incorporate dermatological ultrasound as a diagnostic tool in their practice. Whether you're new to ultrasound or looking to enhance your skills, join this workshop to explore the diverse applications and techniques of ultrasound in dermatology.



Room D203 8:30 – 11:45

Laser treatment for beginners

Chair: Albert Wolkerstorfer (NL)

The main goal of the workshop is to gain essential knowledge about laser dermatology in order to improve outcomes in laser therapy. It will focus on vascular lesions, pigmented lesions, laser endpoints, how to avoid complications, laser assisted drug delivery and ablative and fractional lasers. Each of these topics will be systematically approached by an expert through 1) a short introduction, 2) an overview of available devices, 3) a review of indications, 4) an interactive panel discussion with tips, tricks and pitfalls.



Room D202 14:15 – 17:30

Allergology: Skin environmental induced contact dermatitis

Chair: Ana Maria Gimenez-Arnau (ES)

The workshop will focus on theoretical and practical aspects to correctly diagnose etiologically immunologic cutaneous disorders. These conditions include dermatitis / eczema (contact or atopic) and urticaria (acute or chronic) trigger by environmental stimuli and agents. Its clinical identification would need some specialized complementary tests in order to typify the responsible agent, assess severity, implement correct treatment and also preventive measures. For this is essential a training. How to identify and demonstrate type I and type IV hypersensitivity in cutaneous Immunol allergic diseases and how to make a correct differential diagnosis of inducible chronic urticarias is the main goal of this workshop.



Room D203 14:15 – 17:30

STI diagnosis and treatment

Chair: Georg Stary (AT)

In this interactive workshop, our aim is to let both residents and dermatologists walk away with fresh knowledge and inspiration with regard to the approach of STI. The workshop will consist of presentations with up-to-date knowledge on STI diagnosis and treatment options. Topics include syphilis, other ulcerative STI, and HIV-indicator diseases. Management of infectious diseases more and more calls for knowledge on mechanisms of antimicrobial resistance (AMR) and how to detect AMR in pathogens. Background information on mechanisms of AMR and (molecular) techniques for detection of AMR for practical use will be discussed.

Participants are encouraged to share local guidelines and experience, and individual cases for discussion.




Room D202 8:30 – 11:45

Dermoscopy – practical and conceptual

Chair: Giuseppe Argenziano (IT)

Dermoscopy is commonly used to improve the diagnosis of neoplastic and non-neoplastic disease. This interactive workshop will discuss practical problems of dermoscopy, including applications beyond its traditional use in pigmented neoplastic lesions.




Room D203 8:30 – 11:45

Medical photography in dermatology

Chair: Paola Pasquali (ES)

Medical photography is a non-invasive imaging technique that is used for recording ailments, make diagnosis, monitoring, get second opinions, indicate surgical site, among many uses. The following workshop is aimed at familiarizing participants in medical photography: what makes it similar to other uses of photography, what makes it different.




Room D203 14:15 – 17:30

Playing with AI in dermatology

Chair: Harald Kittler (AT)

This workshop offers an exploration into the innovative intersection of Artificial Intelligence (AI) and Dermatology. You will explore the potential of AI in various aspects, from diagnostics to treatment strategies. Gain insights into the latest advancements, methodologies, and practical applications in field. Participants will discover how AI technologies can increase clinical decision-making, optimise workflow efficiencies, and enhance patient care. Additionally, discussions will cover the advantages and disadvantages of integrating AI into dermatological practices.



Room D202 14:15 – 17:30

Chemical peelings

Chairs: Fotini Bageorgou (GR), Marina Landau (IL)

Designed for dermatologists seeking to elevate their proficiency in techniques, the Chemical Peeling workshop will cover peel types, patient selection, application methods, safety measures, and treatment strategies. This workshop offers a unique opportunity for skill enhancement in the field.



Room D202 8:30 – 11:45

Phlebology for beginners

Chair: Felizitas Pannier (DE)

The participants will be introduced to the main principles of phlebology. To start, the following topics will be explained and discussed:

- The anatomy and physiology of the lower limbs
- The diagnostics and investigations used by phlebologists
- The therapy of varicose veins according to the newest guidelines, including sclerotherapy

Afterwards, participants will be divided in 4 rotating groups for hand-on learning.

In addition, there will be time to discuss questions around indications, techniques, side effects and results of sclerotherapy.



Room D203 8:30 – 11:45

Dermal fillers

Chair: Bertrand Richert (BE)

The Dermal Fillers workshop is designed for dermatologists willing to improve their skills in dermal filler procedures. This workshop will cover the principles of facial anatomy, injection techniques, product selection, safety considerations, advanced applications of dermal fillers and will especially focus on potential side effects and how to deal with them. Videos of injecting procedures will be displayed.



Room D202 14:15 – 17:30

Conquer your audience: perfect your presentation skills

Chairs: Christa de Cuyper (BE), Paola Pasquali (ES)

Enhance your presentation skills with our interactive workshop. Participants will deliver a presentation of up to 7 minutes, which will be evaluated by a panel of four experts. Each presentation will be scored on scientific content, graphical quality, message delivery, and overall impression, providing valuable feedback to help you master the art of public speaking.



Room D203 14:15 – 17:30

Use of botulinum toxin in cosmetic and medical dermatology

Chair: Samira Baharlou (BE)

The workshop will focus on the practice of use of botulinum toxin in a dermatologist office.

This workshop gives theory behind the use of botulinum toxin for aesthetic and medical dermatological indications. The hands-on part to study the practical use of toxins and to learn where to place the injections points for successful treatment outcomes.

Practical workshops

Saturday 28 September 2024




Room D202 8:30 – 11:45

Surgery – Basic

Chair: Victoria Marmgren (SE)

In the first part of the workshop, we will learn about preparation for surgical procedures, facial anatomy, anesthesia, instruments and suturing. The second part will focus on exercising punch biopsy, ellipse excision and different suture techniques. At the end, basic principles of flaps and grafts will be reviewed shortly. All aspects will be discussed and illustrated with pictures, followed by hands-on training in groups. During the training, live video will be used to visualize anesthetic procedures, use of instruments and suturing.

A quiz will be held at the end of workshop.




Room D203 8:30 – 11:45

Get your papers published: tips and tricks from the editors

Chair: Carle Paul (FR)

This workshop is designed to clarify the process of academic publishing in dermatology. Gain insider knowledge and practical advice from experienced editors to boost your chances of getting published. It is intended to be a highly interactive session, so participants are encouraged to bring their own research projects or article drafts.



Room D202 14:15 – 17:30

Surgery – Intermediate

Chair: Victoria Marmgren (SE)

In the first part of the workshop, we will interactively discuss details and pitfalls in preparation of surgical procedures, facial anatomy, anaesthesia, instruments and suturing. This will be followed by hands-on training of some special aspects of suturing and biopsy. The second part will focus on the principles of flaps and grafts. The different techniques will be discussed and illustrated with lots of pictures, followed by hands-on training in groups. During the training, live video will be used to visualize the procedures. A quiz will be held at the end of workshop.



Room D203 14:15 – 17:30

Wound healing

Chair: Elena Conde Montero (ES)

Discover the latest in leg ulcer diagnosis and treatment through interactive group sessions. You'll learn holistic wound assessment, considering not just the wound but also the surrounding skin and patient health. Gain practical experience with diagnostic tools, including performing ankle-brachial index measurements yourself. We'll provide practical tips for achieving systematic and efficient differential diagnoses, illustrated with rich visuals. Explore the benefits and applications of compression therapy for various leg ulcers, understand the range of commercially available wound dressings, and learn about their components and indications. Additionally, delve into the concepts of wound infection continuum and antimicrobial stewardship, and discover the technique of punch grafting for promoting epithelialization.

Patient organisations area

EADV actively works to develop a synergic action between the patient community and key healthcare providers.

We invite all Congress attendees to visit the Patient Organisations Area taking place from 25 to 28 September 2024 in the Hall 2. In this dedicated area you have the opportunity to meet with leaders of the represented patient organisations, discuss activities of common interest, explore different perspectives, needs and roles and how to fit them into the larger world of European dermatology.

We acknowledge and thank the below patient organisations for their commitment and involvement during this year's Congress:



More info eadv.org/congress/patient-organisations-area/

General information

Organiser's address and contact

European Academy of Dermatology & Venereology
Via S. Balestra 22B, 6900 Lugano – Switzerland

Website: eadv.org

Congress venue

RAI Amsterdam
Entrance K, Europaplein 24, 1078 GZ Amsterdam

Website: rai.nl

Venue opening hours

- Wednesday 25 September 07:30 – 22:30
- Thursday 26 September 07:30 – 21:30
- Friday 27 September 07:30 – 20:30
- Saturday 28 September 07:30 – 19:00

Destination management company

RAI Amsterdam

Official booking platform: eadv.org/eadv-congress-accommodation

Internet access / Wi-Fi

Free Wi-Fi access will be available in the common areas of the venue and in the session rooms.

Network: **EADV2024** Password: **EADV2024**



General information

Onsite facilities

Registration area

The registration area is located in the Hall 2. The registration area will be open as follows:

- Wednesday 25 September 07:30 – 18.00
- Thursday 26 September 07:30 – 16.30
- Friday 27 September 07:30 – 16.30
- Saturday 28 September 07:30 – 14.30

MyEADV area

The MyEADV area is located in Hall 2.

We invite you to visit the MyEADV booth dedicated to showcasing the diverse offerings and initiatives of the European Academy of Dermatology and Venereology (EADV). Our booth is your go-to destination for comprehensive information on EADV Membership, educational opportunities, and our journals JEADV and JEACV. Additionally, we are proud to highlight our ongoing sustainability efforts. Whether you're a current member or new to EADV, this space is designed for you to connect with our membership representatives and explore the full spectrum of benefits and resources that EADV has to offer.

Join us at MyEADV and discover how EADV is advancing the field and supporting its community.

Speaker preview room

The speaker preview room is in Hall 2 and will be open as follows:

- Tuesday 24 September 15:00 – 18.00
- Wednesday 25 September 07:30 – 18.00
- Thursday 26 September 07:30 – 17.00
- Friday 27 September 07:30 – 17.00
- Saturday 28 September 07:30 – 17.00

All presentations must be in English. Speakers should also verify in the online programme that the name of the room and time of session have not changed.

Speakers must upload their presentation 3 hours (minimum) before the lecture if not already uploaded.

Speakers with a presentation during the first time slot of the morning are requested to upload their PowerPoint presentation the day before.

General information

Official language

English is the official language of the EADV Congress. No simultaneous translation will be provided at any EADV scientific session.

Scientific sessions

The Scientific Session rooms for the EADV Congress are located in the Europe Complex (Hall 3 and Hall 7) and in the Congress Centre (Auditorium, Elicium, Emerald, Forum, E and G Rooms). Please refer to the [floor plans](#) for orientation.

Seating is regulated on a first-come, first-served basis. We recommend you go to the session room well in advance of the session to ensure your place. Due to safety regulations, the organisers will close the access to the session if all seats are occupied. Delegates are not permitted to stand in the aisles of the session rooms.

In the event of high attendance, the following rooms will be available to accommodate additional participants:

- Ruby Lounge → overflow for E102
- E105 → overflow for E103-E104
- E106 → overflow for E107-E108
- G107 → overflow for G102-G103
- G106 → overflow for G104-G1050

Recording during scientific sessions



The use of mobile phones as well as audio and video recording devices are strictly prohibited within the scientific session rooms. Please ensure that you have your mobile phone switched off when attending a session. Photography is not permitted.

Certificates and accreditation

All registered participants will be able to download their certificates online based on their level of engagement:

- A **Certificate of Attendance** is available for all registered participants who have a valid registration badge and attended at least 1 session.
- A **CME-CPD Certificate** is available for all participants who actively attended scientific sessions, have their badge scanned and completed the online evaluation forms.
- An **ePoster Certificate** is available for all leading ePoster authors.
- An **Oral presentation Certificate** is available for all presenters of an abstract accepted for an oral presentation.
- A **Speaker presentation Certificate** is available for all presenters who have delivered a lecture in a scientific session
- A **Workshop Certificate** is available for all for all Workshop participants.

The certificates are not sent out automatically. They can be downloaded from our platform by entering the [email address and password used during the registration process](#) OR the [EADV member log-in details](#) (if a EADV member).

Platform URL: eadv.org/congress/account

General information

Abstracts and ePosters

Accepted abstracts will be made available on our website eadv.org/scientific/abstract-books/

Abstracts selected for ePosters will be published as electronic posters during the Congress and will be available for viewing in the ePoster area, located in the Hall 3.

30 big screens are provided and configured exclusively to display the ePosters.

The ePosters can be viewed sequentially by number, submission topic or searched individually by title, key word, or author.

The ePoster area will be open as follows:

- Wednesday 25 September 07:30 – 18.30
- Thursday 26 September 07:30 – 18.30
- Friday 27 September 07:30 – 18.30
- Saturday 28 September 07:30 – 12.00

Exhibition hall

The Congress will host an exhibition hall of more than 15.000sqm, located in Hall 1 of the RAI Amsterdam. The exhibition halls can be accessed from Entrance K, Hall 2, Hall 3, and Hall 6.

Please note that the exhibition hall is open to Healthcare Professionals (HCPs) only, as prescription medical products will be advertised.

According to the European Union Directive 2001/83/EC (and amended version 2010/84/EU), the promotion of prescription-only medicines should be directed solely at Healthcare Professionals or any person who is authorised to prescribe or handle them.

The National Dutch laws, codes and regulations are applied during the EADV Congress in Amsterdam. Therefore, access to the Exhibition halls, Satellite Symposia and Industry expert hub sessions dealing with development, research or other related to prescription medicine will be restricted to Healthcare Professionals only.

The exhibition hall will be open during the following hours:

- Wednesday 25 September 12:00 – 17:30
- Thursday 26 September 09:00 – 17:30
- Friday 27 September 09:00 – 17:30
- Saturday 28 September 09:00 – 12:00

Exhibitors can enter the exhibition hall 1 hour before and after the opening hours except for the closing time of the last day.



General information

Other services

Cloakroom

The Cloakroom is in the Hall 2 and will be open as follows:

- Wednesday 25 September 07:30 – 22.00
- Thursday 26 September 07:30 – 21.30
- Friday 27 September 07:30 – 20.00
- Saturday 28 September 07:30 – 19.00

Lost & found

Please hand in all found items and ask for lost items at the cloakroom.

Catering facilities

Lunches and coffee breaks are not included in the registration fees.

Meals and snacks can be purchased within the Congress venue during the opening hours in various catering areas.

Childcare facility

An on-site professional childcare service is located on room K101-K102 on level 1, directly accessible through an escalator from the main entrance "K".

The service is designed for children aged 6 months to 14 years old and will be overseen by a professional childcare agency to assure you that your children will receive attentive care while you actively participate in the conference activities.

The childcare service fee is 10€ for the full day. More info: eadv.org/congress/childcare-facility

First aid room and emergency numbers

In case of need please visit the Medical Centre, located just outside the Hall 2, close to the Cafe Amsterdam.

Emergency number: +31 (0) 20 549 1234

Closest hospital to RAI Amsterdam:

Amsterdam UMC

De Boelelaan 117, 118, 1081 HV Amsterdam – +31 (0) 20 444 4444



General information

Opening plenary session and networking symposium

Join us to celebrate the start of the 2024 EADV Congress and participate in the first plenary lecture of this year's edition

Prof. Martin Röcken will officially inaugurate the 2024 EADV Congress followed by the keynote speaker Dr. Bertrand Piccard, a modern-day pioneer in aviation exploration and innovation who achieved a record-breaking around-the-world balloon journey in 1999. He will discuss the human impact on the climate and suggest actionable steps we can take in our personal lives to protect our planet

Following the enriching session, starting at 19:00, we invite you to join us for a networking reception in the Auditorium Lounge.

Let's celebrate the beginning of an incredible congress together.

DATE: Wed, 25 Sep 2024	TIME: 17:45	LOCATION: Auditorium
----------------------------------	-----------------------	--------------------------------



General information

Privacy

Use of private data

The data made available through the Registration Portal for Congresses and Symposia are gathered and treated by the EADV in compliance with the Swiss regulation on data protection and the General Data Protection Regulation. We advise you to read full EADV Privacy Policy on eadv.org/privacy-policy.

Transferring the data to the industry session organiser

During the EADV Congress you have the right to transfer the data collected by EADV to another controller ("the Industry session organiser", "Industry"). It might happen through scanning a badge, QR code or other means. Each participant shall consider that by accepting any scanning of the badge, QR code or other means at any industry session at the Congress, the participant gives authorization to the EADV to transfer the data of the participant to the Industry.

The EADV is obliged to make this process possible but does not take any responsibility for what happens with the data after it is transferred to the Industry session organiser. We advise to make sure that Industry presents Privacy Policy and read it carefully. It may occur that purposes described by the Industry Exhibitor might include the promotion of pharmaceutical products and similar.

Transfer of the data from the EADV to exhibiting Industry does not mean the removal of original data from EADV. If you wish for the data to be removed or have any request or questions, please contact us at any time by writing to eadvoffice@eadv.org.

Third-party registration

The EADV does not officially support or authorize any third-party organization that creates registrations for individuals or groups. We strongly advise to register accordingly to official fees and only on EADV official websites.

Liability disclaimer

The Organisers cannot be held liable for any hindrance or disruption to the EADV Congress arising from political, social or economic events or any other unforeseen incidents beyond their control. The Organisers will accept no liability for any personal injuries sustained or for loss or damage to property belonging to Symposium participants, either during or as a result of the Congress or during all tours and events. Registration of a participant entails acceptance of these conditions.

Official mobile app

Bring the EADV Congress to your smartphone!

Get instant access to the full scientific programme, abstracts, ePosters, session surveys, industry sessions, and the latest news before, during and after the meeting! Interactions during sessions will be facilitated by the EADV Congress 2024 app, allowing you to send questions, vote and evaluate.

Scientific programme

Access the full programme and create your own agenda

Abstracts and ePosters

Access the latest research from your device

Session evaluations


Evaluate all sessions and gain your CME-CPD credits

Interactivity

Participate to the sessions by answering the polls and ask your questions



SCAN TO LEARN MORE
or visit eadv.org/congress/app/




The venue

The EADV Congress 2024 will be held at the RAI Amsterdam, the main entrance of the Congress is Entrance K.


➔ **RAI Amsterdam - Entrance K, Europaplein 24, 1078 GZ Amsterdam**

Session rooms are located in Hall 3, Hall 7 and in the Congress Centre, these areas are connected by an internal walkway.



The venue

LEVEL 1



Registration

Any person who wishes to make a registration for the EADV Congress can proceed online on the registration system platform available on eadv.org/congress/registration. Fees, deadlines, policies and other import information are published at the same link.

EADV Congress ticket types

The EADV Congress offers **3 ticket options** to participate with flexibility.

The EADV Congress **Full Ticket** includes:

- Admission to live Congress Scientific Sessions
- Access to the virtual Congress Platform
- Admission to the Networking Symposium on Wednesday, 25 September 2024 (No entertainment)
- Access to Subspecialty Society Meetings
- Access to the ePoster area, MyEADV booth and Patient Advocacy Booth
- For Healthcare Professionals and Non Members (INDUSTRY) access to the Exhibition Hall
- Access to Satellite Symposia Sessions and Industry Expert Hub sessions *
- Eligibility to claim ECMEC Credits for participating in the live Scientific Sessions
- Transportation pass (read more on eadv.org/congress/about/the-venue)
- **Along with all benefits of the virtual registration**

The EADV Congress **Virtual Ticket** includes:

- Access to the virtual Congress Platform with live-streamed scientific sessions
- Access to all on-demand content until 31 December 2024
- Access to the streaming of Subspecialty Society Meetings
- Access to the online library of ePosters and abstracts
- Access to the online EADV area and Patient Organisation Hub
- For Healthcare Professionals and Non Members (INDUSTRY) access to the exhibiting company profiles
- Live-streaming of selected Satellite Symposia Sessions and Industry Expert Hub *
- Eligibility to claim ECMEC Credits for participating in the live-streamed Scientific Sessions

EADV Congress **1-Day Ticket**

A 1-Day Ticket is limited to one ticket per participant and is available for on-site attendance only. To attend the Congress for more than one day, a Full Ticket valid for the whole duration of the event needs to be purchased. Transportation pass and Virtual Access after the event are not included.

** IMPORTANT: Industry Session organisers could limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the industry session. The organising company reserved the right to refuse single categories, in particular if not adequately related to the objective and purpose of the session.*

Registration

Name badge

Registered participants are invited to print out their badge at the self-printing machines on arrival to the Registration area. The name badge is the official EADV Congress identification document and should be worn at all times in order to gain entry to the various Congress areas.

The name badge is your ticket for booked activities and sessions. Admission to other areas of the venue is not permitted without badge identification.

The badge includes a QR-code containing your full address and email. It is the participant's decision to disclose these details to the Industry Session's organisers with a scanner.

Press information for journalists and media representatives

Journalists who are working for and representing recognised news organisations are encouraged to attend the Congress as Press. To register, journalists must complete the online application, upload a valid press card, and confirm adherence to the Embargo policy.

All registered Press members must adhere to the EADV Press & Media Guidelines, Embargo Policy and Filming/Photography/Recording Policy for Professionals. Registered Press can access all scientific sessions, but not the Exhibition Area, Satellite Symposia or Industry Expert Hub sessions. Only specialised press representatives can access the Exhibition area.

For further information about registration, the EADV Press and Media Guidelines and the Embargo Policy, please visit the press page on our website eadv.org/congress/press.

Healthcare professional information and definition

Access to the different areas and sessions of the Congress depends on the status. Please read the description below to ensure you/your delegates comply with the regulations in place. EADV Members are not designated as Healthcare Professionals by default. Please attribute the correct status (HCP or Non-HCP) during registration.

Definition

A multidisciplinary audience will attend the EADV Congress, and the EADV will assign different classes to healthcare professionals (HCP) and non-Healthcare Professionals (non-HCP) to ensure compliance with these regulations.

Chapter 3 of the Dutch CGR code defines HCPs as follows:

"3.1 In the purpose of this Code of Conduct, the following terms shall bear the following meaning: healthcare professionals: persons qualified to prescribe or supply prescription-only medicinal products."

Further explanation is provided in The General information about organising scientific meetings and Frequently Asked Questions from the CGR (Dutch Foundation for the Code for Pharmaceutical Advertising (to be referred to as the general information document from here on out) ([20170214 CGR informatie congresorganisaties](#)), where it states (at section 2 a, page 2) that:

"In the Netherlands the group of healthcare professionals comprises: physicians, physicians who are being trained to become a specialist ('artsen in opleiding'), pharmacists, pharmacist's assistants, obstetricians, dentists, physician assistants, nurse practitioners and specialised nurses."

Dutch nurses, in particular

It further clarifies that:

"... 'Specialised nurses (limited to the lung, diabetes and oncology areas) only have independent prescription authority if they have completed a specific training programme for this purpose. The completion of this training is entered in the BIG register and so can be checked by anyone. This means that all of the other healthcare providers, such as regular nurses, dieticians, dental hygienists or supportive GP practitioners ('praktijkondersteuners'), are not healthcare professionals and so – just like patients – belong to the 'general public'. This group will be referred to below as 'non-healthcare professionals'."

In terms of specialised nurses, the explanatory notes to the CGR code ([20200701 Explanatory Notes CGR per 20200701](#)) provide a specific list to be taken into consideration:

3.1.d Definition of "healthcare professional"

.... pharmacist's assistants and nurses with the additional BIG registrations:
Specialised nurses (gespecialiseerd verpleegkundigen):

- Diabetes nurses
- Pulmonary care nurses
- Oncology nurses

Specialised nurses may only be considered as healthcare professionals if their BIG registration states that they have prescription authority. Nurse specialists (NS) (verpleegkundig specialisten):

- NS providing general healthcare
- NS providing mental healthcare"

Healthcare professional information and definition

Residents

Lastly, the explanatory notes state (at page 3) that:

"Physicians in training to become a specialist (artsen in opleiding) are also considered as healthcare professionals within the meaning of the Code of Conduct. Medical students are not considered healthcare professional (see Newsletter 2006/4)."

Other Categories

The general information document (sections 2d and e, page 3) goes on to clarify that industry employees and specialised journalists can be exposed to promotional content. Yet patients, patient representatives, and regular press or specialised journalists who target the general public will still be considered non-HCPs and should not be exposed to promotional content.

STUDENTS are NOT considered as Healthcare Professionals under the current guidelines and will be automatically classified as NON-HEALTHCARE PROFESSIONALS.



CONGRESS



AMSTERDAM

25-28 SEPTEMBER 2024

EUROPEAN ACADEMY
OF DERMATOLOGY & VENEREOLOGY

EXHIBITION

Exhibitor list - See floor plan on next page


B24	A.D.O. MEDICAL S.R.L.
A15	AbbVie Inc.
B63	Adamo Srl
A42	Aerolase
B44	ALLERGIKA Pharma GmbH
B61	Almirall
B47	ALTRUIST
B25	Amgen
B57	AMI Inc
B37A	APS SRL
A07	Archidemia
A38	AURORA MEDICAL
A52	Beijing Syntech Laser Co.,Ltd
B67	BIOGENED SA
A11	Bioneer Corp.
A63	BODERM S.A.
A26	Boehringer Ingelheim
A28	Boehringer Ingelheim
B17	BRADERM S.R.L.
A60	Bristol Myers Squibb
B24A	Brymill Cryogenic Systems
B10	Canfield Scientific Inc.
A25	Cantabria Labs
B38	Caregen Co., Ltd.
B03	CASIO Europe GmbH
B15	CATALYSIS, S. L.
B70	Celldex Therapeutics
B69	Celltrion, Inc.
B71	CERAMOL
B68A	CeraVe
A29	Chiesi Pharmaceuticals BV
B01	CLARTEIS
B41	Cortex Technology ApS
B73	Cosmed Cosmeceuticals
B50	COVERMARK & COVERDERM Dermocosmetics (Farmeco S.A.)
B14	CRX NORDIC AB (CAREX SWEDEN)
B59	Daavlin
A40	DAMAE Medical
A30	Dermaceutic Laboratoire
B40	DERMACTIVE GLOBAL LLC
B34	DermapenWorld
A50	DermLite
A57	Dermus Ltd.
B54	Dr. Wolff Group
A14	Eli Lilly and Company
B62	Estée Lauder Companies - CLINIQUE

A17	Eucerin by Beiersdorf AG
A21	Eucerin by Beiersdorf AG
A55	Floxia
A47	FotoFinder Systems GmbH
B19	Galderma SA
A18	GME German Medical Engineering
B07	Haim Aesthetics
A59	HD COSMETIC EFFICIENCY
B49	HEINE Optotechnik
B22	ILLUCO Co., Ltd.
B32	Images en Dermatologie
A20	Incyte
B64	INMODE
B12	Innovaderm Research Inc.
B36	ISISPHARMA
A09	Isocell Nutra
A22	Istituto Ganassini S.p.A. di Ricerche Biochimiche
A41	JBP Korea Co., Ltd.
A23	Johnson & Johnson
B16	Karger Publishers
B26	Kenvue
B27A	Kenvue
B09	Ker Sun
A19	KERNEL MEDICAL EQUIPMENT CO.LTD
A51	KREUSSLER PHARMA
B68	LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE
A24	Laboratoire ACM
A39	Laboratoire SVR
A65	Laboratoires Dermatologiques Gamarde
B66	Laboratoires Expanscience
B65	Laboratoires Uriage
B51	Laboratorios Viñas
B13	LC Cell USA
B28	LEO Pharma
A02	Lipotype GmbH
B72	L'Oréal Dermatological Beauty
B74	L'Oréal Dermatological Beauty
B68C	L'ORÉAL PARIS
A54	Lusiné Bruxelles
A44	MartiDerm
A58	MDPI
A16	medac GmbH
B39	MESOESTETIC PHARMA GROUP

B37	MoonLake Immunotherapeutics
A12	NAOS
A01	NeoGen
B27	NeoStrata Company,Inc./Kenvue
B32A	Nia Health
B52	NOREVA LED
A46	Novartis Pharma AG
A03	OCULO-PLASTIK, INC.
B43	Omnidoc
A49	OPATRA LONDON
B35	Pfizer
B20	Pharmaceris
B45	PHLECS
B33	Pierre Fabre SA
A33	QuantifiCare
A10	Regeneron Pharmaceuticals Inc
B05	Replior AB
A27	Sanofi
A13	Sanofi Regeneron
A62	Sesderma
A04	SKIN TECH PHARMA GROUP SL
B31	Softwave Medical Ltd
B02	Speclipse Europe GmbH
A61	Swift Microwave Therapy
A48	Swiss4ward
A35	Sylton
B29	Symbio Proinnovera
B30	Takeda Pharmaceuticals
A64	terraplasma medical GmbH
A37	TKL Research
B53	Topicrem
B23	TSK Laboratory Europe BV
A34	UCB
B48	UCB
B48A	UCB
A36	UNIVA
B68B	VICHY LABORATOIRES
B11	VivaScope GmbH
A43	Vydence Medical
B21	Wasserman Medic AB
A05	Wisepress Medical Bookshop
B04	WIZMEDI CO.,LTD.
B46	Woorhi Mechatronics
A53	Zero Gravity Skin
B06	Zhuhai Yasha Medical Instrument Co., Ltd

Floor plan: Hall 1 – Exhibition

You can also view the exhibition floor plan on the [EADV Virtual Platform](#) on the industry section or the interactive exhibition floor plan available on the [EADV Congress website](#).



Main sponsors

PLATINUM SPONSORS

sanofi | REGENERON®



GOLD SPONSORS

abbvie



Johnson & Johnson

NOVARTIS | Reimagining Medicine

GALDERMA
EST. 1981



Bristol Myers Squibb®

SILVER SPONSORS



L'ORÉAL
Dermatological Beauty



BRONZE SPONSORS

REGENERON®



Dermapenworld



URIAGE
EAU THERMALE



Acknowledgements

SPONSORS OF THE HEALTH CARE
PROFESSIONAL SCHOLARSHIP



CONTRIBUTION TO SHIPMENT
AND LOGISTICS



WORKSHOPS SPONSORS

WOUND HEALING



MEDICAL PHOTOGRAPHY IN DERMATOLOGY



DERMOSCOPY – PRACTICAL AND CONCEPTUAL



BASICS OF ULTRASOUND IMAGING IN DERMATOLOGY



ALLERGOLOGY: SKIN ENVIRONMENTAL INDUCED CONTACT DERMATITIS





CONGRESS

SEE YOU IN
AMSTERDAM